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Summary 
Colorectal cancer (CRC) is a major cause of cancer mortality. Whereas some patients respond 
well to therapy, others do not, and thus more precise methods of CRC stratification are 
needed.  
We analysed the intracellular protein expression from 28 CRC primary tumours and 
corresponding normal intestinal mucosa using saturation-DIGE/MS and Explorer antibody 
microarrays. Changes in protein abundance were identified at each stage of CRC. Proteins 
associated with proliferation, glycolysis, reduced adhesion, endoplasmic reticulum stress, 
angiogenesis, and response to hypoxia represent changes to CRC and its microenvironment 
during development. Molecular changes in CRC cells and their microenvironment can be 
incorporated into clinico-pathological data to help sub-classify tumours and personalise 
treatment.        
DotScan antibody microarray analysis was used to profile the surface proteome of cells 
derived from 50 CRC samples and corresponding normal intestinal mucosa. Fluorescence 
multiplexing enabled the analysis of two different sub-populations of cells from each sample: 
EpCAM
+
 cells (CRC cells in the tumours or normal epithelial cells in normal mucosa) and 
CD3
+
 T-cells (tumour-infiltrating lymphocytes). Unsupervised hierarchical clustering of the 
CRC and T-cell surface profiles defined four clinically relevant clusters, which showed some 
correlation with histopathological and clinical characteristics such as cancer cell 
differentiation, peri-tumoural inflammation and stimulation of infiltrating T-cells. The 
observed relationship between the surface antigen expression profiles of patients’ CRC cells 
and their corresponding tumour infiltrating T-cells suggests that CRC surface proteins may 
play a direct role in influencing the activity (and hence surface protein expression) of 
neighbouring T-cells and/or vice versa. We conclude that the application of surface profiling 
may provide improved patient stratification, allowing more reliable prediction of disease 
progression and patient outcome.  
 Chapter 1 General introduction 
1 
 
 
 
 
Chapter 1  
General introduction 
 
 
 
 
 
1.1 Colorectal cancer overview 
Colorectal cancer (CRC) is a cancer of epithelial origin, localised to the large intestine and 
rectum. It has the highest incidence of all malignant cancers in Australia (excluding skin 
cancers other than melanoma) and accounts for 9.3 per cent of all cancer related deaths in this 
country  (Statistics from Australian Institute of Health and Welfare. Cancer in Australia: an 
overview, 2012).  Treatment of patients with primary CRC is often restricted to surgical 
resection of the tumour. The risk of recurrence and the decision for adjuvant therapy 
following surgery depend on a number of prognostic factors for relapse and survival, i.e. 
clinico-pathological staging based on the extent of tumour invasion, involvement of regional 
lymph nodes and metastatic spread to other organs (Figure 1.1).  
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Figure 1.1 a) Graphical representation of CRC progression. Stage 0 (tumour-in-situ) adenoma 
initiates at the innermost layer of the colon/rectum, the mucosal surface. Malignant stage I tumours 
propagate outwards beyond the mucosa into the submuscosa but not beyond the muscularis properia. 
Stage II tumours invade beyond the muscularis properia into the subserosa and serosa. Stage III 
tumours are characterised by the presence of cancer cells in one or more local and/or regional lymph 
nodes. Stage IV tumours have metastasised into distant organs. (Image from National Cancer Institute 
colon and rectal cancer: www.cancer.gov/cancertopics/types/colon-and-rectal). b) Adenocarcinoma of 
the transverse colon. The fungating ACPS B1 adenocarcinoma projects into the lumen but has not 
caused obstruction (circled in green). c) Transverse slice of the primary tumour. The serosa is painted 
blue for orientation and to visualise tumour infiltration (photo taken at The Royal Prince Alfred 
Hospital). 
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If metastasis has occurred, the patient 5-year survival rate falls dramatically from 90% to less 
than 10% (O'Connell et al., 2004). Stage C patients (30 – 60%) survive the first 5 years 
depending on the number of involved lymph nodes and the benefit of adjuvant chemotherapy. 
For stage B patients (without lymph node involvement), the use of adjuvant chemotherapy 
remains controversial (Kopetz et al., 2008). This is because the clinical course for individuals 
remains difficult to predict, largely due to prognostically heterogeneous groups within same-
stage tumours. Therefore, there is a need for more reliable methods of CRC stratification to 
predict CRC progression, identify patients at risk of recurrence and those most likely to 
benefit from adjuvant therapy.   
 
1.2 Tumour microenvironment 
The evolution of CRC from an adenomatous polyp to metastatic disease is dependent not 
only on progressive accumulation of genetic and epigenetic abnormalities (Moyret-Lalle et 
al., 2008), but also on the complex interactions of different sub-populations of cells within 
the tumour microenvironment (cancer cells, normal stromal cells, infiltrating leukocytes and 
the soluble factors they produce) (McAllister and Weinberg, 2010).  
The stroma consists of the non-malignant cells of the tumour: fibroblasts, infiltrating 
leukocytes and cells of the blood vessels. The tumour stroma plays an essential role in the 
development of CRC and is referred to as a “reactive stroma” (Kalluri and Zeisberg, 2006). 
This reactive stroma is associated with an increased number of fibroblasts, enhanced capillary 
density and deposition of a new extracellular matrix (ECM) rich in type-1-collagen and 
fibrin. There is evidence indicating that the primary neoplasm and the reactive stroma 
communicate in a reciprocal way via the basement membrane (Kalluri and Zeisberg, 2006). 
A loss of basement membrane components due to degradation by proteolytic enzymes and/or 
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a lack of biosynthesis are correlated with tumour progression. For example, Type VII 
collagen is lost early in the development of several cancers (Havenith et al., 1988). Similarly, 
laminin-5 is commonly lost in colon carcinomas but not in pre-malignant tumours (Sordat et 
al., 1998). These modifications of the basement membrane occur simultaneously to changes 
in trans-membrane adhesive receptors expressed by tumour cells in response to degradation 
of ECM. Metabolism of ECM molecules is an important aspect of tissue homeostasis and 
determines how cells respond to acute and chronic stresses. Various types of proteinases 
participate in ECM turnover, but matrix metalloproteinases (MMPs) are the principal ECM-
degrading enzymes. These enzymes have a central role in cancer progression, given that 
ECM degradation products can influence stroma-cancer cell interactions. In particular, 
metastatic colon cancer cells are able to induce the expression and/or secretion of MMP-2 
and MMP-9 in stromal cells, either via direct contact, or via a paracrine regulation (Mook et 
al., 2004).  
Inflammatory reactions in tumours can have a positive influence on survival (Klintrup et al., 
2005) or alternatively can be associated with development of metastases and disease 
progression (Jedinak et al., 2010). The presence of large numbers of tumour infiltrating 
lymphocytes (TILs) at the invasive tumour front has been associated with a good prognosis 
for CRC patients (Katz et al., 2009). Patients with high levels of CD3
+
, CD8
+
, CD25
+
, 
CD45RO
+
 or CD71
+
 TILs appear to have a better clinical course (Lee et al., 2010) than those 
with low levels, particularly in early disease stages (Deschoolmeester et al., 2010). The 
importance of the intra-tumoural location, immunophenotype and density of these infiltrates 
has been demonstrated (Halama et al., 2009, Pages et al., 2008).  
The role of tumour-associated macrophages (TAM) in tumourigenesis is complex because 
TAMs can either prevent or promote tumour development. While Foressell et al. showed that 
a dense TAM infiltration at the tumour front positively influenced prognosis in colon cancer 
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(Forssell et al., 2007), strong pro-tumourigenic effects of TAMs in CRC have also been 
reported (Jedinak et al., 2010, Kaler et al., 2010). It has been suggested that the balance 
between pro- and anti-tumourigenic properties of TAMs may depend on their interaction with 
cancer cells, other stromal cells, and the tumour microenvironment (Jedinak et al., 2010) or 
be influenced by the degree of cell-cell contact (Forssell et al., 2007).  
 
1.3 The current state of cancer classification 
The role of the histopathologist is no longer limited to issuing an accurate tissue diagnosis, 
but is increasingly directed towards the provision of prognostic information and additional 
findings directly relevant to patient management. This ongoing refinement of reporting is 
heavily dependent on the fundamental role of the pathologist in the accurate classification of 
disease. Classification is more than the naming of disease entities or even the collation of 
their particular diagnostic features. It includes the elucidation of clinico-pathological 
correlations that are the starting point for investigation of the causation, evolution and natural 
history of the disease. It is necessary for a disease to be properly classified to achieve 
effective clinical management and meaningful laboratory investigation of the underlying 
mechanisms. The classification of cancer has traditionally been based mainly on microscopic 
morphology, supplemented in more complex forms of malignancy, by immunohistochemistry 
and sometimes molecular approaches.  
In the case of CRC, both clinical management and research have continued for many decades 
to classify CRC based on histological features, such as tumour grade (differentiation) and 
tumour stage (Table 1.1) (Newland et al., 1981, Fielding et al., 1991) that is based on depth 
of tumour invasion, involvement of regional lymph nodes and metastatic spread to other 
organs (Compton, 2003). These staging systems offer systematic evaluation of tumours and 
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provide the basis for prediction of survival and choice of initial treatment. By placing patients 
into groups with different risks of disease progression, clinico-pathological staging has 
become widely accepted and is comparatively easy to perform. However, these anatomically 
based staging systems have limited use beyond local therapies (surgical resection, radio-
frequency ablation, regional radiotherapy) and have proven to be unreliable in intermediate 
stage B and C patients, where tumours of similar histological appearance can follow different 
clinical courses and show different responses to therapy (Eschrich et al., 2005). 
 
Table 1.1 The main CRC stratification systems used in Australia. Duke’s classification is the oldest 
CRC staging method. The American Joint Committee on Cancer (AJCC) system and TNM (tumour 
node metastasis) staging are extensions based on the original Duke’s methods. The Australian clinico-
pathological staging (ACPS) system has been adopted by several Australian Hospitals, in particular 
Concord Repatriation General Hospital that developed a more specific version of the ACPS in 1971.  
2011 7
th
 edition TNM classification 
 of malignant tumours 
AJCC 
stage 
TNM stage 
ACPS  
(Concord 
sub-stage) 
Duke’s 
classifi-
cation 
Tumour confined to mucosa (cancer-in-situ) Stage 0 Tis N0M0 A1 
 
Tumour invades submucosa Stage I T1 N0M0 A2 A 
Tumour invades muscularis properia 
 
T2 N0M0 A3 B1 
Tumour invades subserosa or beyond (without other 
organs involved)  
Stage IIA T3 N0M0 B1 B2 
Tumour invades adjacent organs or perforates the serosa  Stage IIB T4 N0M0 B2 B3 
Metastasis to 1 to 3 local lymph nodes Stage IIIA T-2 N1M0 C1 C3 
Metastasis to 1 to 3 regional lymph nodes Stage IIIB T3-4 N1M0 C2 C2-3 
Metastasis to 4 or more regional lymph nodes Stage IIIC Any T N2M0 D1 C1-3 
Distant metastases present  Stage IV 
Any T any N 
M1 
D2 D 
 
The introduction of molecular factors has complicated the situation, as well as providing new 
opportunities for predicting prognosis. The genetic evolution of CRC was understood to 
proceed on the basis of a relatively uniform and linear sequence of steps, with APC 
inactivation initiating adenomas and additional genetic changes, notably KRAS mutation, and 
TP53 inactivation, promoting the emergence of increasingly aggressive sub-clones 
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(Vogelstein et al., 1988). The condition familial adenomatous polyposis (FAP), caused by 
germ-line mutation of APC, was perceived as the hereditary counterpart to sporadic CRCs 
(Fodde et al., 2001). These genetic biomarkers have shown great potential in predicting 
specific phenotypes in hereditary CRC patients (i.e. those with FAP); however, it remains 
difficult to correlate phenotype in sporadic CRC with its cellular genotype (Soravia et al., 
1998). Sporadic CRC represents 90% of all cases, exhibiting a wide diversity of cellular 
dysfunctions (Steinert et al., 2002), even between histologically identical tumours. 
In the search for tumour progression markers, there has been a concerted effort to define gene 
expression profiles at the transcript level (Ross et al., 2000, Scherf et al., 2000). However, it 
is clear that mRNA expression data alone are insufficient to predict functional outcomes for 
the cell. For instance, mRNA expression data provide very little information about activation 
state, post-translational modification or localisation of corresponding proteins. Moreover, 
there are numerous reports highlighting the disparity between mRNA transcript and protein 
expression levels (Gygi et al., 1999). The inherent advantage of proteomics is that the 
identification of proteins is itself the biological endpoint. Comparative studies of protein 
expression in normal and disease tissue have led to the identification of aberrantly expressed 
proteins that may assist in diagnosis, outcome prediction and drug development (Hanash, 
2003). 
 
1.4 Protein biomarkers 
Despite the discovery of a range of intra- and extra-cellular protein biomarkers for CRC and 
continuing efforts to discover potentially prognostic and predictive markers using various 
approaches (Alfonso et al., 2008, Andre et al., 2006, Barderas et al., 2010, Friedman et al., 
2004, Gil-Bazo, 2007, Habermann et al., 2008, Jimenez et al., 2010, Luque-Garcia et al., 
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2010), the translation of this increasing volume of differential proteomic data into patient care 
remains a major challenge. This is partly due to the heterogeneous nature of CRC (Hlubek et 
al., 2007, Li et al., 2007b) and the complexity of processes involved in its development and 
spread, but also to challenges in detecting and characterising glycoproteins and low 
abundance proteins (Ahn et al., 2009, Rho et al., 2008) in complex mixtures. In addition, 
validation of candidate proteins as prognostic markers is time-consuming and expensive, and 
recent critical reviews of differentially expressed proteins from comparative proteomic 
studies have suggested that reported proteins may be associated with general cellular stress 
response, rather than being disease-specific biomarkers (Petrak et al., 2008, Wang et al., 
2009). The development of a reliable assay for CRC stratification, determining prognosis and 
guiding post-surgical therapy, therefore remains elusive. There is a general consensus that 
individual biomarkers cannot provide enough prognostic information to replace 
histopathological staging and that the application of multiple biomarkers will be required; 
innovative approaches are needed to translate accumulating data into a useful method for sub-
classifying CRC patients for disease stage and those likely to benefit from available 
treatment.  
The metastatic potential of CRC may already be encoded in the primary tumour (Yamasaki et 
al., 2007), and molecular staging using a classifier based on 43 genes has yielded more 
reliable prognostic information than the traditional clinical staging, particularly for 
intermediate stage B and C patients (Eschrich et al., 2005). While genomics and mRNA 
expression based technologies will continue to contribute substantially to biology and 
medicine, there are limits to the type and amount of information such studies can provide. 
Comparisons of transcript and corresponding protein expression have shown that mRNA and 
protein levels are not necessarily correlative (Steiner and Witzmann, 2000, Celis et al., 2000). 
In addition, proteomics can provide information on the post-translational modifications such 
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as phosphorylation (Mann, 2006, Rush et al., 2005, Dwek et al., 2001) or glycosylation 
(Dwek et al., 2001). Moreover, since almost all therapeutic intervention strategies involve 
targeting and modulating protein function and activity, it is imperative that analyses of 
mechanism underlying tumourigenesis include proteomics. Identification of disease 
signatures based on protein expression profiles in primary CRC tissue may provide a more 
accurate representation of disease progression and metastasis, and enable these signatures to 
be used to predict patient recovery and survival after surgical removal of the primary CRC. 
The use of immunohistochemistry for analysis of CRC tissue sections for multiple potentially 
prognostic/predictive markers (Fernebro et al., 2004, Lyall et al., 2006) has the advantage of 
revealing antigen location in sections; however the method is relatively low throughput, 
expensive, labour-intensive, and quantification is difficult. The use of high throughput 
techniques, such as Saturation-DIGE and antibody microarrays, enable analysis of a large 
number of samples simultaneously. 
 
1.5 Proteomic techniques  
Sample preparation determines the success or failure of protein expression profiling in 
tumour tissue. Factors such as time between surgical removal and sample processing impact 
significantly on the integrity of the proteins. To obtain the most accurate representation of the 
cancer proteome, samples should be assessed and sliced immediately by the pathologist and 
snap-frozen at -80°C within 12 h of surgical removal to avoid protein degradation. To ensure 
that experimental findings relate directly to changes in the cancer cells, it is desirable that the 
cancer cells are free of contaminating serum proteins, haemopoietic cells, stroma and necrotic 
tissue. Depending on tissue type, enrichment for specific sub-populations of cells has been 
performed using techniques such as micro-dissection (Lawrie and Curran, 2005, Sheehan et 
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al., 2008), fluorescence activated cell sorting (FACS) (Dalerba et al., 2007b) or antibody-
conjugated magnetic beads (Dalerba et al., 2007b, Kaufman et al., 2010).  
Traditionally, proteome profiling of complex mixtures, such as whole-cell lysates, has 
involved the combination of two-dimensional electrophoresis (2DE) protein profiling with 
mass spectrometry (MS) for protein identification (Friedman et al., 2004, Alfonso et al., 
2005). 2DE separates proteins by charge in the first dimension and molecular weight in the 
second dimension, enabling visualisation of thousands of proteins in a single experiment. 
However, owing to the complexity of whole cells or tissues, a single separation strategy such 
as 2DE will probably reveal only a subset of the total proteome. The problems associated 
with solubility of various classes of proteins, can further reduce the window of proteins that 
can be recovered for identification.  
Advances in 2DE technology, such as the multiplexing of samples for DIGE analysis have 
enabled the user to identify protein abundance changes with a higher degree of confidence 
than with the use of the standard ‘one sample per gel’ method. This has resulted in less 
variation between gels, and requires fewer replicates to be confident that an observed 
difference is genuine (Shaw et al., 2003). Conventional DIGE technology utilises three mass- 
and charge-matched cyanine dyes (Cy2, Cy3, and Cy5) that, as N-hydroxy-succinmidyl 
esters, undergo nucleophilic substitution with ε-amine groups of lysine residues of proteins. 
The dye to protein ratio must be kept low (approximately 5%) in order to avoid multiple dye 
additions on each protein molecule that would give rise to multiple spots per protein on a 2D 
gel. Saturation of lysine would produce more reliable results but is not a practical solution as 
most proteins have a typically high lysine content (e.g., 10.1% across eight random proteins 
(Lehninger, 1972) it would be difficult to force the labelling reaction to saturation without the 
need for excessive amounts of reagent. To improve sensitivity, it would be preferable to label 
an alternative, less prevalent, amino acid to saturation. Saturation-labelling technology (GE 
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Healthcare Amersham) uses one such amino acid, cysteine, which is less prevalent in proteins 
than lysine (e.g., 2.47% across eight random proteins (Lehninger, 1972)), yet also has 
chemistry amenable to chemical modification through reaction with its thiol group. 
Saturation-labelling delivers all the advantages of conventional DIGE with improved 
sensitivity of detection (Shaw et al., 2003). By labelling the proteins to saturation the amount 
of sample required is reduced from 50 -100 µg for conventional DIGE to 5 – 10 µg for 
saturation-DIGE. Although saturation DIGE has led to the discovery of a number of 
differentially expressed proteins in CRC (Alfonso et al., 2008), there are inherent limitations 
in this method; in particular, up to 40% of high-molecular-weight material becomes insoluble 
upon labelling and some proteins lacking cysteine residues are not labelled with the 
saturation-labelling dyes, resulting in the loss of a subset of proteomic data.  
 
Mass spectrometry (MS) has increasingly become the method of choice for analysis of 
complex protein samples. MS-based proteomics is a discipline made possible by the 
availability of gene and genome sequence databases and technical and conceptual advances in 
many areas. The classical proteomic quantification methods utilise high-resolution protein 
separation (e.g. 2D gels), which limits their applicability to abundant and soluble proteins; 
and second, they do not reveal the identity of the underlying protein. Recent developments in 
modern LC-MS/MS techniques have overcome these problems by enabling proteome-wide 
quantification (Bantscheff et al., 2007, Ong and Mann, 2005). Many of these advances can be 
achieved through improved MS instrumentation, more intelligent algorithms and software. 
Most of these methods employ differential stable isotope labelling to create a specific mass 
tag, which can be introduced into proteins or peptides. In contrast, label-free quantification 
approaches aim to correlate the mass spectrometric signal of intact proteolytic peptides or the 
number of peptide sequencing events with the relative or absolute protein quantity directly 
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(Old et al., 2005). A multitude of methods has emerged for the analysis of simple and 
complex proteomes using quantitative mass spectrometry, and the field is beginning to learn 
for which type of study these methods can be meaningfully applied. However, significant 
further improvements to experimental strategies are required particularly for the quantitative 
analysis of post-translational modifications.   
Antibody microarrays hold great promise as a valuable tool for cancer research. The low 
volume requirement and the multiplexing capability of microarrays enable optimal use of 
precious clinical samples, and because the assays are rapid and amenable to automation, large 
sample sets required for biomarker studies can be processed and analysed (Sutandy et al., 
2013). The first model to demonstrate the application of antibody microarrays employed the 
“analyte-labelled” assay format. In this format, proteins are pre-labelled with biotin before 
antibody capture, and once bound they can be detected after incubation with a secondary 
labelled binder (Haab, 2005). Using this format, Knezevic et al. (Knezevic et al., 2001) found 
changes in protein expression during cancer cell development. This approach enables the 
simultaneous analysis of hundreds of different proteins on the same slide, and allows for 
fluorescence multiplexing, i.e., the comparison of two or more samples labelled with different 
fluorophores, on the same microarray. However, this method lacks specificity in protein 
target labelling and has poor sensitivity for low-abundance proteins (Sutandy et al., 2013). 
Moreover, targeted protein labelling may lead to epitope destruction by some chemical 
reactions (Poetz et al., 2005). Therefore, the sensitivity of analyte-labelling microarrays is 
highly dependent on the selection of high-affinity antibodies recognising antigen epitopes 
unaffected by the labelling.   
A novel application of antibody microarrays is the surface antigen profiling of whole cells 
using the DotScan antibody microarray (Zhou et al., 2010, Zhou et al., 2011). The DotScan 
CRC antibody microarray allows rapid immunophenotyping of 122 surface antigens on a 
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population of disaggregated live tumour cells in suspension, requiring 4 × 10
6
 cells per assay. 
Density of cell binding per antibody dot depends on the proportion of positive cells in the 
population, level of antigen expression and affinity of the antibody. The optical binding 
pattern reflects the immunophenotype of the mixed cell population, while the CD3-
Phycoerythrin (PE) and EpCAM-Alexa Fluor 647 staining allow for the detection of T-cells 
and cancer/epithelial cells, respectively. This approach generates dot patterns that define the 
surface immunophenotype of each sub-population of captured cells.  
 
1.6 Aims  
This PhD project aims to apply proteomic analysis to the stratification of CRC.  We hope to 
obtain expression profiles from intracellular- and surface-proteins in CRC cells that can be 
used to generate “disease signatures” correlating with CRC stage, invasion, metastasis and 
patient outcome. 
Access to fresh surgically resected CRC tissue has enabled us to obtain an accurate 
representation of the cancer cell proteome. We have developed a cell disaggregation method 
for CRC and normal intestinal mucosa tissue, to yield viable single cells for downstream 
analysis.   
To gain a better understanding of the processes involved in CRC tumourigenesis and provide 
additional markers for classification, CRC tumours from every ACP stage were disaggregated 
and depleted of CD45
+
 leukocytes to enable identification of differentially expressed proteins 
in CRC using Saturation DIGE (GE Healthcare Amersham) and Explorer antibody 
microarrays (FullMoon).   
 Chapter 1 General introduction 
14 
 
Changes in the cell surface proteome of CRC cells and tumour infiltrating T-cells (TILs) 
from different patients may enable the sub-classification of clinico-pathologically similar 
CRC tumours. In addition, correlations between the surface profiles of cancer cells and TILs 
from the same patient may reflect the influence on CRC tumours of their stromal 
microenvironment, and the contribution leukocytes make to tumourigenesis. The 
immunophenotypes of cancer cells and T-cell sub-populations from 50 CRC tumours have 
been determined with the DotScan antibody microarray (Medsaic Pty Ltd).  
 
 
 Chapter 2 Material and methods 
15 
 
 
 
 
Chapter 2 
Material and methods 
 
 
 
 
 
The discovery and analysis of cancer biomarkers is a multi-phased process (Figure 2.1). In 
this PhD project we have utilised two proteomic analysis techniques, saturation-DIGE/MS 
and Explorer antibody microarrays, to profile the CRC proteome and identify protein 
alterations during CRC progression. A third technique, DotScan antibody microarrays, was 
used to profile the surface antigen expression on CRC cells and tumour-infiltrating T-cells. 
This high throughput immuno-assay has been used to generate disease signatures for the sub-
classification of CRC and prediction of overall survival. Figure 2.2 summaries the work flow 
for this PhD project.    
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Figure 2.1 Work flow for the identification of novel protein biomarkers. ‘Number of 
analytes’ refers to the number of proteins evaluated as candidate biomarkers in each phase of 
development. ‘Number of samples’ refers to the number of samples required for each phase. 
DIGE, two-dimensional fluorescence difference gel electrophoresis; MS, mass spectrometry.  
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Figure 2.2 Workflow for identification of CRC biomarkers 
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2.1 Materials 
 
Table 2.1 List of materials/equipment and the company supplier 
Materials and equipment Company 
15 ml Falcon tubes BD Biosciences (Franklin Lakes, NJ, USA) 
2-D Cleanup Kit Bio-Rad (Hercules, CA, USA) 
2-D Quant Kit Bio-Rad (Hercules, CA, USA) 
50 ml Falcon tubes BD Biosciences (Franklin Lakes, NJ, USA) 
Agilent 1100 HPLC system Agilent (Palo Alto, CA, USA) 
Airpure® biological safety cabinet class II Westinghouse (Butler County, PA, USA) 
Analyst OS 2.0 software AB Sciex (Foster City, CA, USA) 
Antibody array assay kit Full Moon BioSystems (Sunnyvale, CA, USA) 
C18 separation nanocolumn ZORBAX 300SB-C18 Agilent (Palo Alto, CA, USA) 
C18 trap column ZORBAX 300SB-C18 Agilent (Palo Alto, CA, USA) 
C18 Zip-tip Merck Millipore (Billerica, MA, USA) 
CD45-Dynabead Invitrogen Life Technologies (Carlsbad, CA, USA) 
Centrifuge 5810 R Eppendorf (Hamburg, Germany) 
Cryo freezing contrainer Nalgene (Rochester, NY, USA) 
CyDye DIGE fluor labeling kit for scarce samples GE Healthcare (Buckinghamshire, UK) 
Cyrovial tubes Greiner bio-one (Kremsmuenster, Austria) 
DotReaderTM Medsaic (Sydney, NSW, Australia) 
DotScanTM  microarray wash tray Medsaic (Sydney, NSW, Australia) 
DotScanTM antibody microarray kit Medsaic (Sydney, NSW, Australia) 
Eppendof tubes Greiner (Frickenhausen, Germany) 
Explorer antibody microarray Full Moon BioSystems (Sunnyvale, CA, USA) 
Filcon filter (200 µm) BD Biosciences (Franklin lakes, NJ, USA) 
Filcon filter (50 µm) BD Biosciences (Franklin lakes, NJ, USA) 
GS-800 calibrated densitometer Bio-Rad (Hercules, CA, USA) 
Haemocymeter Technocolour Neubar Hirschmann (Eberstadt, Germany) 
Harris uni-core 2 mm (spot cutter) Electron Microscopy Sciences (Hatfield, PA, USA) 
ImageQuant TL software GE Healthcare (Buckinghamshire, UK) 
Light microscope Nikon (Tokyo, Japan) 
LoBind plate Eppendorf (Hamburg, Germany) 
LoBind tube Eppendorf (Hamburg, Germany) 
MultiExperiment Viewer v4.4 TM4 Microarray Software Suite (Boston, MA, USA) 
Nanodrop 3300 Thermo Fisher Scientific (Waltham, MA, USA) 
Nikon TMS microscope Nikon (Kanagawa, Japan) 
Probot microfraction collector Dionex/LC Packings (Lane Cove, NSW, Australia) 
Progenesis SameSpot Nonlinear Dynamics (Newcastle, UK) 
Protean plus dodeca cell Bio-Rad (Hercules, CA, USA) 
Protein extraction kit Full Moon BioSystems (Sunnyvale, CA, USA) 
ProteinPilot 3.0 AB Sciex (Foster City, CA, USA) 
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Materials and equipment Company 
QSTAR Elite mass spectrometer AB Sciex (Foster City, CA, USA) 
ReadyStripTM IPG strip, 17 cm, pH 3-10 Non-linear Bio-Rad (Hercules, CA, USA) 
Strong cation exchange column Agilent (Palo Alto, CA, USA) 
Surgical blades Livingstone International (Toronoto, Canada) 
Terumo
®
 Syringe (10 mL) Terumo Medical Co. (Tokyo, Japan) 
Typhoon FLA 9000 biomolecular imager GE Healthcare (Buckinghamshire, UK) 
Vacuum centrifuge Thermo Fisher Scientific (Waltham, MA, USA) 
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2.2 Reagents 
 
Table 2.2 List of reagents and the company of purchase  
Reagent Company 
3-[(3-Cholamidopropyl) dimethylammonium]-1-
propanesulfonate (CHAPS) 
Sigma-Aldrich (St. Louis, MO, USA)  
4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid 
(HEPES) 
Sigma-Aldrich (St. Louis, MO, USA)  
85% phosphoric acid Sigma-Aldrich (St. Louis, MO, USA)  
Acetonitrile Sigma-Aldrich (St. Louis, MO, USA)  
Agarose Sigma-Aldrich (St. Louis, MO, USA)  
AlexaFluor647-conjugated EpCAM BioLegend (San Diego, CA, USA) 
Ammonium Biocarbonate Sigma-Aldrich (St. Louis, MO, USA)  
Ammonium persulphate (APS) Sigma-Aldrich (St. Louis, MO, USA)  
Ammonium sulphate Sigma-Aldrich (St. Louis, MO, USA)  
Ampholyte (broad range pH 3-10) Bio-Rad (Hercules, CA, USA) 
Benzonase Nuclease (ultrapure) >99% Sigma-Aldrich (St. Louis, MO, USA)  
Bovine serum albumin (BSA) Sigma-Aldrich (St. Louis, MO, USA)  
Bovine serum albumin (BSA) Sigma-Aldrich (St. Louis, MO, USA)  
Bromophenol blue Sigma-Aldrich (St. Louis, MO, USA)  
Collagenase type 4 Worthington Biochemical Corporation (Lakewood 
Township, NJ, USA) 
Coomassie Brilliant Blue G250  Sigma-Aldrich (St. Louis, MO, USA)  
Cy3-streptavidin GE Healthcare (Buckinghamshire, UK) 
Deoxyribonuclease 1 (DNAse) Sigma-Aldrich (St. Louis, MO, USA)  
Dimethyl sulphoxide (DMSO) Sigma-Aldrich (St. Louis, MO, USA)  
Dimethylformamide (DMF) Sigma-Aldrich (St. Louis, MO, USA)  
Disodium hydrogen orthophosphatedodecahydrate 
Anhydrous 
Univar (Redmond, WA, USA) 
Dithiothreitol (DTT) Sigma-Aldrich (St. Louis, MO, USA)  
Ethylenediaminetetraacetic acid (EDTA) Univar (Redmond, WA, USA) 
Fetal calf serum (FCS) Gibco/Invitrogen (Carlsbad, CA, USA) 
Fetuin Sigma-Aldrich (St. Louis, MO, USA)  
Formaldehyde 37% Sigma-Aldrich (St. Louis, MO, USA)  
Formic acid Sigma-Aldrich (St. Louis, MO, USA)  
Glycine Univar (Redmond, WA, USA) 
GluFib Sigma-Aldrich (St. Louis, MO, USA) 
Hanks' balanced salt solution (HBSS) Sigma-Aldrich (St. Louis, MO, USA)  
Heat-inactivated AB serum 2% Gibco/Invitrogen (Carlsbad, CA, USA) 
Methyl alcohol (methanol), absolute Sigma-Aldrich (St. Louis, MO, USA)  
Mineral Oil Sigma-Aldrich (St. Louis, MO, USA) 
Phosphate Univar (Redmond, WA, USA) 
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Reagent Company 
Phycoerythrin-conjugated CD3 Beckman Coulter (Brea, CA, USA) 
Potassium chloride (KCl) Univar (Redmond, WA, USA) 
Potassium di-hydrogen orthophosphate Univar (Redmond, WA, USA) 
Renin Sigma-Aldrich (St. Louis, MO, USA) 
RPMI 1640 with 2 mM Hepes Sigma-Aldrich (St. Louis, MO, USA)  
Sequencing grade trypsin Promega (Fitchburg, WI, USA) 
Sodium chloride (NaCl) Univar (Redmond, WA, USA) 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich (St. Louis, MO, USA)  
Sypro Ruby Sigma-Aldrich (St. Louis, MO, USA)  
Tetramethylethylenediamine (TEMED) Sigma-Aldrich (St. Louis, MO, USA)  
Thiourea Sigma-Aldrich (St. Louis, MO, USA)  
Tris-(2-carboxyethyl) phosphine hydrochloride 
(TCEP) 
Sigma-Aldrich (St. Louis, MO, USA)  
Tris (hydroxymethyl) aminomethane (Tris) Univar (Redmond, WA, USA) 
Trypan blue solution 0.4% Sigma-Aldrich (St. Louis, MO, USA)  
Urea Sigma-Aldrich (St. Louis, MO, USA)  
 Chapter 2 Material and methods 
22 
 
2.3 General solutions 
 
2.3.1 Tissue disaggregation and storage 
Collagenase solution pH 7.4 
Collagenase (2 % (v/v))       500 mg 
RPMI 1640 medium        25 ml  
 
DNAse solution 
DNAse I (0.1% (w/v))       10 mg 
MilliQ water         1 ml 
 
Cell storage solution 
DMSO (20% (v/v))        2 ml 
Made up in foetal calf serum (FCS)      8 ml 
Added to cell in FCS 1:1 volume 
 
HEPES-HBSS pH 7.3 
Hanks’ balanced salt solution (HBSS) 
HEPES (25 mM)        12 g  
  
MilliQ water         1 L 
 
10 × Phosphate buffer saline (PBS) pH 7.5 
Sodium chloride (80 g/L)       80 g   
Potassium chloride (2 g/L)       2 g 
Potassium di-hydrogen orthophosphate (14 mM)    2 g 
Di-sodium hydrogen orthophosphate-dodecahydrate (43mM)  6.1 g 
MilliQ water         1 L 
Dilute 1 in 10 in MilliQ water for general use (1×PBS) 
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2.3.2 Leukocyte depletion with CD45 DynaBeads  
Dynabead buffer 1 
EDTA (1 mM)        29.2 mg 
BSA          0.1g 
1 × PBS         100 ml 
 
Tris-HCl stock solution pH 8 
Tris (100 mM)        12.1 g 
MilliQ water         Up to 1 L 
Dissolve, check pH, adjust to pH 8. Store at 4 – 8oC up to 1 month 
 
Cell lysis buffer pH 8 
100 mM Tris-HCl pH 8 stock (30 mM)     6 ml 
Urea (7 M)         8.41 
Thiourea (2 M)        3.041 g 
CHAPS (4% (w/v)        800 mg 
MilliQ water         Up to 20 ml  
Dissolve. Adjust to pH 8 with 1M HCl. Aliquot and store at -20
o
C for up to 3 months 
 
2.3.3 Saturation-DIGE for analytical and preparative gels 
DTT (dithiothreitol) stock solution  
DTT (1 M)         3.09 g 
MilliQ water         Up to 20 ml 
Aliquot and store at -20
o
C 
 
TCEP (Tris (2-carboxyethyl) phosphine) reducing solution 
TCEP (2 mM for analytical gel)      5 mg 
MilliQ water         8.7 ml 
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TCEP (20 mM for preparative gel)      5 mg 
MilliQ water         870 µl 
Use immediately (unstable) 
 
1 × Sample buffer 
Urea (7 M)         16.82 g 
Thiourea (2 M)        6.08 g 
CHAPS (4% (w/v)        1.6 g 
MilliQ water         Up to 40 ml 
 
Stop mixture 
Immediately before use add  
Ampholyte (2% (v/v)         4.5 µl 
DTT (130 mM)        4.5 µl 
1 × sample buffer        445.5 µl 
Use immediately and discard any unused material 
 
Rehydration solution 
Immediately before use add  
Ampholyte (1% (v/v))       10 µl 
DTT stock (13 mM)        13 µl 
1 × sample buffer        977 µl 
Use immediately and discard any unused material 
 
IPG equilibration solution  
1 M Tris-HCl pH8 stock (0.1M)      10 ml 
Urea (6 M)         36 g 
Glycerol (30% (v/v))        30 ml 
SDS (2% (w/v))        2 g 
 Chapter 2 Material and methods 
25 
 
MilliQ water         Up to 100 ml 
Prepare DTT-free stock and store at room temperature for up to 6 months. 
 
Immediately before use add  
1M DTT stock (0.5% (w/v))     32.5 µl per ml of DTT free stock 
Use immediately and discard any unused material 
 
5 × Gel buffer pH 8.8 
Tris (1.87 M)         227 g 
MilliQ water         Up to 1 L 
Adjust to pH 8.8 with 1M HCl 
 
Glycerol solution 
Glycerol (50% (w/v))        500 g 
MilliQ water         Up to 500 ml 
 
APS (ammonium persulphate) solution 
APS (10 % (w/v))        0.1 g 
MilliQ water         1 ml 
Store at -20
o
C 
 
10 – 18 % (w/v) acrylamide gel recipe for 12 gels 
10 % (w/v) light gel  
5 × gel buffer (45.8 mM)       70 ml 
Acrylamide/Bis (10% (v/v))       88 ml 
MilliQ water         192 ml 
APS (0.05% (w/v))        560 µl 
TEMED (0.1% (v/v))        56 µl 
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18% (w/v) heavy gel  
5 × gel buffer (45.8 mM)       70 ml 
Acrylamide/bis (18% (v/v))       158 ml 
Glycerol (17.4% (v/v))       122 ml 
APS (0.05% (w/v))        560 µl 
TEMED (0.1% (v/v))        56 µl 
 
SDS stock solution 
SDS (20% (w/v))        200 g 
MilliQ water          1 L 
 
10 × Tris-glycine running buffer 
Glycine (192 mM)        576 g 
Tris-HCl pH 8 (24.8 mM)       132 g 
20% SDS stock solution (5% (v/v))      200 ml 
MilliQ water          4 L 
 
Overlay solution 
Agarose (0.5 % (w/v))       0.25 g 
Bromophenol blue (0.001 % (w/v))      0.5 mg 
1 × Tris-glycine running buffer pH 8      Up to 50 ml 
 
Fix/wash 
Methanol (10% (v/v))        50 ml 
Acetic acid (7% (v/v))       35 ml 
MilliQ water         Up to 500 ml 
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Coomassie Blue stock solution  
Ammonium sulphate (17% (w/v))      50 g 
85% Phosphoric acid (3% (v/v))      6 ml 
Coomassie G-250 (0.1% (w/v))    0.5 g in 10 ml water 
MilliQ water         500 ml 
 
Coomassie destain/gel storage solution 
Acetic acid (2.5 % (v/v))       5 ml 
MilliQ water         500 ml 
 
2.3.4 Peptide digestion 
1 M stock ammonium bicarbonate  
Ammonium bicarbonate       0.79 g 
MilliQ water         10 ml 
 
20 mM working ammonium bicarbonate solution 
1 M stock ammonium bicarbonate      20 µl 
MilliQ water         1 ml 
 
Destain 
20 mM ammonium biocarbonate (12 mM)     6 ml 
Acetonitrile (40% (v/v))       4 ml 
MilliQ water         10 ml 
 
Resuspension buffer 
Acetic acid (50 mM)        30 mg 
MilliQ water          10 ml 
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Trypsin solution 
Trypsin (12 ng/µl)        20 µg 
Resuspension buffer        166.7 µl 
Heat at 30°C for 15 min 
NH4HCO3 (50 mM)        Dilute 1:10 
Aliquot and store at -80°C 
 
2.5% (v/v) formic acid stock 
100 % formic acid        25 µl 
MilliQ water         975 µl 
   
Zip Tip wetting solution 
2.5% Formic acid (0.1% (v/v))      40 µl 
Acetonitrile (50% (v/v))       500 µl 
MilliQ water         460 µl 
 
Zip Tip wash/HPLC solution 
Formic acid (0.1% (v/v))        40 µl 
MilliQ water         960 µl 
 
Zip Tip elution solution 
Formic acid (0.1% (v/v))       40 µl 
Acetonitrile (70% (v/v))       700 µl 
MilliQ water         260 µl 
 
SCX buffer A pH 2.5 
Acetonitrile (25% (v/v))       250 ml 
Formic acid (0.05% (v/v))       0.5 ml 
MilliQ water         Up to 1 L 
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SCX buffer B pH 2.5 
Acetonitrile (25% (v/v))       250 ml 
Ammonium formate (0.5 M)       31.5 g  
Formic acid (2% (v/v))       20 ml 
MilliQ water         Up to 1 L 
 
LC-MS standard  
BSA (1 pmol/µl)        10 µl 
Fetuin (200 fmol/µl)        2 µl 
GluFib (1 pmol/µl)        1 µl 
Renin (100 fmol/µl)        10 µl 
Acetonitrile (5% (v/v))       50 µl 
Formic acid (0.1% (v/v))       1 µl 
MilliQ water         926 µl 
Aliquot and freeze. For QSTAR make dilution 1:10 with addition of 45 µl of 0.1% (v/v) 
formic acid, load 5 µl on standard 30 min gradient.  
  
Solvent B  
Formic acid (0.1% (v/v))       0.1 ml 
Acetonitrile         100 ml 
 
2.3.4 Explorer antibody microarray  
Buffer 1 
EDTA (1 mM)        29.2 mg 
BSA (0.1% (w/v))        0.1 g 
PBS          100 ml 
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2.3.5 DotScan antibody microarray  
DotScan fixative solution 
Formaldehyde (3.7 % (v/v))       370 µl 
PBS          10 ml 
 
DotScan blocking buffer pH 7.3 
BSA (2 % (w/v))        0.2 g 
Heat-inactivated AB serum (0.02 % (v/v))     2 µl 
PBS          10 ml 
 
Multiplexing solution 
Phycoerythrin-anti-CD3 (1:7.5 dilution)     20 µl 
Alexa Fluor 647-anti-EpCAM (1:15 dilution)    10 µl 
Heat-inactivated AB serum 1.5 % (v/v)     2 µl 
DotScan blocking buffer       150 µl 
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2.4 Methods 
2.4.1 Tissue disaggregation and storage 
Surgically resected samples were collected from the Royal Prince Alfred Hospital 
(Camperdown, NSW, Australia) and Concord Repatriation Hospital (Concord West, NSW, 
Australia) with ethical approval under protocol No. X08-164 by NSW Local Health District.  
The optimisation of solid tumour and normal intestinal mucosal tissue disaggregation was 
discussed in detail in Zhou, Honours thesis (Zhou, 2008). Surgically resected CRC tumours 
were selected and sliced by the pathologist, while control samples were taken from healthy 
intestinal mucosa at least 10 cm from the primary tumour site. Samples were stored in Hanks’ 
balanced salt solution pH 7.3 (HBSS) at 4°C for no more than 12 h after resection. Clinical 
samples were sliced into 2 mm strips and incubated with collagenase solution at 37°C for 1 h. 
Semi-digested tissue was passed through a fine wire mesh strainer using a plunger from a 10 
ml syringe, cells were washed through with HBSS. The cell suspension was then passed 
through 200 µm and 50 µm Filcon filters resulting in a single cell suspension. The cells were 
pelleted (400 × g, 20°C, 5 min) and resuspended in cell storage solution for long term storage 
and lysis of red blood cells (up to 1 year, -80°C).  A total of 254 CRC patient samples was 
collected and processed for cryostorage over a period of 4 years (2008 – 2012).      
 
2.4.2 Leukocyte depletion with CD45 Dynabeads 
For CD45
+
 leukocyte depletion, the cryostored cell suspension was thawed in a 37°C water 
bath and washed with HBSS. The Trypan blue exclusion procedure was used to determine 
cell viability and numbers. Cell suspensions (10 l) were mixed with equal volumes of 
Trypan blue and 10 l was pipetted into the haemocytometer chamber. A Nikon TMS 
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microscope (Nikon, Kanagawa, Japan) was used to determine cell density and viability. 
Viable cell density (i), dead cell density (ii), viability (iii), were determined using the 
following equations.  
 Xv (cells/mL) = (Cav x D) / 10
-4
  (i)  
 Xd (cells/mL) = (Cad x D) / 10
-4
  (ii) 
 V [%] = Cav/(Cav+Cad)   (iii) 
 
Xv – Viable cell density (cells/mL) 
Xd – Dead cell density (cells/mL) 
Cav – Average number of viable cells per haemocytometer square (1 mm
2
) 
Cad – Average number of dead cells per haemocytometer square (1 mm
2
) 
D – Dilution factor (cell solution/Trypan blue) = 2 
10
-4
 – volume of haemocytometer cell (mL)  
 
Approximately 180 µl of CD45 Dynabead solution density was used per 10
7
 viable cells. 
CD45 Dynabeads were pre-washed in buffer 1 and recovered using magnets before being 
resuspended in 180 µl of buffer 1. The cell suspension (10
7
 viable cells per 1 ml of HBSS) 
was incubated with 10 µl heat-inactivated AB serum for 5 min at 4°C before adding the 
CD45-Dynabeads, then incubated for 45 min at 4°C with gentle rotation. The cell/bead 
suspension was diluted into 12 ml of buffer 1 and gently mixed by pipetting, and placed on a 
magnet for 10 min to separate the CD45
+
 cells bound to beads from unbound cells. The 
unbound fraction was transferred to a centrifuge tube and spun (400 × g, 5 min, 25°C). The 
bound fraction was resuspended a second time in 12 ml of Buffer 1 and recaptured on a 
magnet. The remaining unbound cells were combined with the original unbound fraction and 
spun (400 × g, 5 min, 25°C). The cell pellet, consisting of CRC/epithelial enriched cells, was 
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washed twice with cold PBS in preparation for cell lysis. The CD45
+
 cell fractions were 
stored at -80°C for future analysis. 
 
2.4.3 Protein lysate clean-up and quantification 
A small volume of cell lysis buffer was added to CRC/epithelial enriched cells 
(approximately 100 µl per 10
7
 cells). The cells were incubated with a small amount of 
benzonase nuclease (1-2 µl) on ice in a water bath sonicator for 1 h. The mixture was 
centrifuged (20,000 × g, 15 min, 4°C) and the clear protein supernatant collected.  
The 2D Quant Kit (Bio-Rad) was used to determine protein concentrations prior to use of the 
2D Clean-up Kit. This method was carried out according to the manufacturer’s instructions. 
A standard curve was prepared with 2 mg/ml BSA (0 – 50 µg protein). The sample (1– 50 
µg) was assayed in duplicate. In summary, 500 µl of precipitation buffer was added to each 
tube, the mixture was vortexed briefly and incubated for 3 min at room temperature. Co-
precipitation buffer (500 µl) was added and mixed until precipitation became visible, the 
mixture was centrifuged (20,000 × g, 5 min, 4°C). The supernatant was carefully decanted 
without disturbing the pellet. The tubes were repositioned and pulse centrifuged before the 
remaining supernatant was pipetted out. Copper sulphate solution (100 µl) and 400 µl milli-Q 
water were added to the pellet and vortexed. Finally 1 ml working colour reagent (100 parts 
of colour reagent A to 1 part colour reagent B) was introduced rapidly by pipette. The 
solution was incubated at room temperature for 20 min, and the absorbance measured using a 
spectrophotometer at 480 nm. A standard curve was generated by plotting the absorbance of 
the standards against 5 – 50 µg of protein and used to determine the protein concentrations of 
the samples. 
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The 2D Clean-up Kit (BioRad) was used to remove salts and other contaminants that may 
affect isoelectric focusing (IEF). The method was carried out according to the manufacturer’s 
instructions. In summary, a maximum of 100 µl (1 – 500 µg) protein solution was added to 
300 µl of ‘precipitating agent 1’ and vortexed for 30 s. The solution was incubated on ice for 
15 min before 300 µl of ‘precipitating agent 2’ was added and vortexed for 30 s. The solution 
was centrifuged (20,000 × g, 5 min, 4°C) to remove the supernatant, followed by a pulse spin 
to remove any residual liquids. Wash reagent 1 (40 µl) was added to the pellet and vortexed 
to resuspend the pellet. The sample was centrifuged (20,000 × g 5 min, 4°C) to remove wash 
reagent 1, followed by addition of 25 µl of milliQ water and vortexing until the pellet was 
redissolved. Wash reagent 2 (1 ml) and Wash additive (5 µl) were added and the mixture and 
vortexed for 1 min. This was incubated at -20°C for 30 min, with 30 s vortexing at 10 min 
intervals and centrifuged (20,000 × g , 5 min, 4°C) to remove the supernatant, followed by a 
pulse spin to remove residual liquids. The pellet was air dried for 5 min, changing from white 
to translucent. It was then resuspended in 75 µl of cell lysis buffer and vortexed until proteins 
were fully dissolved. The samples were stored at -80°C for up to 12 months. Protein 
quantification was repeated with the 2D Quant Kit prior to saturation-DIGE labelling.   
 
2.4.4 Saturation-DIGE (labelling and gel electrophoresis)  
CyDye DIGE Fluor Labeling Kit for scarce samples (GE Healthcare) was used for saturation-
DIGE; the method was carried out according to the manufacturer’s instructions for analytical 
gels. Optimisation of this technique was performed with the whole cell lysates of 3 CRC cell-
lines (CaCo, LIM1215 and HT29) and 6 patient samples (ACPS B tumours and controls). 
Saturation-DIGE and data analysis were performed on 16 CRC patient samples (4 tumours 
and controls from each ACP stage). Cy3 and Cy5 dye powder was reconstituted in 
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dimethylformamide (DMF) to give a 2 mM working solution. That was vortexed, 
centrifuged, and stored for up to 8 weeks at -20°C. The global standard was generated by 
pooling the lysates of all tumours and controls. The protein concentration was quantified 
using the 2D Quant Kit. For each Saturation-DIGE gel, 10 µg of the protein sample and 10 
µg of global standard were made up to 9 µl with cell lysis buffer in separate tubes. Reducing 
solution, TCEP (1 µl), was added to each of the protein lysates and mixed by pipetting. The 
tubes were incubated at 37°C in the dark for 1 h. Cy Dye solution (2 µl) was added to each 
tube (Cy3 to global standards and Cy5 to a sample) and mixed by pipetting. The tubes were 
incubated for 30 min at 37°C. The reaction was quenched with an equal amount of stop 
mixture and the two tubes combined. The final volume was made up to 300 µl with 
isoelectric focusing (IEF) rehydration buffer. This solution was pipetted along the well of a 
rehydration tray and a 17 cm pH 3-10 non-linear IEF strip placed gel side down over the 
solution, to allow for overnight in-gel rehydration. The gel strips were transferred to an IEF 
tray and covered with mineral oil to prevent drying. IEF focusing was conducted with a six-
step process (3 h at 100 V, 2 h at 300 V, 2 h at 1 kV, 2 h at 2.5 kV, 99,999 Vh at 5 kV and a 
hold step for 24 h at 100 V). After focusing, the IPG strips were equilibrated for 20 min in 
equilibration buffer, then transferred into a second dimension polyacrylamide gel (8 – 18% 
linear gradient) and sealed with overlay solution. Second dimensional electrophoresis was 
carried out using a Protean Plus Dodeca cell (Bio-Rad) at 10
o
C following a three-step 
program, 50 V for 30 min, followed by 100 V for 16 h then 200 V for 1 – 1.5 h for the dye to 
run off the bottom of the gel. The analytical gels were scanned with a Typhoon FLA 9000 
Biomolecular Imager (GE Healthcare) using the Cy3 and Cy5 filters. Image quantification 
and statistical analysis (student’s t-test and ANOVA) were conducted with Progenesis 
SameSpot version 4.1.3884.12788.  
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Parallel preparative gels were run for spot cutting and peptide digestion. CyDye DIGE Fluor 
Labelling Kit for scarce samples (GE Healthcare) was used for the preparative gel. The 
method was carried out according to the manufacturer protocols for preparative gel. The 16 
CRC patient samples were pooled into tumour or normal lysate. Nine preparative gels were 
created, 6 to optimise the method and 3 were used for spot cutting, each gel contained 500 µg 
of protein made up to 250 µl with cell lysis buffer. Reducing solution TCEP (1 µl) was added 
and mixed by pipetting. The tubes were incubated at 37°C in the dark for 1 h.  Cy5 dye 
solution (20 µl) was added to each tube then mixed by pipetting. The tubes were incubated 
for 30 min at 37°C for labelling. Ampholytes (2% (v/v)) and DTT (13 mM) were added to 
quench the reaction. The final solution was made up to 300 µl with rehydration buffer. The 
solution was pipetted along the well of a rehydration tray and a 17 cm pH 3-10 non-linear 
isoelectric focusing strip placed gel side down over the solution, covered with 1 – 2 ml 
mineral oil and left at room temperature to rehydrate overnight. The IEF and gel 
electrophoresis protocol for preparative gels was identical to that of analytical gels.  
A double staining procedure was used for spot visualisation on preparative gels. Gels were 
left in fix/wash solution for 2 h, then stained with Sypro Ruby overnight. Gels were briefly 
washed in fix/wash for 1 h before being scanned on a Typhoon FLA 9000 Biomolecular 
Imager using Sypro Ruby filter (filter: LPB 510LP, wavelength: 510 nm). Gels were 
transferred to Coomassie blue working solution (4 parts Coomassie stock solution and 1 part 
methanol), covered with cling wrap and left on a shaker overnight. Gels were immersed in 
Coomassie destain for 1 h before being scanned using GS-800 calibrated densitometer 
(fluorescent white, 12-bit pixel density). Gels could then be kept in sealed plastic bags with 
10 ml of Coomassie destain for up to 6 months.    
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2.4.5 Peptide digestion and MS identification 
Differential spots were cut out using a Harris Uni-core (2 mm) spot cutter. Each gel plug was 
transferred to a LoBind tube and washed with destain until all Coomassie stain was removed. 
The gel plugs were washed with 100% (v/v) acetonitrile, at which point the gel plug changed 
from translucent to solid white. A vacuum centrifuge (30 min, 40°C) was used to completely 
dry the plugs. Plugs were immersed in trypsin solution (10 µl), then incubated for 1 h at 4°C, 
after which they became translucent. Following the incubation, trypsin residues were 
removed and 15 µl of ammonium bicarbonate (20 mM) was added prior to overnight 
incubation at 37°C. The gel plug solution was adjusted to pH 2 with formic acid prior to C18 
ZipTip purification. To purify peptides, C18 ZipTips were rehydrated in 2 washes with 
wetting solution, C18 columns were activated with 2 aliquots of wash solution, samples were 
pipetted slowly 10–15 times to allow peptide binding, peptides were washed twice with wash 
solution, and eluted with elution solution into LoBind tubes. The peptides were vacuum 
centrifuged (30 min, 40°C) to dry, before adding 45 µl of HPLC solution and transferring to a 
LoBind plate for HPLC.       
Prior to MS analysis, peptides from each gel plug fraction were fractionated using a strong 
cation exchange column (ZORBAX Bio-SCX series II, 3.5 mm, 50 x 0.8 mm) on an Agilent 
1100 HPLC system in off-line mode. The peptides (30 µg) were loaded onto the column with 
SCX buffer A (25% (v/v) acetonitrile, 0.05 % (v/v) formic acid, pH 2.5). The peptides were 
eluted from the column with SCX buffer B (25% (v/v)) acetonitrile, 0.5 M ammonium 
formate, 2% (v/v) formic acid, pH 2.5 using a gradient of 0 - 20% over 42 min, 20 – 100% 
SCX buffer B over 14 min and 100% SCX buffer B for 5 min. Fractions (30) were collected 
for each sub-cellular fraction at 2 min intervals, using a Probot micro-fraction collector. 
 Chapter 2 Material and methods 
38 
 
Prior to loading the samples, a LC-MS standard was run to test the performance and dynamic 
range of the instrument (0.1 µM BSA, 20 nM fetuin, 0.1 µM GluFib and 10 nM renin in 0.5% 
(v/v) acetonitrile with 0.01% (v/v) formic acid). The gel plug peptides were analysed using a 
Agilent 1100 HPLC system interfaced with a QSTAR Elite mass spectrometer. Peptides were 
diluted with wash/HPLC solution and loaded onto a C18 trap column (ZORBAX 300SB-
C18, 300 µm × 5 mm, 5 µm) at 10 µl/min and washed for 7 min before switching the trap 
column in line with the C18 separation nanocolumn (ZORBAX 300SB C18, 3.5 µm, 150 × 
0.1 mm). The peptides were eluted directly into the ionisation source of the mass 
spectrometer at 0.3 µl/min with the following gradient: 0 min, 5% solvent B; 8 min, 5% B; 10 
min, 15% B; 90 min, 30% B; 105 min, 60% B; 115 min, 5% B; 120 min, 5% B.  
The nano-LC-ESI-MS/MS system was set to perform data acquisition in the positive ion 
mode, with a selected mass range of 350-1750 m/z. Peptides with +2 to +4 charge states were 
selected for tandem mass spectrometry, and the time of summation of MS/MS events was set 
to 2 s. The three most abundantly charged peptides above a count threshold >30 were selected 
for MS/MS and dynamically excluded for 30 s with (50 milli-mass units mass tolerance). The 
instrument acquired data in information dependent acquisition (IDA) mode, using Analyst QS 
2.0 software. Automatic collision energy and automatic MS/MS accumulation modes were 
used in the advanced IDA settings.  
The data files from each 2D gel experiment were analysed using ProteinPilot 3.0 software, 
which uses the Paragon
TM
 algorithm to perform protein identification. All MS/MS spectra 
were searched against a combined Swiss-Prot protein database, version uni_sprot_20070123. 
Parameters set in ProteinPilot 3.0 were set to: Fixed modifications (oxidation (m), 
propionamide (c)), Enzyme digestion (trypsin), Species (Homo sapiens), Peptide tolerance 
(0.2), MS/MS tolerance (0.2), Peptide charge (+2 and +3) and Instrument (ESI-QUAD-TOF). 
The following processing options were used: quantitative, bias correction, background 
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correction, biological modifications and thorough identification search. A concatenated 
target-decoy database search strategy was also employed to estimate the rate of false 
positives. Only proteins identified with at least 95% confidence and ProtScore of >300 were 
reported. 
 
2.4.6 Explorer antibody microarrays 
Technique optimisation was performed on 2 CRC patient samples. The subsequent analysis 
was performed on whole cell lysate from 12 patient samples (3 tumours and controls from 
each ACP stage). The protein extraction and purification procedures were carried out with the 
Explorer Micorarray Protein Extraction Kit (FullMoon). In summary, the buffer exchange 
spin column was prepared by adding 650 µl labelling buffer, vortexed for 20 s to remove all 
air bubbles and left at room temperature to hydrate for 1 h. Once hydrated, the spin columns 
were centrifuged (750 × g, 2 min, 25°C) to remove excess fluid. The single cell suspension 
was thawed quickly from cryostorage in a 37°C water bath and washed with PBS. The cell 
pellet was lysed down with extraction buffer (100 µl for 2.5×10
6
 cells) and lysis beads. The 
mixture was incubated on ice for 1 h and vortexed for 60 s at 10 min intervals. The mixture 
was centrifuged (20,000 × g, 15 min, 4°C) and the clear supernatant collected. Protein extract 
(100 µl) was transferred to the spin column. Care was taken not to disturb the gel layer. The 
columns were placed into collection tubes and spun at 750 × g for 2 min to collect the 
purified protein fraction. The concentration and purity of protein was quantified using a 
Nanodrop 3300. Samples were blanked with labelling buffer, and absorbance recorded at 260 
nm and 280 nm. Purified protein solutions were stored at -80°C for up to 12 months.        
Protein (100 µg) was made up to a final volume of 75 µl with labelling buffer. Biotin 
working solution (3 µl, 10 µg/µl biotin reconstituted in dimethylformamide) was added to the 
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protein solution and incubated at room temperature for 2 h with occasional mixing. Left-over 
biotin working solution was stored at -20°C. Following incubation, 35 µl of stop reagent was 
added and the biotinylated protein was incubated at room temperature for 30 min with 
occasional mixing.          
The Explorer antibody microarray (FullMoon) can be stored at 4°C for up to 6 months. 
Before use, each microarray was left at room temperature in the packaging for 45 min before 
opening to air dry for 15 min. The microarray slide was submerged, antibody side up, in 
blocking solution (30 mg/ml skim milk powder in blocking reagent) and placed on an orbital 
shaker at 55 rpm for 45 min at room temperature. Following blocking, the slide was placed in 
a 50 ml tube filled with milli-Q water and inverted for 20 s. The water was replaced and the 
washing process repeated at least 10 times, or until residual water was uniform on the slide 
surface. The slide was placed into a well of the coupling chamber. Care was taken not to let 
the slide dry out. 
The biotin labelled protein solution was added to 6 ml of coupling solution (30 mg/ml skim 
milk powder in blocking reagent) and vortexed; the whole mixture was poured onto the slide 
contained within a coupling chamber. After 2 h incubation at room temperature on an orbital 
shaker at 35 rpm, the slide was transferred to a petri dish and submerged in 30 ml of 1× wash 
solution and shaken on an orbital shaker at 55 rpm for 10 min at room temperature. The 1 × 
wash solution was replaced and the wash procedure repeated twice. The microarray was 
placed into a 50 ml tube filled with milliQ water and inverted for 20 s. The water was 
removed and the washing process repeated at least 10 times, or until residual water was 
uniform on the slide surface.  
Detection solution was prepared by adding Cy3-streptavidin to detection buffer to a final 
concentration of 0.5 mg/ml. The microarray was submerged in detection solution (30 ml) in a 
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petri dish and incubated in the dark on an orbital shaker at 55 rpm for 20 min at room 
temperature. Following fluorescence labelling, the slide was transferred to another petri dish 
and submerged in 30 ml of 1× wash solution and shaken on an orbital shaker at 55 rpm for 10 
min at room temperature. The 1× wash solution was replaced and the wash procedure 
repeated twice. The microarray was placed into a 50 ml tube filled with milli-Q water and 
inverted for 20 s. The water was replaced and the washing process repeated at least 10 times 
or until residual water was uniform on the slide surface. The slide was placed in an empty 50 
ml tube and quickly dried by centrifugation at 600 × g. Microarrays were scanned with a 
Typhoon FLA 9000 Biomolecular Imager and fluorescence quantified using ImageQuant TL. 
The quantified results were exported to MultiExperiment Viewer and statistical analysis (two 
tailed student t-test, ANOVA) was performed.  
 
2.4.7 DotScan antibody microarrays 
The optimisation of DotScan to analysis CD antigesns on solid CRC tumour cells has been 
discussed in detail (Zhou, 2008, Zhou et al., 2010). Disaggregated cells were brought out of 
cryostorage (-80°C) in a 37°C water bath and washed with HBSS to remove DMSO. Cell 
pellets were treated with DNAse solution to remove any nucleic acid released during 
thawing. The cell pellet was resuspended to a final volume of 10 ml with HBSS and the 
Trypan blue exclusion method was conducted with 10 µl of the cell mixture and equal parts 
of Trypan blue. An optimal count of 6 × 10
6
 viable epithelial cells was required for cell 
capture on DotScan microarray. The appropriate number of cells was pelleted and 
resuspended in 200 µl of RPMI 1640, pH 7.3. 
DotScan microarrays (MedSaic) were stored at 4°C with desiccant for up to 1 year. Before 
use, microarrays were allowed to warm up at room temperature (10 - 20 min). Microarrays 
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were pre-moistened in PBS for 30 s and placed in the incubation chamber. The cell 
suspension was added to the moist nitrocellulose section, introducing drops to each corner to 
ensure an even spread of cells. The microarrays were incubated at 37°C for 1 h. Following 
incubation, unbound cells were washed off by 5 gentle vertical dips in PBS. DotScan fixative 
solution was added to cover the whole microarray. After fixation for 20 min at room 
temperature, the fixative was washed off with 5 vertical dips in PBS and cell binding was 
recorded by optical scanning using the DotScan scanner to provide the antigen expression 
pattern of a mixed cell population, mainly CRC cells, leukocytes and stromal cells. 
Microarrays were not allowed to dry before the next step. 
Microarrays were blocked in 200 µl blocking buffer for 20 min at room temperature, to 
prepare for fluorescence multiplexing. Excess blocking buffer was poured off and 150 µl 
multiplexing solution (phycoerythrin-anti-CD3, Alexa Fluor 647-anti-EpCAM) was added 
and incubated in the dark at room temperature. Unbound antibodies were washed off with 5 
vertical dips in PBS. The microarrays were left to dry in the dark. These could be stored at 
4°C in the dark for up to 3 months without significant loss of fluorescence. Dried microarrays 
were scanned for PE and Alexa Fluor 647 with a Typhoon FLA 9000 scanner (Phycoerythrin 
with 532 nm excitation laser and 580 BP30 emission filter; Alexa Fluor 647 with 633 nm 
excitation laser and 670 BP30 emission filter) with resolution set to 50 µm. Images (.png) 
were adjusted to 17 × 25 cm and resolution 72 pixels/inch and uploaded on to DotScan 
analysis software for quantification. The DotReader (MedSaic) captures a digital image of the 
dot binding pattern and quantifies the density of cell binding on each antibody dot on an 8 bit 
greyness scale (1-256 U). Occasional non-specific isotype control binding occurred and was 
subtracted from binding values for antibodies of corresponding immunoglobulin isotypes. 
The MultiExperiment Viewer (MeV) software suite was used for data normalisation (log2 
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median centring), cluster generation (hierarchical clustering, Euclidean distance, complete 
linkage) and data analysis (2-tailed student’s t-test).          
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Chapter 3 
Proteomic alterations during 
colorectal cancer progression 
 
 
 
 
 
3.1 Introduction  
The first published accounts of CRC evolution were by Morson (Morson, 1974) and Muto et 
al. (Muto et al., 1975). They described the histopathological evolution of CRC based on 
tumour size, differential grade and histological type. In the following year, Peter Nowell 
(Nowell, 1976), published a landmark perspective on cancer as an evolutionary process that 
is driven by step-wise, somatic cell mutations with sequential, sub-clonal selection. Since 
then, studies have implicated mutational and epigenetic changes for the phenotypic traits 
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acquired by CRC and firmly established CRC progression as one of the best-characterised 
models of this multistep process (Fearon and Jones, 1992, Kinzler and Vogelstein, 1996). 
Modern cancer biology is taking the next logical step towards understanding cancer evolution 
through the emerging field of proteomics.  
Cancer is a complex and dynamic disease and a prime target for proteomic research. 
Proteomic analysis can define and characterise regulatory and functional networks, identify 
molecular defects in diseased tissue, and identify biomarkers to diagnose a particular disease 
or stage of a disease. In the past few years, there has been substantial interest in applying 
proteomic methods to the discovery of therapeutic targets and biomarkers for the early 
diagnosis of CRC (Friedman et al., 2004, Alfonso et al., 2005, Uhlen et al., 2005, Bi et al., 
2006). The majority of these proteomic studies have focused on finding differential proteins 
between tumour and normal colorectal tissue. Currently, very little information is available 
on changes in protein expression at different stages of CRC progression. Research into 
modulation of the CRC proteome during tumour development would provide critical insight 
into the dynamic states of the cancer ecosystem and the changing phenotype. Such proteomic 
analysis of CRC would also contribute a novel protein perspective to the well-established 
genetic model of cancer evolution (Greaves and Maley, 2012).   
 
This PhD project investigates the modulation of the CRC proteome at each Australian 
ClinicoPathological Stage (ACPS) of CRC development (ACPS A-D). To obtain accurate 
protein profiles, we have used fresh CRC and normal colon tissue, disaggregated into viable 
single cells, and depleted of CD45 positive leukocytes. The fractionated tumour and normal 
cells were analysed by two complementary protein discovery techniques: saturation DIGE 
and antibody microarrays. Building on knowledge from past research, we have shown that 
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several tumour-associated pathways, such as proliferative self-renewal, aerobic glycolysis, 
angiogenesis and the ER stress response, were altered in tumours compared to normal tissue, 
and modulated at specific stages of tumourigenesis. Pathway analysis revealed that the 
proteomic phenotype reflected the intra- and extra-cellular selection driving CRC progression 
(Figure 3.1). 
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Figure 3.1 Model for proteome-environment interactions in CRC (adapted from Figure in Gatenby and Gillies, 2004, Nature Reviews). The stages of CRC growth and their associated 
proteomic phenotypes are diagrammed, showing that progression from one stage to the next is governed by several selection factors. Normal epithelial cells (grey cells) become 
hyperproliferative (dividing nucleus) following oncogenic induction (nuclei shown as blue in normal cells and orange for tumorigenic mutation). Over-expression of proliferation pathways and 
the deregulation of growth factors (green circles) initiate the first stage of tumour development (purple cells). Cancer cells also reduce adhesion molecules and produce proteases (blue circle) 
to escape contact inhibition imposed by neighbouring cells and the ECM. As cancer cells reach the oxygen diffusion limit, they become hypoxic (blue cells), which can lead to cell death 
(apoptotic cells shown with blebbing), increased angiogenesis (red circles) and emergence of the glycolytic phenotype (green cells). As a consequence of increased glycolysis, tumours become 
acidotic, which selects for apoptosis- and stress-resistant cells (red cells). Eventually, the combination of acidosis and limited substrates leads to motile cells with metastatic phenotypes (yellow 
cells) and breach of the basement membrane. Interaction between cancer cells and blood cells exposes them to increased oxidative stress, cancer cells respond by increased expression of redox 
and ubiquitin-proteasome associated proteins.   
45 
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3.2 Results 
Extensive proteomic profiles were obtained from fresh CRC cells depleted for CD45
+
 
leukocytes. Tumour and adjacent normal intestinal mucosa were collected from 28 CRC 
patients (Table 3.1). Protein profiles were compared between tumour and healthy mucosal 
tissue, ACP stages, and presence of metastasis. Additional factors were considered when 
relevant to the protein of interest.   
 
Table 3.1. Clinico-pathological characteristics of the 28 patients  
 
Saturation-DIGE  
(n=16) 
Explorer microarray 
(n=12) 
Gender No. patients (%) No. patients (%) 
Male 7 (44%) 8 (67%) 
Female 9 (56%) 4 (33%) 
Age   
≤65 3 (19%) 6 (50%) 
>65 13 (81%) 6 (50%) 
ACPS   
A 4 (25%) 3 (25%) 
B 4 (25%) 3 (25%) 
C 4 (25%) 3 (25%) 
D 4 (25%) 3 (25%) 
Differentiation   
Well 0 (0%) 0 (0%) 
Moderate 13 (81%) 12 (100%) 
Poor 3 (19%) 0 (0%) 
TIL   
Present 5 (31%) 3 (25%) 
Absent 11 (69%) 9 (75%) 
Inflammation
†
   
Present 7 (44%) 7 (58%) 
Absent 9 (56%) 5 (42%) 
Mucin*   
Prominent 5 (31%) 3 (25%) 
Scant 11 (69%) 9 (75%) 
ACPS (Australian clinico-pathological staging), TIL (Tumour infiltrating lymphocytes); 
*mucinous tumours (over 30% mucin) 
†
Presence of peri-tumoural inflammation  
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A total of 16 CRC patient samples were analysed by saturation-DIGE and differentially 
abundant spots were excised from three replicate preparative gels and identified by HPLC 
coupled with tandem MS/MS. A reference 2D map of CRC proteins was established (Figure 
3.2); 1159 spots were clearly detected; of these 72 differentially abundant spots were excised 
and 45 unique proteins were identified (Table 3.2). Most of the identified proteins were 
glycolytic enzymes and mitochondrial proteins, involved in the tricarboxylic acid cycle and 
ATP energy metabolism, and metabolite carriers. After statistical analysis of the normalised 
quantities of matched spots, 7 up-regulated and 11 down-regulated proteins were identified in 
CRC tissue compared to controls (Table 3.2a); one-way ANOVA identified 30 spots altered 
between the CRC stages (Table 3.2b). The one-way ANOVA analysis indicated that the 
greatest variation was between tumours with lymph node metastases and those without. 
Comparative analysis between these two groups showed 18 up-regulated and 5 down-
regulated proteins in metastatic CRC, compared to non-metastatic CRC (Table 3.2c).     
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Figure 3.2 A representative 2D map of proteins from CRC. Proteins (5 µg) from 
16 tumour samples (4 per ACP stage) and their corresponding controls (total 32 
gels) were separated on a pH 3-10 NL IPG strip in the first dimension and by 8-
18% acrymlamide SDS-PAGE in the second dimension. Differential spots were 
excised from three preparative gels and identified by RP-LC and tandem 
MS/MS analyses. Spots are labelled numerically and identified proteins are 
listed in Table 3.2.   
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Table 3.2 Significantly altered proteins in CRC cells identified by saturation-DIGE and RP-LC MS/MS. Only proteins with 95% confidence 
interval were selected. 
a) Altered proteins between tumour and normal tissue 
Spot Protein Access #
a
 Score Seq. (%) Function Mass (Da) pI Fold p-value
b,c
 
Elevated in CRC cells         
365 60 kDa heat shock protein (Hsp60) P10809 3133 68 Protein folding 61,016 5.70 1.7 9.81E-04 
382 60 kDa heat shock protein (Hsp60) P10809 2935 73 Protein folding 61,016 5.70 2.6 7.49E-07 
1122 Peroxiredoxin-1 (prdx-1) Q06830 636 50 Redox balance 22,096 8.27 1.6 2.13E-04 
1133 Manganese superoxide dimutase (MnSOD) P04179 518 63 Redox balance 22,176 8.35 1.5 3.03E-04 
1135 MnSOD mutant Q143n P04179 1510 58 Redox balance 22,176 8.35 1.5 4.81E-05 
1136 Peroxiredoxin-1 (Predx-1) Q06830 2020 51 Redox balance 22,096 8.27 1.6 2.74E-06 
1137 Peroxiredoxin-1 (Predx-1) Q06830 310 53 Redox balance 22,096 8.27 1.8 5.45E-07 
Reduced in CRC cells 
128 Aconitate hydratase Q99798 1388 51 Krebs cycle 85,372 7.36 2.1 1.11E-05 
129 Aconitate hydratase Q99798 1344 45 Krebs cycle 85,372 7.36 1.9 2.92E-05 
130 Aconitate hydratase Q99798 1618 50 Krebs cycle  85,372 7.36 2.2 7.23E-05 
131 Aconitate hydratase Q99798 1527 55 Krebs cycle 85,372 7.36 2 2.00E-03 
476 Glutamate dehydrogenase P00367 789 30 Nitrogen metabolism 61398 7.66 3.5 3.75E-10 
485 ATP synthase subunit alpha P25705 1393 51 ATP synthesis 59,714 9.16 3.4 3.87E-09 
660 Acyl-CoA dehydrogenase P16219 1326 47 Lipid metabolism 43,615 7.01 2 1.03E-05 
678 Acyl-CoA dehydrogenase P16219 1326 38 Lipid metabolism 43,615 7.01 2.1 1.11E-05 
793 Malate dehydrogenase precursor P40925 548 31 Krebs cycle 35,509 8.92 1.6 7.48E-05 
837 
Delta (3,5)-delta (2,4)-dienoyl-CoA 
isomerase 
Q13011 1346 54 Lipid metabolism 35,793 8.16 1.9 4.44E-06 
957 Proteasome subunit alpha type 2 P25787 573 51 Proteolysis 25,899 7.29 2 4.70E-07 
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b) One-way ANOVA analysis between all CRC stages 
Spot Protein Access #
a
 Score Seq. (%) Function 
Mass 
(Da) 
pI Elevated stage(s) Fold p-value
b,c
 
219 Glucose-regulated protein (GRP78) P11021 1480 41 Protein folding 72431 5.07 Stage B 2.3 0.004 
275 Calreticulin P27797 1090 49 Protein folding 48297 4.29 Stage C 1.6 0.032 
329 Heat shock protein (Hsp60) P10809 1541 60 Protein folding 61016 5.70 Stage C, Stage D 1.8 0.002 
340 Vimentin P08670 1265 59 Structural 56747 5.98 Stage B 1.7 0.006 
341 Protein disulfide-isomerase A3 (PDI) P30101 1411 62 Protein folding 56747 5.98 Stage A, Stage B 1.5 0.048 
342 Protein disulfide-isomerase A3 (PDI) P30101 1678 64 Protein folding 56747 5.98 Stage B, Stage C 1.6 0.043 
449 Adenylyl cyclase-associated protein Q01518 770 48 Structural 51869 8.24 Stage B 1.9 0.048 
516 Alpha-enolase isoform 1 P06733 1391 72 Glycolysis 47139 7.01 Stage B 1.6 0.030 
520 Alpha-enolase isoform 1 P06733 1291 74 Glycolysis 47139 7.01 Stage B 2.1 0.025 
553 Elongation factor Tu (EF-1α) P49411 1053 49 Translation 49509 7.70 Stage C, Stage D 2 0.032 
560 Elongation factor Tu (EF-1α) P49411 2001 52 Translation 49509 7.70 Stage B 1.7 0.025 
571 Isocitrate dehydrogenase (IDH) O75874 1894 57 Redox balance 46630 6.53 Stage C, Stage D 2 0.046 
595 Annexin A2 P07355 1027 33 
Protein 
degradation 
38618 7.10 Stage B 2.3 0.020 
718 Phosphoglycerate kinase 1 P00558 1621 51 Glycolysis 44586 8.30 Stage C 1.4 0.026 
719 
28S ribosomal protein S22 
(MRPS22)* 
P82650 1307 68 Translation 41254 7.70 Stage C 1.5 0.004 
750 Alcohol dehydrogenase (ADH)* P14550 885 61 
Ethanol 
oxidation 
36550 6.32 Stage C, Stage D 1.7 0.011 
755 
Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) 
P04406 906 55 Glycolysis 36030 8.57 Stage C, Stage D 1.7 0.046 
758 L-lactate dehydrogenase B chain P07195 713 54 Glycolysis 36615 5.71 Stage C 1.5 0.032 
760 m7GpppX diphosphatase Q96C86 383 29 
mRNA 
regulation 
38585 5.93 Stage C, Stage D 1.7 0.035 
777 
Heterogeneous nuclear 
Ribonucleoprotein H3 (hnRNP H3)  
P31942 466 44 DNA repair 36903 6.37 Stage C 2.5 0.025 
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788 
Heterogeneous nuclear 
Ribonucleoproteins A2/B1 (hnRNP 
A2/B1) 
P22626 877 46 DNA repair 35984 8.67 Stage C 1.6 
0.041 
794 Inorganic pyrophosphatase Q15181 927 59 
Phosphate 
metabolism 
32639 5.54 Stage C 3.3 0.002 
806 
3-Mercaptopyruvate sulfur 
transferase isoform 1 
P25325 4431 69 
Sulfide 
metabolism 
35228 6.14 Stage C, Stage D 1.5 0.011 
828 
WD repeat-containing protein 61 
(WDR61)* 
Q9ERF3 1021 57 Transcription 33560 5.16 Stage A 2.3 0.012 
847 Porin 31HM* P21796 2104 69 
Apoptosis/ 
glycolysis 
30623 8.63 Stage C 1.5 0.037 
853 Carbonic anhydrase 1 P00915 1259 65 
Hypoxia 
response 
28852 6.59 Stage C, Stage D 2 0.033 
924 
Endoplasmic reticulum resident 
protein 29 isoform 1 precursor 
(ERp29) 
P30040 639 47 
Protein 
transport 
28975 6.77 Stage C, Stage D 1.9 0.042 
1013 ES1 protein homolog P30042 476 57 Unknown 28153 5.80 Stage A, Stage B 1.7 0.027 
1131 
Manganese superoxide dismutase 
(MnSOD) 
P04179 396 30 Redox balance 22176 8.35 Stage C, Stage D 2.1 0.024 
1152 
PEST proteolytic signal-containing 
nuclear protein (PCNP)* 
Q6P8I4 468 46 Proteolysis 18913 6.86 Stage C, Stage D 2.6 0.013 
 
c) Differential proteins between non-metastatic and metastatic tumours 
Spot Protein Access #
a
 Score Seq. (%) Function Mass (Da) pI Fold  P-value
b,c
 
Elevated in metastatic CRC  
329 60kDa heat shock protein (mito) P10809 1541 60 Protein folding 61016 5.7 1.3 0.031 
571 Isocitrate dehydrogenase (NADP) Cyto O75874 1894 57 Kreb cycle 46630 6.53 1.5 0.027 
599 Reticulocalbin-1 precursor (RCN1) Q15293 1141 53 Ca2
+
 metabolism 38866 4.86 1.3 0.025 
750 alcohol dehydrogenase* P14550 885 61 Ethanol oxidation 36550 6.32 1.3 0.048 
755 Glyceraldehyde-3-phosphate dehydrogenase P04406 906 55 Glycolysis 36030 8.57 1.4 0.014 
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760 m7GpppX diphosphatase Q96C86 383 29 mRNA regulation 38585 5.93 1.5 0.005 
777 Heterogeneous nuclear ribonucleoprotein H3  P31942 466 44 DNA repair 36903 6.37 1.7 0.048 
794 Inorganic pyrophosphatase Q15181 927 59 Phosphate metabolism 32639 5.54 2.0 0.002 
806 3-Mercaptopyruvate sulfur transferase  P25325 4431 69 Sulfide metabolism 35228 6.14 1.3 0.007 
815 Proteasome activator hPA28 subunit beta Q9UL46 228 24 Proteolysis 31821 5.42 1.4 0.040 
846 Proteasome subunit alpha type-1 isoform 2* P25786 503 57 Proteolysis 29537 6.15 1.5 0.011 
853 Carbonic anhydrase 1 P00915 1259 65 Hypoxia response 28852 6.59 1.5 0.017 
874 ER resident protein 29 isoform 1 (ERp29) P30040 639 47 Protein folding 28975 6.77 1.6 0.038 
924 ER resident protein 29 isoform 1 (ERp29) P30040 639 47 Protein folding 28975 6.77 1.4 0.036 
924 ER resident protein 29 isoform 1 (ERp29) P30040 639 47 Protein folding 28975 6.77 1.4 0.036 
1131 Manganese superoxide dismutase (MnSOD) P04179 396 30 Redox balance 22176 8.35 1.5 0.038 
1133 MnSOD mutant Q143n P04179 518 63 Redox balance 22176 8.35 1.4 0.032 
1134 Manganese superoxide dismutase (MnSOD) P04179 890 45 Redox balance 22176 8.35 1.6 0.005 
1152 
PEST proteolytic signal-containing nuclear 
protein (PCNP)* 
Q6P8I4 468 46 Proteolysis 18913 6.86 1.3 0.007 
Reduced in metastatic tumours         
341 Protein disulfide-isomerase A3 (PDI) P30101 1411 62 Protein folding 56747 5.98 1.5 0.032 
342 Protein disulfide-isomerase A3 (PDI) P30101 1678 64 Protein folding 56747 5.98 1.6 0.012 
350 Protein disulfide-isomerase A3 (PDI) P30101 1894 67 Protein folding 56747 5.98 1.5 0.019 
949 Peroxiredoxin-4 precursor (prdx-4) Q13162 1089 54 Redox balance 30521 5.86 1.5 0.044 
923 
Electron transfer flavoprotein subunit beta 
isoform 1 
P38117 27826 51 Electron transport 27826 8.24 1.6 0.040 
949 Peroxiredoxin-4 precursor (prdx-4) Q13162 1089 54 Redox balance 30521 5.86 1.5 0.044 
923 Electron transfer flavoprotein subunit beta  P38117 27826 51 Electron transport 27826 8.24 1.7 0.040 
1013 ES1 protein homolog P30042 476 57 Unknown 28153 5.8 1.5 0.003 
 
a
Reference for protein identification using SWISS-Prot database 
b
Saturation-DIGE and preparative gels were scanned on a Typhoon scanner 
c
Data analysis was conducted with Progenesis SameSpot 
*Novel protein and/or expression pattern associated with CRC development 
Abbreviations: ECM (extracellular matrix), ER (endoplasmic reticulum 
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A total of 12 patient samples were analysed with Explorer microarrays. Each microarray 
contains a duplicate panel of 657 antibodies, of which up to 375 antibodies showed protein 
binding (Figure 3.3) and 42 differential proteins were identified. Most of these proteins were 
of nuclear origin, involved in DNA regulation and repair, transcription, and stress response. 
After statistical analysis of the normalised results identified 20 up-regulated and 2 down-
regulated spots in CRC cells compared to control mucosa (Table 3.3a); one-way ANOVA 
identified 21 spots significantly altered between stages (Table 3.3b). The one-way ANOVA 
analysis indicated that the greatest amount of variation was between individual stages of CRC 
progression. T-test between different stages (ACPS A versus B, ACPS B versus C, and ACPS 
C versus D) identified a further 27 differentially abundant proteins not present in the 
ANOVA results (Figure 3.3c-e).  
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Figure 3.3 A single panel from each antibody microarray showing an example of the protein binding profiles from four CRC samples at different 
ACP stages a) ACPS A, b) ACPS B, c) ACPS C and d) ACPS D. The antibody layout for Explorer microarray is in Appendix Figure 6.1. Proteins 
(100 µg) from 12 samples (3 per ACP stage) and their corresponding controls (total 24 microarrays) were analysed.  
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Table 3.3 Significantly altered proteins in CRC samples identified with Explorer microarrays. Only proteins with over 1.5 fold change and 95% 
confidence interval were selected.  
a) Differential proteins between tumour and normal mucosa tissue 
Protein Uniprot IDa Function Location Fold p-value
b,c
 
Elevated in CRC cells      
Granulocyte White blood cell Immune response Extracellular 4.6 0.004 
Alpha-1-antitrypsin (A1-AT) P01009 Protease inhibitor Extracellular 2.7 0.004 
Keratin 5/6/18 Multiple protein Cytoskeleton organisation Cytoplasm 3.2 0.005 
Keratin 8 P05787 Cytoskeleton organisation Cytoplasm 1.6 0.006 
CD171 P32004 Development Membrane 6.7 0.006 
Keratin 18 P05783 Cytoskeleton organisation Cytoplasm 4.0 0.009 
Prolactin Receptor P16471 Transmembrane receptor Membrane 4.0 0.009 
Keratin 5/8 P13647 Cytoskeleton organisation Cytoplasm 2.3 0.010 
Mitochondria Organelle Energy production Mitochondrial 3.5 0.014 
Keratin 8/18 Multiple protein Cytoskeleton organisation Cytoplasm 1.5 0.014 
Keratin, Multi Multiple protein Cytoskeleton organisation Cytoplasm 2.0 0.015 
Proteinase 3 (PR3)* P24158 Serine-type peptidase activity Lysosome 10.7 0.015 
Milk Fat Globule Membrane Protein Q08431 Cell adhesion molecule Membrane 4.3 0.024 
CREB-Binding Protein (CBP) Q92793 Transcription regulator Nucleus 3.1 0.030 
Alpha-1-antichymotrypsin (A1-Achy) P01011 Protease inhibitor Extracellular 2.5 0.030 
Epithelial Membrane Antigen (Muc1) P15941 DNA damage repair Membrane 3.4 0.033 
CEA / CD66e P06731 Cell adhesion Membrane 3.2 0.034 
Carbohydrate antigen 19-9 (CA19-9) P78552 Transmembrane receptor Membrane 10.9 0.043 
Reduced in CRC cells 
CDC47 P33993 Helicase activity Nucleus 2.4 0.025 
B-cell lymphoma/leukemia 10 (Bcl-10) O95999 Apoptosis Cytoplasm 1.7 0.033 
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b) One-way ANOVA analysis between all CRC stages 
Protein Uniprot ID
a
 Function Location Elevated stage(s)  P-value
b,c
 
p57  P49918 Cell communication Nucleus Stage A, Stage C 5.31E-04 
Vacular endothelial growth factor (VEGF) P15692 Cell communication Extracellular Stage A, Stage C 8.62E-04 
Gamma glutamyl transferase P19440 Metabolism Membrane Stage A 0.002 
CD40 P25942 Cell communication Cytoplasm Stage C 0.006 
Caspase 3 P42574 Apoptosis Cytoplasm Stage A 0.007 
Prostate Specific Antigen (PSA) P07288 Proteolysis Extracellular Stage A, Stage C 0.011 
Nucleophosmin (NPM) P06748 Ribosome assembly Cytoplasm Stage C 0.011 
CD16 P08637 Immune response Membrane Stage A, Stage C 0.011 
Proliferating cell nuclear antigen (PCNA) P12004 DNA repair Nucleus Stage A, Stage C 0.015 
Mek6* P52564 Regulation of cell cycle Nucleus Stage A, Stage C 0.019 
Von Willebrand factor (vWF) P04275 Protein metabolism Extracellular Stage A 0.023 
Transglutaminase II (TGM2) P21980 Metabolism Cytoplasm Stage C 0.031 
DNA repair protein XRCC2* O43543 DNA repair Nucleus Stage B 0.031 
Axonal growth cones Structural fibers Nervous system Extracellular Stage C 0.033 
Gab-1 Q13480 Cell communication Cytoplasm Stage A 0.039 
Moesin P26038 Cell adhesion Cytoplasm Stage A 0.047 
 
 
 
 
 
 
 
 
 
56 
 Chapter 3 Proteomic alterations during CRC progression 
59 
 
Differential proteins between CRC stages 
c) ACPS A versus A  
Protein Uniprot
a
 Function Location Fold change P-value
b,c
 
Reduced in ACPS B      
Synaptophysin P08247 Cellular response Cytoplasm 15.0 0.006 
Caspase 1 P29466 Apoptosis Cytoplasm 6.0 0.017 
Laminin B1/b1 P07942 Cell adhesion ECM 3.0 0.021 
NF kappa B/p65 Q04206 Transcription regulation Nucleus 3.0 0.025 
HDJ-2 Q9NXZ8 Protein folding Cytoplasm 12.0 0.026 
DNA fragmentation factor subunit alpha O00273 Inhibitor  Cytoplasm 3.0 0.029 
Raf kinase (Raf) P04049 Kinase Membrane 6.0 0.033 
Cyclic AMP-responsive element-binding protein 1 (CREB)  P16220 Differentiation/Transcription Nucleus 4.0 0.035 
p130 Q8NE70 Regulation of cell cycle Nucleus 19.0 0.038 
Matrix metalloproteinase-16 (MMP-16)* P51512 Protease ECM 5.0 0.044 
Cullin-3*  Q13618 Transport Golgi apparatus 2.0 0.045 
Ras Protein family Signal transduction Intracellular 2.0 0.047 
E-Cadherin P12830 Cell adhesion Membrane >100 0.050 
d) ACPS B versus C 
Elevated in ACPS C      
Transcription factor E2F-5* Q15329 Transcription Nucleus >100 0.006 
p73 O15350 Apoptosis Cytoplasm 41.0 0.007 
CD63 P08962 Vesicle localisation Membrane 2.0 0.015 
Rhodopsin P08100 Sensory transduction Membrane 5.0 0.016 
Survivin O15392 Apoptosis Centromere 4.0 0.016 
CXC chemokine receptor type 4 (CXCR4) P61073 Signal transduction Membrane >100 0.029 
DNA fragmentation factor subunit alpha O00273 Inhibitor  Cytoplasm 3.0 0.047 
Caldesmon Q05682 Movement Cytoplasm 21.0 0.049 
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e) ACPS C versus D 
Protein Uniprot
a
 Function Location Fold change P-value
b,c
 
Reduced in ACPS D      
Neuron Specific Enolase P09104 Glycolysis Membrane 3.0 0.014 
CD63 P08962 Cellular protein localisation Membrane 2.0 0.014 
CD10 P08473 Metabolism Membrane 6.0 0.038 
CXC chemokine receptor type 4 (CXCR4) P61073 Signal transduction Membrane 14.0 0.042 
Notch P46531 Differentiation Membrane 4.0 0.048 
 
a
Reference for protein identification using SWISS-Prot database 
b
Intensity of the microarray binding was measured with ImageQuant TL 
c
Data analysis was conducted with TM4 MultiExperimentViewer v4.8 
*Novel protein and/or expression pattern in CRC 
Abbreviations: CD (cluster of differentiation), CEA (carcinoembryonic antigen), ECM (extracellular matrix) 
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3.3 Discussion 
Cancer is a disease of clonal evolution within the body (Merlo et al., 2006). The concept of 
an evolutionary problem is not new, but until recently most of the focus has been from a 
genetic or epigenetic perspective. Proteomics offers a fundamental perspective on cancer 
evolution. It allows researchers to observe through protein expression, the heterogeneity 
between cancer cells, selection-induced phenotypic changes, and the consequences of this 
selection. This is one of the first proteomic studies to determine alterations in the CRC 
proteome at different stages of primary tumour development. Fresh CRC samples were 
collected, disaggregated into viable single cells, and depleted of CD45
+
 leukocytes. Two 
proteomic discovery techniques were used, saturation DIGE analysis and Explorer antibody 
microarrays, to obtain ‘molecular snapshots’ of the CRC proteome at the 4 ACP stages of 
development. These proteomic data have mapped out the progression of CRC, with selection 
for proliferation and subsequently, metastasis. Unrestricted proliferation of CRC is driven by 
activated proliferation pathways and reduced cell cycle regulators. This rapid growth 
consumes substrates, and waste accumulates, leading to apoptosis evasion, aerobic glycolysis, 
and the ER stress response. Prolonged stress then selects for motile cells and the metastatic 
phenotype. Increased proliferation and angiogenesis enables cancer cells to invade 
surrounding tissue and to colonise distant sites (Figure 3.1).  
In total, 38 differential proteins have been identified between tumour and normal tissue, and 
101 differential proteins between CRC stages. Interestingly, most proteins detected by 
saturation-DIGE were localised to mitochondria or the endoplasmic reticulum, while the 
majority of proteins identified by Explorer microarrays were of cytoplasmic or nuclear origin. 
These differences may be attributed to differences between the 2D gel-based and antibody 
microarray techniques. 2D gel electrophoresis does not resolve most membrane associated 
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proteins and is limited to detecting proteins of medium abundance, such as those involved in 
glycolysis and protein folding. Antibody microarrays are unhindered by high abundance 
proteins but are limited by antibody availability and specificity, and may not detect proteins 
with multiple isoforms.  
The one-way ANOVA analysis of data from each technique revealed disparate protein 
expression patterns, and therefore branching statistical analysis was applied to the data. Most 
of the differentially expressed proteins identified by saturation-DIGE distinguished non-
metastatic CRC from metastatic CRC. In contrast, the Explorer microarray was better at 
identifying proteins that were differential between the 4 stages of tumour progression. Whilst 
there was no specific protein overlap between the 2 techniques, a number of common 
biological pathways were implicated by the proteins identified by the two techniques. This 
discussion will follow the differential protein expression at each ACPS of CRC progression. 
The changes in protein composition will be discussed, along with their functional 
significance.   
 
3.3.1 Proliferation  
Normal cellular proliferation is controlled by the interactions of a cell with surrounding cells, 
the extracellular matrix (ECM), and levels of growth factors. Regulated cell growth occurs in 
close proximity to blood vessels and within the diffusion limits of oxygen and glucose, 
survival in normal tissue is not constrained by substrate availability (Gatenby and Gillies, 
2004). Therefore, early stages of carcinogenesis require alterations in cellular sensitivity to 
normal growth constraints, rather than adaptations for limited resources. The genetic model 
of CRC progression involves mutations in genes controlling proliferation. Mutations in the 
APC and K-ras genes are early events, while survival gene mutations such as those on 
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chromosome 18q (related to DCC and SMAD4 genes) and mutations in p53 are associated 
with late events in CRC (Fearon and Vogelstein, 1990). 
 
3.3.1.1 Initiators of proliferation 
In ACPS A we found over-expression of several proteins commonly associated with CRC 
proliferation, including the signalling proteins (Gab-1, Ras and Raf; Tables 3.3b and 3.3c), 
oncogene transcription factors (NF-κβ, cyclic AMP-responsive element-binding protein 1 
(CREB), CREB-binding protein (CBP); Tables 3.3a, and 3.3c), DNA replication proteins 
(proliferating cell nuclear antigen (PCNA) and WD repeat-containing protein 61 (WDR61; 
Tables 3.2b and 3.3b).  
Proliferation starts with activation of growth signalling cascades, for example, MAPK/ERK 
is deregulated in ~30% of cancers (Fang and Richardson, 2005), and is initiated by activation 
of the MET (mesenchymal-epithelial transition factor) signalling pathway. Gab-1 is a 
docking adaptor protein, involved in MET activation, that plays a critical role in sustained 
signalling (Maroun et al., 1999) and activates most c-Met-dependent biological functions (Gu 
and Neel, 2003). Following MET activation, the Ras/Raf/MEK/ERK cascade is activated. 
That in turn activates transcription factors for several proto-oncogenes.  
Another proliferation pathway involves the oncogenic transcription factor, NF-κB, regulates 
expression of several anti-apoptotic and tumourigenesis genes used by the cancer to mediate 
cell survival and proliferation (Baldwin, 2001). NF-κβ is activated by various carcinogens 
and tumour promoters (Inoue et al., 2007).  
CREB and CBP are transcription factors only recently found to be involved in cancer 
development. The role of CREB in cancer was identified by Shankar et al. (Shankar et al., 
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2005). Higher CREB was found in acute myeloid leukemia (AML), where it may enhance S-
phase entry and promote growth-factor-independent proliferation. CREB, along with CBP 
and its homolog p300, coordinate a number of transcriptional pathways, including survival, 
proliferation and glucose metabolism (Conkright and Montminy, 2005). Elevated CBP and its 
homolog p300, have been found in CRC; however only p300 over-expression is an indicator 
of poor prognosis, while high CBP correlates with survival (Ishihama et al., 2007).  
Activation of proto-oncogenes increases replication and mitosis. PCNA and WDR61 are both 
required for completion of DNA replication. PCNA accumulates in late G1 and early S-
phase, it is rarely observed in quiescent cells, while WDR61 is a part of the RNA polymerase 
II-associated factor 1 (PAF1). We observed the highest levels of PCNA in ACPS A and C 
primary CRC tumours (Table 3.3b), consistent with rapid cellular proliferation during these 
stages of tumour development. Past research has shown PCNA-positive cells in CRC to be 
inversely related to survival times (Mayer et al., 1993). WDR61 was found elevated in ACPS 
A tumours. Its over-expression has been reported in a poorly differentiated pancreatic cancer 
cell line (Chaudhary et al., 2007). Furthermore, the targeted over-expression of this gene in a 
mouse embryonic fibroblast cell line led to transformation of the cells (Takahasi et al., 2011). 
Quantification of PCNA and WDR61-positive cells may help to decide whether further 
treatment should be administered to patients with local disease, because chemotherapy affects 
mainly dividing cells and should, therefore, be most successful against rapidly proliferating 
tumours.  
 
3.3.1.2 Growth factors 
During early tumourigenesis, signalling pathways that mediate the normal functions of 
growth factors are commonly subverted. The loss of, or reduced requirement for, specific 
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growth factors may help cancer cells evade growth constraints. Mutational changes that 
increase the ability of cancer cells to produce, and respond to, their own autocrine growth 
factors would increase proliferation. We observed the over-expression of 2 serine proteases 
and a growth factor receptor: proteinase 3 (PR3), which confers growth factor-independent 
proliferation, and prostate specific antigen (PSA) and prolactin receptor, which may promote 
proliferation through autocrine, insulin-like growth factor-1 (IGF-1) (LeRoith and Roberts, 
2003) and prolactin (Ben-Jonathan et al., 2002), respectively.  
We observed higher PR3 levels in all tumour cells compared to controls (Table 3.3a); this is 
the first report of elevated PR3 in CRC. The serine protease, PR3, can confer growth factor-
independence on mouse haematopoietic cell lines, and PR3 transfection increases 
proliferation (Desmedt et al., 2006). When aberrantly expressed, PR3 is able to cleave several 
intracellular proteins involved in the cell cycle and differentiation (Lutz et al., 2000). 
Inhibition of the PR3 breast cancer cell line with WGM2 anti-PR3 monoclonal antibody 
induces the opposite effect: increased differentiation and blocked proliferation (Horman et 
al., 2000).  
Another serine protease found at elevated levels in ACPS A and C was PSA (Table 3.3b). 
This protein was originally found in prostate cells, making it a viable marker for early 
detection of prostate cancer. However, PSA has been found in other cancers, including 30% 
of CRC (Levesque et al., 1995). In the tumour micro-environment, PSA has a proteolytic role 
in cleaving a number of proteins involved in tumour proliferation and invasion. PSA cleavage 
of insulin-like growth factor binding protein-3 (IGFBP-3), the major serum binding protein 
for insulin-like growth factor-1 (IGF-1), reduces IGFBP-3 binding to IGF-1 and in turn can 
increase proliferation in response to added IGF-1 (Cohen et al., 1994). PSA may also cleave 
extracellular matrix glycoproteins such as fibronectin and laminin, promoting cell migration 
and metastasis (Webber et al., 1995).   
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All CRC tumours from our study were prolactin receptor positive with 92% showing higher 
than control levels (Table 3.3a). The deregulated production of prolactin might act via 
autocrine mechanisms (Manni et al., 1990), that require prolactin receptor. Prolactin receptor 
over-expression induces mammary carcinoma in prolactin positive mice (Wennbo et al., 
1997). Transcripts of prolactin and its receptor, have been observed during progression of 
CRC from adenomas to liver metastasis (Nagano et al., 1995).   
 
3.3.1.3 Immune suppression 
Elevated levels of α-1-antitrypsin (A1-AT) and α-1-antichymotrypsin (A1-Achy) were 
found in all CRC tissues but not in controls (Table 3.3a). These proteins inhibit several serine 
proteases involved in blood coagulation, fibrinolysis, and inflammatory and immunologic 
processes (Bernacka et al., 1988). Past studies reported increased A1-AT at the invasive CRC 
margin correlating with shorter patient survival times in non-metastatic CRC (Karashima et 
al., 1990). A1-AChy is elevated in the sera of CRC patients (Bradham and McClay, 2006) but 
not in cancer cells. Expression of the protease inhibitors A1-AT and A1-Achy may protect 
cancer cells from the immune response. Leukocytes are frequently found in tumours, 
recruited there as a physiological response to cancer-specific antigens, and tissue injury 
during tumour development. A1-AT can modulate immune responses to favour tumour cells, 
by neutralisation of the lytic signal passed between natural killer (NK) cells and target (Ades 
et al., 1982), and can act as an endothelial cell growth and survival factor (McKeehan et al., 
1986).  
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3.3.1.4 Suppression of regulators 
Following the initial stages tumour progression, many of proliferation-associated proteins 
elevated in ACPS A were reduced in ACPS B, most only returning in the later metastatic 
phase of tumour development (Table 3.2b and 3.3b). The similarities between early 
tumourigenesis and initial metastasis observed here involve a resurgence of several 
proliferation proteins and markers of aggressive cell division in ACPS C. We predict that the 
over-expression of proliferation-associated proteins confers a selective advantage to the 
cancer cells in their microenvironment. Expansion of pre-metastatic cancer would eventually 
be limited by availability of substrates, as cell proliferation carries the population further 
from its blood supply (Gatenby and Gawlinski, 1996) (Figure 3.1). It follows that aggressive 
proliferation would become self-limiting, at least while the basement membrane remains 
intact. At the same time, environmental pressures are selecting for new phenotypes in cancer 
cells to maintain cell division by reducing cell cycle regulators (e.g. E2F5, p130, p57 and 
MEK6 to avoid senescence or apoptosis.  
We observed reduced expression of the cell cycle regulators, p130 and E2F5, in ACPS B, 
followed by an increase in E2F5 in early metastasis (Table 3.3c and 3.3d). This is the first 
report of differentially abundant E2F5 in CRC. Past studies have reported high levels of E2F5 
in early-stage ovarian cancer (Kothandaraman et al., 2010) due to an initial immune response 
to arrest proliferation during the initial stage of CRC. E2F5 binds to p130 during G0 and G1 
phases and inhibits cell cycle progression. Coinciding with CRC progression, reduced E2F5 
would enable proliferation. As the cell progress to late G1 phase, p130 is phosphorylated by 
cyclin dependent kinases. Simultaneously, p130 is targeted for ubiquitin-mediated 
degradation, its levels fall, and E2F5 is shuttled from the nucleus to the cytoplasm (Tsantoulis 
and Gorgoulis, 2005). The fact that E2F5 is no longer bound to p130 may allow binding to 
the antibody microarray and account for the increase in detectable E2F5 proteins for later 
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stage of CRC. An alternative theory proposes that the E2F5 gene that maps to 8q21, is part of 
a region frequently amplified in cancers, that also contains the c-myc and c-mos proto-
oncogenes. Amplification of the E2F5 gene, followed by increased transcription has been 
reported in breast cancer (Polanowska et al., 2000).  
p57, another inhibitor of cell cycle, is lower in ACPS B (Table 3.3b). p57 blocks the cyclin 
dependent kinase (CDK) transition from G1 through to S phase in the cell cycle. Clinical data 
suggest that p57 functions as a tumour suppressor; mutations in the p57 gene are found in 
sporadic cancers and Beckwith-Wiedemann syndrome, a familial cancer syndrome 
(Matsuoka et al., 1995). Noura et al. (Noura et al., 2001) showed that low levels of p57 in 
CRC correlated with large tumour size.  
Mek6 is a stress-induced negative regulator of the cell cycle. The reduced expression of 
Mek6 observed in ACPS B tumours was followed by its resurgence in ACPS C (Table 3.3b). 
To date, no expression data for Mek6 in CRC have been published. Mek6 expression is 
common in oncogenic transformations and may reflect a futile attempt to compensate for loss 
of p53 in the later stages of tumourigenesis (Wong et al., 2001). Increased levels of Mek6 in 
neoplasms are associated with the activation of p38, MAPK and casein kinase 2 (CK2) stress 
response pathways. Up-regulation of Mek6, along with its downstream partner p38, has been 
reported to correlate with the development of ovarian cancer and transformed cell lines 
(Wong et al., 2001).  
 
3.3.1.5 Breaking contact inhibition 
Normal cell growth is restricted by contact inhibition imposed by surrounding cells and the 
ECM. Tumourigenesis relies on cells breaking contact with their neighbours, breaking down 
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surrounding ECM and migrating into the extracellular medium. Compared with normal 
epithelium, cancer cells usually show diminished inter-cellular adhesiveness (Cavallaro and 
Christofori, 2004). Our data show alterations in the levels of adhesion and cytoskelectal 
proteins during early CRC progression, down-regulation of E-cadherin, laminin B1/b1, 
moesin and caldesmon, and up-regulation of CD171, annexin A2 and cytoskeletal 
organisation keratin 5/6/8/18 and vimentin. Down-regulation of adhesion molecules often 
coincides with secretion of proteolytic enzymes, such as matrix metalloproteinases. 
Breakdown and penetration of the ECM provides space into which the cells can move and 
generates gradients in diffusible and fixed ECM proteins for direction of cells (Murphy and 
Gavrilovic, 1999).  
The adhesion protein, E-cadherin, decreased in ACPS B (Table 3.3c). The loss of E-cadherin 
leads to the dissociation of cells from their tissue (Behrens et al., 1985). There is a strong 
correlation between lack of E-cadherin with progression and lymph node metastasis in CRC 
(Gupta and Massague, 2006). In contrast, the adhesion protein CD171, was more abundant in 
tumour cells than control (Table 3.3a). CD171, a neural cell adhesion molecule, is expressed 
at the invasive front of CRC and is associated with tumour progression (Boo et al., 2007, 
Kaifi et al., 2007). CD171 can be cleaved by metalloproteinases at the tumour cell surface 
and in soluble form may aid micro-metastasis (Kaifi et al., 2007). 
Reduced expression of the structural proteins, laminin B1/b1 and moesin in ACPS B (Tables 
3.3b and 3.3c) also indicates reduced cell adhesion. Decreased expression of laminin has 
been implicated in abnormal behaviour of malignant cells (Christensen et al., 1988). Reduced 
extracellular laminin binding to corresponding cell surface receptors, including various 
integrins, decreases the redistribution of cytoskeletal and focal adhesion proteins (Huang and 
Chakrabarty, 1994). Moesin serves as a general cross-linker between plasma membranes and 
actin filaments. Moesin has been detected at low levels in CRC cell lines and in cancer cells 
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in vivo, but found at higher levels in surrounding stromal cells (Nishizuka et al., 2003). A 
decrease in moesin may result from increased cancer cell to stroma ratio.  
The lowest level of Caldesmon was found in ACPS B CRC (Table 3.3d). The actin-binding 
protein caldesmon, negatively regulates the formation and dynamics of podosomes and 
invadopodia in smooth muscle cells, which are mediators of cancer cell invasion, forming 
highly dynamic cell-adhesion structures that degrade the ECM by secreting matrix 
metalloproteases. Evidence suggests that actin and its associated proteins facilitate 
podosomes/invadopodia formation (Albiges-Rizo et al., 2009) and the actin-binding protein 
caldesmon, negatively regulates podosome formation (Yoshio et al., 2007). Yoshio et al. 
(Yoshio et al., 2007), found more invadopodia and increased invasion in caldesmon depleted 
rat fibroblasts (3Y1/BY1), human colon carcinoma (HCA7) and breast cancer cell lines 
(B16F10).  
In contrast, Annexin A2 peaked during ACPS B, followed by a gradual reduction as tumours 
became metastatic (Table 3.2b). A similar trend in annexin A2 levels was observed between 
the metastatic CRC cell line, SW620, and its non-metastatic counterpart, SW480 (Katayama 
et al., 2006). There are several possible mechanisms by which annexin A2 may be involved 
in early tumour cell detachment and invasion. Annexin A2 interacts with tissue-type 
plasminogen activator to facilitate fibrinolysis. In addition, it forms a complex with cathepsin 
B that can initiate proteolytic cascades and degrade ECM proteins (Duncan et al., 2008).  
Matrix metalloproteinases are the best known family of endopeptidases, collectively capable 
of degrading essentially all components of ECM. We observed elevated levels of matrix 
metalloproteinases-16 (MMP-16) in ACPS A CRC (Table 3.3c). This novel finding may 
relate more to the role of MMP-16 as a MMP-2 activator rather than its ECM degradation 
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properties because MMP-2, unlike MMP-16, can degrade type IV collagen in the basement 
membrane enabling accelerated tumour growth and metastasis (Papathoma et al., 2000). 
 
3.3.2 Selection  
Pre-metastatic tumours are often highly vascular as metastatic tumours, but only 
macroscopically. Although a pre-metastatic tumour may have a vascularised stroma, the 
cancer cells are separated from their blood supply by a basement membrane (Figure 3.1). 
Blood vessels are confined to the stromal compartment and, therefore, early development of 
the malignant phenotype occurs in an avascular environment. As a result, substrates, such as 
oxygen and glucose, must diffuse from the vessels across the basement membrane and 
through layers of tumour cells. Models for this diffusion and consumption show near-zero 
partial pressures of oxygen (pO2), only 100 µm from a capillary (Helmlinger et al., 1997). 
Pre-metastatic tumours, with an intact basement membrane, will develop hypoxic regions 
near the oxygen diffusion limit. Persistent proliferation leads to thickening of the epithelial 
layer, pushing cells away from their blood supply. Hypoxia in pre-metastatic tumours has not 
been measured directly, but is consistent with the frequent observation of necrosis in CRC 
tumours, exceeding 20 mm, and the expression of hypoxia-inducible enzyme, carbonic 
anhydrase, in late stage CRC (Tables 3.2b and 3.2c).  
 
3.3.2.1 Molecular response to hypoxia 
The characteristics of hypoxic tumours can be explained, in part, by the up-regulation of a 
number of hypoxia-inducible genes mediated by the activation of the transcription factor, 
hypoxic inducible factor-1α (HIF-1α) (Semenza, 2002). Recently, the tumour-associated 
 Chapter 3 Proteomic alterations during CRC progression 
72 
 
carbonic anhydrase was reported to be a new class of HIF-1 responsive gene (Wykoff et al., 
2000). Studies have shown an important causal link between hypoxia, extracellular 
acidification, and the enhanced expression of carbonic anhydrase in human tumours (Ivanov 
et al., 2001). Expression of hypoxia-inducible carbonic anhydrase-9 is linked to expression of 
proteins involved in angiogenesis, apoptosis inhibition, and cell-cell adhesion disruption in 
small cell lung cancer (Giatromanolaki et al., 2001). In our study, carbonic anhydrase 
expression correlated with metastatic CRC tumours. Similar reported expression of carbonic 
anhydrases I and II have been linked to biological aggressiveness and synchronous distant 
metastasis in CRC (Bekku et al., 2000). 
 
3.3.2.2 Angiogenesis 
Angiogenesis was the first response by CRC cells under hypoxic stress. Vascular endothelial 
growth factor (VEGF), and endothelial marker, Von Willebrand factor (vWF), were both 
elevated during ACPS A (Table 3.3b).  
VEGF is a signalling protein for stimulation of vasculogenesis and angiogenesis. VEGF is 
strongly expressed in several human solid tumours and correlates with the density of 
microvessels in CRC (Takahashi et al., 1995). vWF, a glycoprotein produced uniquely by 
endothelial cells and megakaryocytes, is routinely used to identify vessels in tissue sections. 
VEGF alone can up-regulate vWF mRNA and protein in human endothelial cells (Zanetta et 
al., 2000). We observed significantly higher VEGF and vWF expression in ACPS A and 
stage C tumours compared to all other stages (Table 3.3b). Apart from its role as an 
angiogenesis marker, vWF has been implicated as a promoter of metastasis. There is a direct 
interaction between vWF and cancer cells, through the expression of adhesive ligands for 
vWF (Nierodzik et al., 1992). These interactions promote the binding of malignant cells to 
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platelets, creating heterotypic aggregates that can slip past the immune system undetected and 
are capable of adhering to endothelial surfaces (Floyd et al., 1992).  
Despite the increased angiogenesis, these new capillaries are separated from the tumour cells 
by the basement membrane, which means the diffusion of substrates to cancer cells remains 
largely unaltered. For early cancers, angiogenesis may not relieve hypoxia because of the 
separation between vessels and the cells they feed. Angiogenesis-associated proteins decrease 
following ACPS A, and glycolysis-associated proteins increase for ACPS B. The resurgence 
of angiogenesis, in ACPS C, only occurs following breach of the basement membrane. Only 
then can vascularisation of the tumour be achieved by co-opting pre-existing vessels within 
the stroma and promoting new capillary growth directly into the tumour mass (Gatenby and 
Gillies, 2004). 
 
3.3.2.3 Emergence of the glycolytic phenotype 
Most cancer cells produce ATP by a high rate of glycolysis, with lactic acid produced in the 
cytosol. Comparatively, normal cells have a lower rate of glycolysis, with oxidation of 
pyruvate in mitochondria (Warburg, 1956). Most normal cells prefer to completely oxidise 
glucose to CO2 and H2O under aerobic conditions, but in cancer cells there is a shift toward 
lactate production, even in the presence oxygen. This phenomenon is termed the “Warburg 
effect” or aerobic glycolysis (Warburg, 1956). Persistent or cyclical hypoxia subsequently 
exerts selective pressure that leads to up-regulation of glycolysis. This constitutive up-
regulation might occur through mutations or epigenetic changes such as alteration in the 
methylation patterns of promoters (Gatenby and Gillies, 2004).  
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Evidence for aerobic glycolysis in this study was the increased abundance of several key 
enzymes involved in glycolysis, alpha-enolase, glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and phosphoglycerate kinase 1, as well as the over-expression 
of lactic acid fermentation protein, L-lactate dehydrogenase. These enzymes were 
significantly higher in ACPS B and ACPS C (Table 3.2b).  
A novel protein yet to be associated with CRC glycolysis is porin 31HM, found in the 
mitochondrial outer membrane (Lawen et al., 2005). Traditionally, porin 31HM has been 
associated with the pro-apoptotic proteins Bax and Bak, and the release of cytochrome C 
(Shimizu et al., 1999). Porin 31HM is known to be up-regulated in malignant liver cancer 
(Shinohara et al., 2000), but the increased expression of porin 31HM during CRC 
development (Table 3.2b) has not been reported. In spite of porin’s role in regulation of cell 
death, the differential expression of porin may be more related to glycolysis. Expression of 
porin 31HM is known to coincide with hexokinase I and II (HKI and HKII) expression in 
tumour cells (Shinohara et al., 2000). To enable rapid growth, tumour cells increase the 
activities of enzymes involved in glycolysis. Tumour mitochondria have a higher HK binding 
capability than normal cells, which is facilitated by up-regulation of porin 31HM.  
Consistent with the Warburg effect, there was an impaired aerobic citric acid cycle in CRC as 
evidenced by reduced expression of aconitate hydratase and malate dehydrogenase (Table 
3.2a). Glutamate dehydrogenase, involved in the production of α-ketoglutarate, was also 
reduced in tumour cells (Table 3.2a). These proteins are known to be down-regulated in CRC 
tissue compared to normal mucosa (Bi et al., 2006). 
Mutations in mitochondrial DNA may impair oxidative phosphorylation in cancer (Polyak et 
al., 1998). Data from several studies, including our own, show reduced expression of key 
mitochondrial proteins required for synthesis of ATP. The down-regulation of ATP synthase 
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subunits, β-F1-ATPase (Willers et al., 2010) and reduced α-F1F0-ATPase (Table 3.2a) 
supports the Warburg efftect hypothesis with reduction of oxidative phosphorylation in most 
cancer cells. Decrease of ATPase in our CRC samples is accompanied by reduction of 
proteins involved in mitochondrial energy transduction, electron transfer flavoprotein, 
delta(3,5)-delta(2,4)-dienoyl-CoA isomerase and acyl-CoA dehydrogenase (Tables 3.2a 
and 3.3c). 
 
3.3.2.4 Surviving acidosis 
Up-regulation of glycolysis is a successful adaptation to hypoxia but increases acid 
production. Prolonged exposure to acid stress typically results in necrosis or apoptosis 
through p53- and caspase-3-dependent mechanisms (Park et al., 1999). Therefore, 
constitutive up-regulation of glycolysis requires additional adaptations against the negative 
effects of extracellular acidosis, through resistance to apoptosis or up-regulation of membrane 
transporters to maintain normal intracellular pH. In support of this theory we observed the 
down-regulation of several caspase-associated apoptotic proteins (B-cell 
lymphoma/leukaemia 10 (Bcl-10), caspase 1, caspase 3 and DNA fragmentation factor), 
coinciding with glycolysis in ACPS B CRC (Table 3.3a, b, c).  
Bcl-10 is a caspase-recruitment domain protein involved in the induction of apoptosis and 
activation of the NF-κB complex. Activation of NF-κB complex is connected to pro-
proliferation roles in oncogenesis (Baldwin, 2001) and may be the result of deregulation due 
to Bcl-10 gene mutation, rare in CRC (Stone et al., 1999). We observed a decrease in Bcl-10 
in CRC compared to normal mucosa (Table 3.3a), the decrease in Bcl-10 expression may be 
attributed to its pro-apoptotic role. Previous studies support the pro-apoptotic role of Bcl-10; 
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its over-expression in human embryonic kidney cells (Willis et al., 1999) and in transformed 
cell-lines (Srinivasula et al., 1999) correlates with increased apoptosis.   
Caspase 1, caspase 3 and DNA fragmentation factor were all reduced in ACPS B compared 
to ACPS A (Table 3.3b and 3.3c). Caspases are part of the cysteine-aspartic acid protease 
family and are essential activators in the caspase cascade involved in apoptosis. Caspase 1 is 
an initiator caspase that cleaves inactive pro-interleukin 1β to generate the pro-inflammatory 
cytokine interleukin 1β (Thornberry et al., 1992). Caspase 3 is the ultimate executioner 
caspase that is essential for the nuclear changes associated with apoptosis (Woo et al., 1998). 
Downstream of Caspase 3, DNA fragmentation factor induces DNA fragmentation and 
chromatin condensation during apoptosis (Wolf et al., 1999).  
The combination of acidosis and uncontrolled proliferation of cancers increases the 
probability of DNA damage during cell replication; consequently, there may be over-
expression of DNA repair proteins. One form of DNA repair is through homologous 
recombination; the central protein involved in this pathway is RAD51. This protein ensures 
high fidelity DNA repair by facilitating strand exchange between damaged and undamaged 
homologous DNA segments. Several RAD51-like proteins, including XRCC2, facilitate this 
process (Tambini et al., 2010). Overexpression of XRCC2 is most prevalent in ACPS B 
(Table 3.3b). Variations in the XRCC2 gene may be associated with increased risk of CRC 
(Curtin et al., 2009). The associated protein, RAD51, is constitutively over-expressed in 
several cancer cell lines, and may protect tumour cells from undergoing apoptosis in response 
to DNA damage.  
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3.3.2.5 Endoplasmic reticulum response 
The tumour microenvironment can perturb endoplasmic reticulum (ER) functions. Stress 
factors, in particular, hypoxia, nutrient limitation, and low pH promote activation of 
signalling pathways, from the ER, that are activated by accumulation of misfolded/unfolded 
proteins in the ER (Schroder and Kaufman, 2005). The ER responds to these stresses by 
activating signal transduction pathways that protect against stress-induced apoptosis. 
Alterations in ER protein levels, post-translational modifications, or abnormal secretion of 
ER-resident proteins, are hallmarks of ER deregulation. Levels of the ER chaperone glucose-
regulated protein (GRP) 78, are increased in at least 10 cancers (Moenner et al., 2007). 
GRP78 is the chaperone for Hsp70 and facilitates protein folding and assembly in response to 
extracellular stresses (Brown and Giaccia, 1998). Our results show that GRP78 levels peaked 
during ACPS B (Table 3.2b), and may confer resistance to pro-apoptotic changes (e.g, 
protein denaturation).  
Another Hsp70 chaperone, HDJ-2, was reduced in ACPS B (Table 3.3c). Consistent with 
previous findings that HDJ-2 is absent or reduced in CRC tissue (Kanazawa et al., 2003). 
GRP78 chaperone may confer greater benefits to the tumour during development.   
Disulfide-isomerase A3 (PDI) and endoplasmic reticulum protein 29 (ERp29) are closely 
related proteins involved in secretory protein production (Shnyder and Hubbard, 2002). PDI 
was elevated in non-metastatic CRC tumours (Tables 3.2b and 3.2c). Stierum et al. (Stierum 
et al., 2003) observed a similar increase of PDI levels at the beginning of the differentiation 
process in CaCo-2, a CRC cell-line. Caco-2 in post-confluent phase differentiates into a cell 
type with remarkable small intestinal enterocyte-like features. The association of PDI and 
differentiated cancer cells may explain its reduced expression in metastatic tumours. PDI is 
also involved in peptide binding to major histocompatibility complex (MHC) class I 
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molecules in the ER (Lammert et al., 1997). Reduced expression of PDI in late stage CRC 
could indicate a possible mechanism to avoid immune detection.  
Some ER proteins were over-expressed during late tumourigenesis, coinciding with 
metastatic transformation and are discussed below. Previous studies suggest they possess 
secondary functions as adhesion protein regulators and may contribute to the metastatic 
phenotype.   
Elevated levels of endoplasmic reticulum protein ERp29 were observed in metastatic CRC 
(Table 3.2b), indicating an ER stress response. Similar ERp29 levels have been reported in 
skin basal-cell carcinoma (Cheretis et al., 2006) and CRC serum (Kim et al., 2009). 
Elevated levels of calreticulin were observed in ACPS C tumours (Table 3.2b), consistent 
with previous reports of elevated calreticulin in CRC (Brunagel et al., 2003). Calreticulin is a 
multifunctional protein, that acts as a chaperone for protein folding. Studies have correlated 
elevated ER specific calreticulin in various cancer models with enhanced resistance to stress 
(Delom et al., 2007). Additionally, calreticulin modulates steroid hormone receptors and 
retinoic acid receptors. It is also involved in the regulation of cell adhesion via interaction 
with the α-subunits of integrins (Brunagel et al., 2003).  
Up-regulation of Reticuloclabin-1 (RCN1) was observed in metastatic CRC (Table 3.2c), 
consistent with the report of RCN1 levels correlating with metastasis and reduced expression 
of Ca
2+
-dependent cadherin in breast cancer and CRC cell lines (Nimmrich et al., 2000). 
RNC1 is a protein reported to reside in the ER lumen and has a classic ER retention signal, 
C-terminal Lys-Asp-Glu-Leu sequence. The function of RCN1 is unknown, but it may play a 
role in Ca
2+
 dependent cell adhesion and intracellular Ca
2+
 metabolism (Nimmrich et al., 
2000).  
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3.3.3 Metastasis 
Hypoxia and acidification are strong selection forces affecting evolution of the metastatic 
phenotype. Most solid tumours eventually metastasise. Fidler (Fidler, 1970) attempted to 
quantify metastasis by tracking cancer cells with 
125
I-iodo-deoxyguanidine. His study showed 
that within 24 of entry into the circulation, fewer than 0.1% of tumour cells were still viable, 
and of those cells, fewer than 0.01% survived to produce metastases. The inefficiency of the 
metastatic process implies that healthy tissues display a marked hostility towards invading 
tumour cells. To achieve metastasis, cancer cells must therefore evade or co-opt multiple 
barriers that have been refined over hundreds of millions of years of organismal evolution. 
Therefore, several studies, including our own, have found metastasis to be a highly selective 
process; actively selecting for cancer cells with metastatic phenotype to increase metastatic 
success.  
 
3.3.3.1 Metastatic proliferation 
We observed an interesting expression profile during early metastasis (ACPS C), reminiscent 
of early tumourigenesis (ACPS A). The resurgence of proliferation-associated proteins 
observed in ACPS A (including PCNA and PSA; Table 3.3b), along with the up-regulation of 
other pro-proliferation/anti-apoptosis proteins (survivin, 60 kDa heat shock protein (Hsp60), 
transglutaminase II (TGM2) and notch; Tables 3.2b, c, d, e) indicate return to aggressive 
proliferation. This characteristic of ACPS C tumours may address the metastatic paradox, that 
in theory metastatic tumours should have a fitness disadvantage relative to non-metastatic 
tumours, owing to the loss of constituent cells that emigrate (Merlo et al., 2006). We predict, 
in response to this loss of cells, metastatic tumours increase proliferation to ensure successful 
colonisation of distant sites and to maintain heterogeneity within the primary population.  
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Survivin is a known inhibitor of apoptosis; in CRC it is a predictive indicator of poor 
prognosis and shorter survival rates (Kawasaki et al., 1998). Another pro-survival protein is 
mitochondrial Hsp60. Several studies show Hsp60 up-regulation in colonic polyps (Melis 
and White, 1999) and during colorectal carcinogenesis (Cappello et al., 2003). Both proteins 
were significantly higher in metastatic tumours compared to non-metastatic tumours. 
TGM2 levels were increased in ACPS C tumours (Table 3.3b). Several studies have reported 
that increased expression of TGM2 indicates prolonged cell survival and prevention of 
apoptosis in various cancers (Boehm et al., 2002). It is suggested that the induction of these 
signalling pathways is a result of TGM2 promoted interaction with ECM protein components 
in association with members of the integrin family of proteins (Herman et al., 2006). Other 
reports suggest that TGM2 regulates activation of NF-kB by forming a ternary complex with 
NF-kB/IkBa and inhibition of apoptosis through transamination and GTP-binding activity 
(Mann et al., 2006). A recent study by Miyoshi et al. (Miyoshi et al., 2010) found a 
correlation between high TGM2 mRNA in CRC and lymph node metastasis, tumour invasion 
and poorer post-operative survival rate.  
Notch signalling has also been shown to contribute to CRC development through the 
maintenance and self-renewal of cancer stem cells (CSC) (Sikandar et al., 2010). Notch 
signalling, along with associated notch proteins was reported to show 10- to 30-fold increase 
in CSCs compared to CRC cell lines (Sikandar et al., 2010). We found elevated notch 
expression in ACPS C cancer cells, followed by a reduction in ACPS D (Table 3.3e). The 
role of CSC in cancer metastasis has only recently been explored. The inherent characteristics 
of CSCs make them more adept at survival in a foreign environment. Tumour-initiating 
capacity and increased genetic instability in metastatic CSCs are likely to provide a selective 
advantage in adapting to foreign sites (Li et al., 2007a). Production of CSC with metastatic 
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potential may increase during ACPS C, followed by a reduction of these CSC in ACPS D, a 
result of metastatic CSCs migrating away from the primary tumour site.  
Surprisingly, some transcription regulators, that were reduced in ACPS B, are elevated in 
ACPS C (Mek6, E2F5 and p57 (Table 3.3b, d), along with the first appearance of p73 (Table 
3.3d). This may reflect a futile attempt of the transformed cell lines to compensate for a loss 
of p53 function or may possess beneficial functions during metastasis. 
p73 protein is homologous to p53, sharing common functions such as activating transcription 
of genes, inhibiting cell growth, and inducing apoptosis (Jost et al., 1997). However, 
activation of the p73 allele may also support tumour progression, as increased levels of p73 
mRNA transcripts are found in many tumour cells compared to their normal counterpart 
(Sunahara et al., 1998). In support of our results, the over-expression of p73 has been 
correlated with CRC metastasis and poorer survival (Sun, 2002).  
 
3.3.3.2 Ribosomes 
Further evidence of accelerated growth was observed through the up-regulation of 
translation- and ribosome-associated proteins. The ribosome assembly protein, 
nucleophosmin (NPM), was most abundant in metastatic stage C CRC (Table 3.3b), along 
with ribosome proteins, (elongation factor Tu (EF-1α) and 28S ribosomal protein S22 
(MRPS22); Table 3.2b) and translation regulators (M7GpppX diphosphatase, heterogeneous 
nuclear ribonucleoprotein (hnRNP) H3 and hnRNP A2/B1; Table 3.2b). Each of these is 
discussed below.  
NPM was found to peak in ACPS C tumours (Table 3.3b); similar NPM over-expression 
were found in bladder and breast cancer, where the increased NPM mRNA correlated with 
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tumour progression (Tsui et al., 2004, Skaar et al., 1998). Nozawa et al. (Nozawa et al., 
1996), showed that NPM, and its mRNA, increased in CRC adenomas when compared to 
normal mucosa; however its expression in tumours varied widely, with no direct correlation 
to proliferation.  NPM has proven to be a multifunctional protein that is involved in many 
cellular activities, including ribosome assembly and transport; it is related to both 
proliferative and growth-suppressive roles in cells. Due to these properties, NPM falls into a 
new category as a proto-oncogene and a tumour-suppressor. Depending on expression levels 
and gene dosage, either a partial functional loss of NPM or aberrant overexpression can lead 
to neoplastic transformation through distinct mechanisms (Grisendi et al., 2006).  
EF-1α expression was observed to increase with tumour progression (Table 3.2b). Its 
function supports our result, as EF-1α is a GTP-binding protein that catalyses the binding of 
aminoacyl-transfer RNAs to the ribosome, an essential step in translation (Moldave, 1985). It 
is likely that EF-1α functions as a tumour promoter by making cells competent for growth 
(Tatsuka et al., 1992). Previous research found higher EF-1α levels in CRC compared with 
normal tissue (Kuramitsu and Nakamura, 2006). Over-expression of EF-1α mRNA has been 
correlated with increased metastatic potential in mammary adenocarcinoma (Edmonds et al., 
1996). EF-1α from metastatic cells has reduced affinity for actin, the distribution of EF-1α 
and filamentous actin in the cytoskeletal structure is thought to be important for supporting 
the cellular motility required for metastasis.  
MRPS22 was found at the highest level in ACPS C tumours (Table 3.2b). Recent studies 
have correlated MRPS22 expression with Tiam1 (T-cell lymphoma invasion and metastasis-
inducing protein 1) up-regulation (Liu et al., 2008). They also found Tiam1 to promote 
tumour progression and increase metastatic potential in CRC cell lines (Liu et al., 2008). The 
down-stream expression of MRPS22, following Tiam1 over-expression, may contribute to 
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one or several of the pro-metastatic pathways, including inhibition of apoptosis, reduction of 
cellular adhesion (Minard et al., 2006) and increase in cell migration (Bassi et al., 2008).  
M7GpppX diphosphatase is a decapping scavenger enzyme that catalyses the cleavage of a 
residual cap structure following the degradation of mRNA by the exosome-mediated mRNA 
decay pathway (Gu et al., 2004). M7GpppX diphosphatase was more abundant in metastatic 
CRC compared to non-metastatic CRC (Table 3.2b, c). The 5’-cap structure (m7GppN, where 
m7G is 7-methylguanosine and N is the first nucleotide of the mRNA) plays a critical role in 
the life cycle of mRNA and is necessary for efficient gene expression and cell viability 
(Topisirovic et al., 2011).  
HnRNP is a family of proteins that bind RNA polymerase II transcripts to form hnRNP 
particles. To our knowledge, there have been no previous reports of the differential 
expression of hnRNP H3 and hnRNP A2/B1 in cancer (Table 3.2b). HnRNP H3 and hnRNP 
A2/B1, along with similar hnRNPs (H, H’, and F), are involved in pre-mRNA processing and 
in cellular differentiation. HnRNP H/H’ and F are up-regulated in gastric carcinomas (Honore 
et al., 2004) and play fundamental roles in controlling gene expression. Model studies have 
shown that they participate in alternative splicing of the c-src gene (Min et al., 1995), the β-
tropomyosin gene (Chen et al., 1999) and the thyroid hormone receptor gene (Hastings et al., 
2001). Furthermore, changes in their expression levels are important for various cellular 
differentiation processes (Liu et al., 2001). HnRNP 2H9 is the most recently identified 
member of this family, and little is known about its functions except for a role in the splicing 
arrest induced by heat shock (Mahe et al., 2000). Mahe et al. have also observed hnRNP M 
and H3 intervention in the functional flexibility of the splicing machinery in mouse 
embryonic development. HnRNP H3, like its epitopes hnRNP H/H’ and F, could participate 
in tissue-specific and developmental regulation of gene expression.  
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3.3.3.3 Metastatic angiogenesis  
In order to metastasise, cancer cells must invade tumour associated vasculature to gain access 
to distant sites in the body. This is facilitated partly through induced outgrowth of the pre-
existing vasculature and partly through de novo recruitment of vascular cell precursors from 
the circulation. The observed re-emergence of VEGF and vWF (Table 3.3b), along with 
metastatic-specific expression of the endothelial homing receptors, carbohydrate antigen 19-9 
(CA19-9), epithelial membrane antigen (Muc1) and CXC chemokine receptor type 4 
(CXCR4) in ACPS C and D cancer cells are evidence of this event.  
Cancer cells expressing CA19-9 bind to the endothelial cell-surface receptors E-selectin and 
P-selectin (Berg et al., 1992); this attachment is important in the development of tumour 
metastasis. CA19-9 is a tumour marker for CRC (Nakayama et al., 1997b). Muc1 apomucin 
is the glycoprotein that carries the CA19-9 antigen (Baeckstrom et al., 1993) and is itself a 
predictor of tumour progression. Our results confirm the over-expression of Muc1 and CA19-
9 in all CRC samples. The highest CA19-9 level was found for metastatic tumours (Table 
3.3a), but the CA19-9 levels were variable for metastatic and non-metastatic. A reason for 
this could be that CA19-9 is expressed as a mono-sialo-ganglioside in cancer tissue, whereas 
in serum CA19-9 is found on mucin-type glycolipids (Magnani et al., 1982). Nakayama et al. 
(Nakayama et al., 1997a) showed that CA19-9 serum levels were better predictors of 
recurrence than tissue CA19-9.  
Recent evidence indicates an important role for CVCL21 (CXC chemokine) and its receptor 
CXCR4 in the metastatic homing of tumour cells (Murphy, 2001). Ottaiano et al. (Ottaiano et 
al., 2006) showed concurrent expression of CXCR4 and VEGF in >50% of Duke’s stage B 
and C CRCs. Increased CXCR4/CXCL12 contributes to the attachment of CRC cells to the 
endothelium leading to cancer metastases. We found elevated levels of CXCR4 in ACPS C 
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that was reduced in ACPS D (Tables 3.3d, e), suggesting the possibility that CXCR4-positive 
cells were better adapted to escape from the primary tumour, the highest CXCR4 levels are 
found on liver metastases of CRC patients (Scala et al., 2005). 
 
3.3.3.4 Oxidative stress 
Once malignant CRC cells have broken through the basal membrane and invaded the 
circulatory compartment, they attain ready access to virtually all organs of the body. 
However, these cells must survive extracellular stresses such as increased reactive oxygen 
species (ROS), exacerbated as a result of metastases. We found progressively increased 
expression of redox proteins (e.g. peroxiredoxin, manganese superoxide dimutase) in early 
metastatic tumour compared with normal mucosa.    
Numerous studies have shown that the level of oxidants and peroxides are higher in tumours 
than in the surrounding tissue (Dreher and Junod, 1996). Transformed cells have an increased 
growth rate, and produce higher levels of reactive oxidative species from accelerated cellular 
respiration (Toyokuni et al., 1995). Some cancer cells also produce higher levels of pro-
inflammatory cytokines that stimulate tumour growth (Dreher and Junod, 1996), that places 
additional oxidative stress upon cancer cells. We have found that different redox regulation 
proteins were expressed at different stages of CRC development. Constitutive expression of 
peroxiredoxin-1 (Prdx-1) was found in all tumours (Table 3.2a), while peroxiredoxin-4 
(Prdx-4) was only expressed in non-metastatic CRC (Table 3.2c). Metastasis correlated with 
the over-expression of manganese superoxide dismutase (MnSOD) and isocitrate 
dehydrogenase (IDH) (Table 3.2c), possibly as a response to oxygen from blood cells, once 
the tumour has penetrated the basement membrane (Nishikawa, 2008).  
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Prdx-1 and Prdx-4 are members of a highly conserved 2-Cys peroxiredoxin family that 
regulates the cellular redox state by breaking down H2O2 (Rhee et al., 2005). Studies, 
including this one, have shown that Prdx-1 is elevated in CRC (Rho et al., 2008) (Table 3.2a), 
while Prdx-4 has been found reduced in CRC (Jang et al., 2004) (Table 3.2c). High levels of 
Prdx in cancers are associated with increased resistance to radiation (Park et al., 2000) and 
resistance to some anti-cancer drugs (Chung et al., 2001), whereas Prdx deficiency can 
sensitize cells to apoptosis (Pak et al., 2002). Residing in the ER, Prdx4 serves as a regulatory 
factor for NF-κB, an oxidative stress activated transcriptional factor (Park et al., 2009). The 
exact reason for down-regulation of Prdx4 in CRC remains unknown.  
MnSOD is an antioxidant enzyme that suppresses cell growth of a variety of cancer cell lines 
(Liu et al., 1997). The MnSOD growth-retarding effects are at least partially due to triggering 
of a p53-dependent cellular senescence program (Behrend et al., 2005). Despite its general 
tumour suppressor activity, there are conflicting reports with regard to MnSOD level in CRC 
tumours. MnSOD level positively correlates with tumour grade in colorectal carcinoma 
(Nozoe et al., 2003) and with invasion and metastatic phenotype (Cullen et al., 2003). The 
discrepancy between growth inhibition and association with malignancy can be explained 
with the tumour progression model for CRC suggested by Kinzler and Vogelstein (Kinzler 
and Vogelstein, 1996). In low-grade CRC with predominantly functional p53, MnSOD levels 
are low, since high levels of MnSOD would result in p53 induced growth arrest. As tumour 
progression proceeds, p53 becomes inactivated, leading to accumulation of mutations and an 
increasing loss of growth control. At this point, high levels of MnSOD, no longer able to 
induce senescence and growth control due to the lack of p53, can activate matrix 
metalloproteases, that might drive the invasive phenotype of high-grade tumours.    
IDH1 and IDH2 are found in the cytoplasm and mitochondria, respectively, producing 
NADPH by converting isocitrate to α-ketoglutarate (αKG). However, with ROS IDH activity 
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is increasing, while the activities of other tricarboxylic acid cycle enzymes decrease 
(Mailloux et al., 2007), IDH may play a role in the cellular response to ROS, in addition to 
the normal role in cellular metabolism. Mutations of IDH1 and IDH2 have been found in 
liver metastasis of a CRC patient (Sjoblom et al., 2006), acute myeloid leukaemia, and 
gliomas (Cairns et al., 2011). These specific mutations cause IDH1 and IDH2 to acquire a 
novel enzyme activity that converts α-ketoglutarate to 2-hydroxyglutarate in a NADPH-
dependent manner (Reitman and Yan, 2010). The function of this novel metabolite is not 
known and further investigation is required to determine if these IDH mutations occur as part 
of metastatic transformation in CRC. 
 
3.3.3.5 Proteasome and protein degradation pathways 
Increased proteasome activity is a survival response for cancers under oxidative stress. 
Prolonged exposure to ROS causes accumulation of abnormal proteins in cells, impeding 
cellular functions and initiating apoptosis. The up-regulation of the ubiquitin-proteasome 
pathway degrades any damaged proteins formed during oxidative stress, promoting cell 
survival (Kwak et al., 2003). Inhibition of proteasome function has been shown to induce 
apoptosis in cancer cells (Almond and Cohen, 2002).  
Proteasome sub-units alpha type-1, proteasome activator hPA28 subunit beta, ubiquitin-
associated protein and PEST proteolytic signal containing nuclear protein (PCNP), are 
elevated in metastatic CRC (ACPS C and D; Table 3.2c). Their expression could be a 
defensive response to increased oxidative stress as a result of metastasis; degradation of the 
basement membrane and increased angiogenesis. Evidence for the expression of the 
proteasome in late stage CRC has suggested survival and growth advantages for tumours. 
(Osburn and Kensler, 2008). The pro-cancer properties of proteasome activity may be limited 
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to advanced CRC, proteasome subunit alpha type-2 was found reduced in tumour tissue 
compared to normal tissue (Table 3.2a). The expression of the proteasome in normal colon 
tissue provides protection from potential mutagenic attack and down-regulation leads to the 
accumulation of abnormal proteins and tissue damage, potential promoters of tumourigenesis 
(Hayes and McMahon, 2009). It has also been proposed that reduced expression of 
proteasome subunits leads to the loss of HLA class I expression and may assist in immune 
evasion by cancer cells (Miyagi et al., 2003). Following metastasis, proteasome activity may 
re-emerge to promote tumour survival and growth advantages (Osburn and Kensler, 2008).      
We also found elevated levels of PCNP, a part of the ubiquitin-proteasome pathway, in 
metastatic CRC tumours (Table 3.2c). The PEST hypothesis predicts that the proteins with 
‘PEST sequences’ are degraded rapidly, often via the ubiquitin-proteasome pathway 
(Rechsteiner and Rogers, 1996). Mori et al. (Mori et al., 2004) suggest that PCNP and its 
ubiquitin ligase (Np95/ICBO90-like RING finger protein) may constitute a novel signalling 
pathway with some relation to cell proliferation. Recent studies have found PCNP to be 
involved in monkey embryonic stem cell proliferation (Nasrabadi et al., 2009), and Np95 to 
have an oncogenic role in CRC (Wang et al., 2012), but to our knowledge, our study is the 
first to correlate PCNP over-expression with CRC metastasis. 
Cullin-3, another ubiquitin-associated protein, was reduced at later stages from the level in 
ACPS A (Table 3.3c). The human cullin protein family consists of seven members that 
function as scaffold proteins in the E3 ligases. Little is known about the physiological 
function of cullin-3, but it has a role in controlling cell proliferation (Du et al., 1998), and 
may be required for efficient TOP1 (DNA topoisomerase I)  degradation by the ubiquitin-
proteasome system (Zhang et al., 2004). Additional studies, especially identification of Cul3-
containing E3 ligase complexes, will be needed to establish the molecular roles of Cul3 in 
TOP1 ubiquitylation and CRC metastasis.   
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3.3.3.6 Novel cancer-related protein 
Alcohol dehydrogenases (ADH) are enzymes that oxidise ethanol to acetaldehyde. 
Subsequent oxidation of acetaldehyde to acetate is catalysed by aldehyde dehydrogenases 
(ALDH). There is sufficient evidence that, in the colon, acetaldehyde is involved in alcohol-
induced colorectal carcinogenesis (Seitz et al., 1990). Acetaldehyde can be produced by 
colonic bacteria and, to a much lower degree, by intestinal mucosal ADH. This study was not 
the first to observe increased expression of ADH in CRC (Jelski et al., 2004) relative to 
normal mucosa, but we are the first to show significantly elevated ADH in metastatic CRC 
compared to levels in non-metastatic CRC (Table 3.2b). Jalski et al. (Jelski et al., 2004) 
found a much higher ADH:ALDH ratio in CRC than in normal mucosa, suggesting that the 
cancer cells have a high capability to oxidise exogenous ethanol to acetaldehyde, but a low 
capacity to remove acetaldehyde. The build-up of acetaldehyde derived from systemic blood 
or from luminal microbial fermentation can have direct mutagenic and carcinogenic effects. 
Acetaldehyde interferes at many sites with DNA synthesis and repair (Jelski et al., 2004). 
Moreover, Homann (Homann, 2001) showed that high acetaldehyde correlated with low local 
folate concentrations in the colon and may increase susceptibility to CRC. Further studies are 
required to investigate the role of ADH in metastatic tumours and to establish whether 
elevated levels of acetaldehyde contribute to disease progression and promote metastasis in 
CRC.   
 
3.3.4 Future work and conclusions 
This study focused on the expression patterns of intracellular proteins during the development 
and progression of primary CRC tumours. However, we note that local lymphatic and 
secondary distant organ metastases are also of great importance to the understanding of 
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cancer progression. Our work on primary tumours restricts our understanding of CRC 
metastasis to the selection for cancer cells bearing metastatic phenotype during early 
metastasis followed by their release into the blood vessels, evidenced by an increase in 
metastasis-associated proteins in stage C tumours followed by their reduction in stage D 
tumours (notch proteins, CXCR4; Table 3.3e). In future studies we wish to isolate and profile 
CRC-derived cancer cells from blood vessels, lymph nodes and secondary tumours. A review 
by Gupta and Massague (Gupta and Massague, 2006) highlights the evolving framework for 
metastasis and the selection factors influencing malignant cells to overcome diverse 
environmental defences. Defining protein expression profiles of cancer cells at different 
stages and locations of metastasis will contribute to our understanding of CRC and help 
predict CRC metastatic behaviour.   
 
Proteomics has been used to identify processes that direct CRC progression, including 
interactions between cancer cells and their surroundings. Multiple mutations lead to 
development of cancerous tissue, allowing for aggressive growth, unrestricted by normal 
cellular constrains. Inevitably, uncontrolled proliferation results in hypoxia. Faced with this 
challenge cancer cells respond with a range of adaptations, with glycolytic phenotype as one 
of the preferred solutions. By-products of glycolysis provide the next selection force, 
acidosis. Tumours respond by reducing apoptosis-associated proteins and increasing stress 
response proteins, but ultimately the combination of acidosis and limited resources result in 
the metastatic phenotype. Following the breach of the basement membrane, direct exposure 
of cancer cells to blood vessels sees them respond to the oxidative stress and utilise 
endothelial homing proteins to begin metastasis. The metastatic transformation leads to 
migration of cancer cells towards secondary sites.  
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Our proteomic data have contributed towards an understanding of the processes involved in 
CRC progression at different stages of development. We have established protein expression 
profiles that provide markers of physiological events within cancer cells. These protein 
profiles provide a novel approach to CRC stratification and may improve patient outcome 
prediction and tailored therapy.   
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4.1 Introduction 
Treatment for CRC is determined from the disease stage. Surgery may be curative with 
optional adjuvant therapy. Currently, chemotherapy is offered to all Australian Clinico-
pathological Stage (ACPS) C and D patients. Although the majority of ACPS A and B 
patients will be cured by surgery alone, ~35% of stage B patients would benefit from further 
therapy (Morris et al., 2007). At least one third of ACPS C patients are cured by surgery and, 
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undergo unnecessary and debilitating further cytotoxic treatment (Durrant et al., 2003). This 
problem arises because of the heterogeneous nature of CRC (Li et al., 2007b) and the 
complexity of its development and spread. As a result, the clinical course for individuals 
remains difficult to predict even for same stage tumours. Additional discriminatory markers 
could enable prediction of cancer behaviour and selection of the best course of treatment. 
The progression of CRC from adenomatous polyp to metastatic disease occurs due to 
progressive accumulation of mutations, epigenetic abnormalities (Moyret-Lalle et al., 2008), 
and complex interactions of different sub-populations of cells within the tumour 
microenvironment (cancer cells, normal stromal cells, infiltrating leukocytes and cytokines 
they produce) (McAllister and Weinberg, 2010). For the majority of CRC, cell dysfunction 
results from numerous mutations that modify proteins expressed and post-translational 
modifications (Steinert et al., 2002). A number of cell surface antigens, including cluster of 
differentiation (CD) antigens, have been identified as potential prognostic biomarkers in CRC 
(Belov et al., 2010). Levels of these antigens may change with tumour progression or 
interactions with other cell types, such as tumour-infiltrating lymphocytes (TIL).  
Immunohistochemistry (IHC) for cancer stratification and prognostication is well established 
for some tumour types (Eifel et al., 2001, Swerdlow, 2008). Currently for CRC, the use of 
IHC is used to detect DNA microsatellite mismatch repair (MMR) protein to identify a 
subgroup of tumours (10 – 15%) that may be associated with a familial cancer syndrome, 
hereditary non-polyposis colorectal cancer, and development of metachronous tumours 
(Duffy et al., 2007, Greenson et al., 2009).  Single markers do not provide prognostic 
significance greater than clinico-pathological staging and are not used for routine pathology 
of CRC.  
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A recent approach to stratify CRC phenotypes uses surface protein profiles of multiple 
markers. Proteomic techniques such as iTRAQ enable discovery of biomarkers (Xiao et al., 
2008), but are too complex for routine use in diagnostic laboratories, and cannot distinguish 
different cell types in a mixed population. In addition, relatively large amounts of tumour 
tissue are required for profiling of membrane glycoproteins.  
In this PhD project, we developed a method for surface proteome profiling of live cells from 
disaggregated CRC samples using DotScan
TM
 CRC antibody microarrays. The 122-antibody 
microarray consists of a standard 82-antibody region recognising a range of lineage-specific 
leukocyte markers, adhesion molecules, receptors and markers of inflammation and immune 
response (Belov et al., 2003), with additional antibodies for detection of 40 prognostic 
markers for CRC (Zhou et al., 2010). Whole cells are captured only on antibodies for which 
they express the corresponding antigens. We have profiled the surface antigen expression of 
EpCAM
+
 CRC cells and CD3
+
 T-cells within samples of primary CRC and normal mucosa 
from 50 patients. Hierarchical clustering of binding patterns for these two sub-populations of 
cells yielded clusters of patients that correlated with differentiation, ACP stage and 
inflammation. We found that the immunophenotypes of tumour cells correlated with the 
infiltrating T-cells, indicating a strong influence of the microenvironment on the surface 
proteomes of these cells. Disease signatures from surface protein markers may be more 
accurate than gene expression profile data. When applied with clinico-pathological features, 
immunophenotyping could further stratify intermediate stage CRC and improve prediction of 
patient outcomes.  
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4.2 Results 
Surface antigen profiles of cell subtypes were obtained from 97 samples (adenoma, tumour 
and normal mucosa) from 50 patients. Clinicopathological and histological characteristics of 
the 50 patients are listed in Table 4.1. The tumours collected were predominantly 
intermediate stage (ACPS A3, B1, B2 and C1) tumours (78%). Clinico-pathology reports and 
haematology information were collected for each patient. No correlation was found between 
the ACPS and circulating lymphocyte levels (p=0.87) or ACPS and circulating neutrophil to 
lymphocyte ratio (NLR) (p=0.45).  
 
Two cell types, EpCAM
+
 cancer cells and CD3
+
 T-cells, were profiled in each sample. 
Surface profiles (97) were obtained for CRC and normal mucosa cells, while 75 profiles were 
obtained for T-cells; 22 T-cell profiles were omitted due to low or zero cell binding. A total 
of 38 antibodies on the DotScan microarray showed positive cell binding in the EpCAM
+
 cell 
profiles and 46 antibodies for CD3
+
 T-cells.  
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Table 4.1 Clinico-pathological and haematological characteristics of the 50 CRC patients  
 No. patients (%) 
Gender  
Male 24 (48%) 
Female 26 (52%) 
Age  
≤ 65 33 (66%) 
> 65 17 (34%) 
Location  
Left (caecum, ascending colon, transverse) 26 (52%) 
Right (descending colon, sigmoid, rectum) 24 (48%) 
Australian clinico-pathological stage (ACPS)  
Adenoma 2 (4%) 
A2 3 (6%) 
A3 9 (18%) 
B1 18 (36%) 
B2 2 (4%) 
C1 10 (20%) 
C2 2 (4%) 
D0 1 (2%) 
D2 3 (6%) 
Infiltration  
Submucosa 6 (12%) 
Muscularis propria 12 (24%) 
Subserosa 26 (32%) 
Serosa 6 (12%) 
Differentiation  
Adenoma 2 (4%) 
Well 2 (4%) 
Moderate 42 (80%) 
Poor 6 (12%) 
Peri-tumoural inflammation  
Present 21(42%) 
Absent 29 (58%) 
Tumour infiltrating lymphocytes (TIL)  
Present 5 (10%) 
Absent 45 (90%) 
Circulating lymphocyte count  
< 1 × 10
9
/L (low) 16 (32%) 
1.0-3.0 × 10
9
/L (normal) 32 (64%) 
Circulating neutrophil to lymphocyte ratio (NLR)  
≤ 5  23 (46%) 
> 5 27 (54%) 
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4.2.1 Tumour versus normal 
The Student’s t-test was used to compare protein levels in CRC with normal mucosa. A total 
of 50 EpCAM
+
 CRC cell profiles were compared with 47 EpCAM
+
 normal mucosa profiles. 
A total of 38 surface antigens showed positive cell binding; of these, 4 antigens were 
significantly elevated, while 20 antigens were significantly reduced on CRC cells compared 
with the matching normal mucosa counterpart (Table 4.2a). Hierarchical clustering was 
performed on the antigen profiles (38 positive proteins) (Figure 4.1) to sub-classify samples 
on the basis of their EpCAM
+
 cell profiles.    
A total of 42 CD3
+
 tumour-associated T-cell profiles were compared to 33 CD3
+
 normal 
mucosa-associated T-cell profiles. A total of 46 surface antigens showed positive cell 
binding; of these 6 antigens were significantly elevated while 18 antigens were significantly 
reduced on tumour-infiltrating T-cells compared to T-cells from normal mucosa (Table 4.3a). 
Hierarchical clustering was performed with the antigen profiles (46 positive proteins) (Figure 
4.2) to stratify samples on the basis of their cancer infiltrating T-cells and intra-epithelial T-
cells.  
Differential analysis between metastatic (ACPS C and D) and non-metastatic (ACPS A and 
B) EpCAM
+
 cell profiles showed altered expression of 4 surface antigens (Table 4.2b). 
Comparison of T-cell profiles from metastatic (ACPS C and D) and non-metastatic (ACPS A 
and B) tumours identified 4 differentially abundant surface antigens (Table 4.3b). Antigen 
levels for cancer cells and T-cells between normal and high NLR (NLR ≤5 and NLR >5).  
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Table 4.2 Significantly altered surface proteins on EpCAM
+
 CRC cells compared to EpCAM
+
 normal mucosal cells as identified by DotScan 
antibody microarray. Only proteins with 95% confidence interval and >1.5-fold change are shown.  
a) Differentially expressed proteins on tumour and normal mucosa cells 
Protein Uniprot ID
a
 Protein family  Function p-value
b,c
 Fold 
Elevated on CRC cells 
CD66c P40199 Immunoglobulin superfamily Adhesion 9.29E-07 4.3 
HLA-DR P01903 MHC class II receptor Immune response 0.025 1.6 
CD55 P08174 Receptors of complement activation Complement regulation 0.049 1.4 
CD98 Q01650 L-type amino acid transporter Amino acid transporter 0.028 1.6 
Reduced on CRC cells 
CD9 P21926 Tetraspanin family Adhesion 6.32E-07 2.8 
CD13 P15144 Peptidase M1 family Aminopeptidase 1.39E-04 2.1 
CD15 Carbohydrate Carbohydrate adhesion molecule Phagocytosis regulation 0.001 2.2 
CD29  P05556 Integrin beta chain Adhesion 2.50E-05 2.6 
CD38 P28907 ADP-ribosyl cyclase Cyclic ADP-ribose synthesis 1.52E-04 2.5 
CD40 P25942 Tumour necrosis factor receptor Signal transduction 0.039 1.5 
CD43 P16150 Glycoprotein Negative regulator of T-cell activation 0.014 1.5 
CD49d P12612 Integrin alpha chain Adhesion 4.99E-05 2.0 
CD95 P25445 Tumour necrosis factor receptor Caspase recruiter 3.49E-08 5.3 
CD47 Q08722 Immunoglobulin-like protein Adhesion 1.59E-05 2.1 
CD49f P23229 Integrin alpha chain Adhesion 3.99E-06 2.3 
CD59 P13987 Glycoprotein Complement inhibitor 0.015 1.6 
CD63 P08962 Tetraspanin family Cellular protein localisation 1.44E-08 2.6 
CD66e (CEA) P06731 Immunoglobulin superfamily Adhesion 0.005 1.8 
CD104 P16144 Integrin beta chain Adhesion 9.03E-07 2.8 
CD151 P48509 Tetraspanin family Adhesion 5.07E-07 3.5 
CD324 P12830 Cadherin family Adhesion 0.045 1.5 
CD326  P16422 Cadherin family Adhesion 9.18E-07 2.6 
Claudin-4 O14493 Claudin family Structural 9.82E-04 2.0 
HLA-ABC Multiple proteins MHC class I receptor  Immune response 3.74E-06 2.5 
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b) Differentially expressed proteins on non-metastatic and metastatic CRC cells 
Protein Uniprot ID
a
 Protein family  Function p-value
b,c
 Fold 
Elevated on metastatic CRC 
CD13 P15144 Peptidase M1 family Aminopeptidase 0.03 1.8 
CD66c P40199 Immunoglobulin superfamily Adhesion 0.02 2.2 
CD26 P27487 Peptidase S9B family T-cell activation  0.02 2.0 
Reduced on metastatic CRC 
HLA-DR  MHC class II receptor Immune response 0.002 2.3 
CD Cluster of differentiation  
HLA Human leukocyte antigen  
CEA Carcinoembryonic antigen 
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Figure 4.1 Hierarchical clustering of the EpCAM positive cell profiles from 97 CRC and normal samples. Each sample is identified with tumour 
(T) or normal (N), the Australian clinico-pathological stage (A – D) and the neutrophil to lymphocyte ratio (2 – 28). Hierarchical clustering 
(Euclidean distance, complete linkage) was conducted on the antigen profiles (38 positive proteins). 
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Table 4.3 Summary of significantly altered surface proteins on CD3
+
 tumour infiltrating T-cells compared to normal intestinal intra-epithelial T-
cells identified with DotScan antibody microarrays. Only proteins with 95% confidence interval and >1.5-fold change are listed.  
a) Differential expressed proteins on T-cells from tumour and normal tissue 
Protein Uniprot ID
a
 Protein family  Function P-value
b,c
 Fold  
Up-regulated on tumour infiltrating T-cells 
CD11c P20702 Integrin alpha chain Adhesion 0.023 1.8 
CD49e P08648 Integrin alpha chain Adhesion 6.00E-05 2.5 
CD66c P40199 Immunoglobulin superfamily Adhesion 0.004 2.2 
CD71 P02786 Peptidase M28 family Transferrin receptor activity 1.42E-09 5.4 
CD86 P42081 Immunoglobulin-like protein Stimulate T-cell proliferation 0.002 1.9 
HLA-DR  MHC class II receptor Immune response 6.98E-07 4.2 
Down-regulated on tumour infiltrating T-cells 
CD2 P06729 Immunoglobulin-like protein Adhesion 0.018 1.5 
CD3 P09693 Immunoglobulin-like protein Signal transduction 0.004 1.8 
CD7 P09564 Immunoglobulin-like protein T-cell activation 0.012 1.5 
CD9 P21926 Tetraspanin family Adhesion 5.93E-05 2.9 
CD11a P20701 Integrin alpha chain Adhesion 0.001 1.5 
CD29 P05556 Integrin beta chain Adhesion 0.001 1.7 
CD31 P16284 Immunoglobulin-like protein Adhesion 0.006 1.8 
CD38 P28907 ADP-ribosyl cyclase Cyclic ADP-ribose synthesis 0.009 1.6 
CD43 P16150 Glycoprotein T-cell costimulation 1.06E-05 1.9 
CD44 P16070 1 link domain protein Adhesion 0.002 1.6 
CD45 P08575 Protein-tyrosine phosphatase family Leukocyte differentiation/proliferation 0.001 1.5 
CD49d P13612 Integrin alpha chain Adhesion 0.004 1.5 
CD103 P38570 Integrin alpha chain Adhesion 3.58E-05 2.7 
CD47 Q08722 Immunoglobulin-like protein Adhesion 0.001 1.6 
CD55 P08174 Receptors of complement activation Complement regulation 0.006 1.5 
CD63 P08962 Tetraspanin family Cellular protein localisation 4.82E-04 1.9 
CD151 P48509 Tetraspanin family Adhesion 0.048 1.5 
HLA-ABC  MHC class I receptor Immune response 0.001 1.7 
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b) Differentially expressed proteins on T-cells from non-metastatic and metastatic CRC 
Protein Uniprot ID
a
 Protein family  Function P-value
b,c
 Fold  
Up-regulated in metastatic CRC 
CD26 P27487 Peptidase S9B family T-cell activation  0.004 1.6 
CD151 P48509 Tetraspanin family Adhesion 3.45E-04 1.8 
Down-regulated in metastatic CRC 
CD11c P20702 Integrin alpha chain Adhesion 0.029 1.9 
CD31 P16284 Immunoglobulin-like protein Adhesion 0.032 1.8 
CD Cluster of differentiation  
HLA Human leukocyte antigen  
CEA Carcinoembryronic antigen 
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Figure 4.2 Hierarchical clustering of the CD3 positive cell profiles from 75 tumour and normal samples. Each sample is identified as tumour (T) 
or normal (N), the Australian clinico-pathological stage (A – D) and the neutrophil to lymphocyte ratio (2 – 28). Hierarchical clustering 
(Euclidean distance, complete linkage) was conducted on antigen profiles (46 positive proteins).   
10
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4.2.2 Hierarchical clustering 
Hierarchical clustering (Euclidean distance, complete linkage) was used to identify pattern 
similarity. Unsupervised hierarchical clustering of the EpCAM
+
 CRC profiles produced a 
dendrogram with 4 well-defined clusters (Figure 4.3). The clinico-pathological properties of 
each cluster is summarised in Table 4.4. Differentially expressed proteins were identified 
between related clusters generated from the split. The first split generated 2 clusters; cluster 1 
(blue) and cluster 2 (green) consisted of 11 and 39 profiles, respectively. Proteins (15) were 
reduced in cluster 2 compared to cluster 1 (Table 4.5a). Further down the hierarchy, cluster 2 
was split into clusters 3 (red) and 4 (yellow), consisting of 22 and 17 profiles, respectively. 
Comparison of cluster 3 with cluster 4 showed reduced binding levels for 13 proteins, and 
increased levels for 2 (Table 4.5b). The clinico-pathological information showed that CRC 
cluster 1 contained the lowest number of metastatic tumours (18%) compared with clusters 3 
and 4 (32%, 35% respectively). Cluster 1 was associated with only well, and moderately, 
differentiated tumours, while clusters 2, 3 and 4 contained moderate and poorly differentiated 
tumours (Table 4.4).  
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Figure 4.3 Hierarchical clustering of the EpCAM
+
 cell profiles from 50 CRC samples. Each 
sample is labelled with the Tumour ID (T#), Australian clinico-pathological stage (A – D) 
and the neutrophil to lymphocyte ratio (2 – 28). Hierarchical clustering (Euclidean distance, 
complete linkage) split the profiles into 4 clusters (Cluster groups 1 – 4).   
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Table 4.4 Patient clinico-pathological and haematological characteristics within EpCAM
+
 
CRC cell clusters.   
 Cluster 1 
(n=11) 
Cluster 2 
(n=39) 
Cluster 3 
(n=22) 
Cluster 4 
(n=17) 
  No. patients (%) 
Gender     
Male 6 (55%) 18 (46%) 9 (41%) 9 (53%) 
Female 5 (45%) 21 (54%) 13 (59%) 8 (47%) 
Age     
≤ 65 3 (27%) 16 (41%) 8 (36%) 8 (47%) 
> 65 8 (73%) 23 (59%) 14 (64%) 9 (53%) 
Location     
Left (caecum, ascending colon, transverse) 5 (45%) 16 (41%) 10 (45%) 6 (35%) 
Right (descending colon, sigmoid, rectum) 6 (55%) 23 (59%) 12 (55%) 11 (65%) 
Australian clinico-pathological stage (ACPS)    
Adenoma 2 (19%) 0 (0%) 0 (0%) 0 (0%) 
A 3 (27%) 9 (23%) 4 (18%) 5 (29%) 
B 3 (27%) 17 (44%) 11 (50%) 6 (36%) 
C 3 (27%) 9 (23%) 4 (18%) 5 (29%) 
D 0 (0%) 4 (10%) 3 (14%) 1 (6%) 
Infiltration     
Submucosa 3 (28%) 3 (8%) 2 (9%) 1 (6%) 
Muscularis propria 4 (36%) 8 (21%) 4 (18%) 4 (24%) 
Subserosa 4 (36%) 22 (56%) 13 (58%) 9 (53%) 
Serosa 0 (0%) 6 (15%) 3 (14%) 3 (18%) 
Differentiation     
Adenoma 2 (18%) 0 (0%) 0 (0%) 0 (0%) 
Well 2 (18%) 0 (0%) 0 (0%) 0 (0%) 
Moderate 7 (64%) 33 (85%) 20 (91%) 13 (76%) 
Poor 0 (0%) 6 (15%) 2 (9%) 4 (24%) 
Peri-tumoural inflammation      
Present  5 (45%) 16 (41%) 10 (45%) 6 (35%) 
Absent  6 (55%) 23 (59%) 12 (55%) 11 (65%) 
Tumour infiltrating lymphocytes (TIL)     
Present 1 (9%) 4 (10%) 2 (9%) 2 (12%) 
Absent 10 (91%) 35 (90%) 20 (91%) 15 (88%) 
Circulating lymphocytes count     
< 1 × 10
9
/L (low) 4 (36%) 12 (31%) 7 (32%) 5 (29%) 
1.0-3.0 × 10
9
/L (normal) 7 (64%) 27 (69%) 15 (68%) 12 (71%) 
Circulating neutrophil to lymphocyte ratio (NLR)    
≤ 5  4 (36%) 17 (44%) 10 (45%) 7 (41%) 
> 5 7 (64%) 22 (56%) 12 (55%) 10 (59%) 
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Table 4.5 Significantly altered surface proteins between clusters of EpCAM
+
 CRC cells. Only proteins with 95% confidence interval and over 
1.5-fold change are listed.  
a) Cluster 1 versus 2 
Protein Uniprot ID
a
 Protein family  Function p-value
b,c
 Fold  
Reduced on cluster 2 CRC cells 
CD9 P21926 Tetraspanin family Adhesion 1.72E-11 5.1 
CD13 P15144 Peptidase M1 family Aminopeptidase 0.0074 1.7 
CD15 (Lewis x) Carbohydrate Carbohydrate adhesion molecule Adhesion 5.85E-10 6.8 
CD24 P25063 CD24 family Leukocyte signal transducer 3.12E-04 3.7 
CD29  P05556 Integrin beta chain Adhesion 2.31E-08 5.5 
CD43 P16150 Glycoprotein Negative regulator of T-cell activation 0.045 1.7 
CD95 P25445 Tumour necrosis factor receptor Caspase recruiter 0.045 2.4 
CD181 P25024 G-protein coupled receptor 1 Neutrophil activator 7.34E-05 2.6 
CD15s (Sialyl Lewis x) Carbohydrate Carbohydrate adhesion molecule Adhesion 0.028 3.1 
CD47 Q08722 Immunoglobulin-like protein Adhesion 3.28E-04 3.4 
CD49f P23229 Integrin alpha chain Adhesion 9.18E-08 4.8 
CD66e (CEA) P06731 Immunoglobulin superfamily Adhesion 3.03E-10 5.5 
CD104 P16144 Integrin beta chain Adhesion 9.86E-04 4.4 
CD324 P12830 Cadherin family Adhesion 0.006 2.3 
CD326 (EpCAM) P16422 Cadherin family Adhesion 2.15E-10 5.6 
CD98 Q01650 L-type amino acid transporter Amino acid transporter 0.004 3.3 
Claudin-4 O14493 Claudin family Structural 0.002 3.1 
FAP Q12884 Peptidase S9B family Proteolysis 0.029 1.6 
HLA-ABC MHC family MHC class I receptor  Immune response 1.07E-07 5.5 
MMP-14 P50281 Peptidase M10A family Endopeptidase 1.87E-04 2.6 
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5 
 Chapter 4 Immunophenotyping of CRC cells and TIL for improved stratification 
108 
 
b) Cluster 3 versus cluster 4 
Protein Uniprot ID
a
 Protein family  Function p-value
b,c
 Fold  
Elevated on cluster 4 CRC cells 
CD49d P12612 Integrin alpha chain Adhesion 0.008534 2.1 
CD49e P08648 Integrin alpha chain Adhesion 0.001013 3.0 
Reduced on cluster 4 CRC cells 
CD9 P21926 Tetraspanin family Adhesion 1.89E-04 2.4 
CD15 Carbohydrate Carbohydrate adhesion molecule Phagocytosis regulation 0.006341 2.3 
CD29  P05556 Integrin beta chain Adhesion 0.017996 2.7 
CD15s (Sialyl Lewis x) Carbohydrate Carbohydrate adhesion molecule Adhesion 0.074097 2.1 
CD47 Q08722 Immunoglobulin-like protein Adhesion 4.25E-04 2.0 
CD49f P23229 Integrin alpha chain Adhesion 4.77E-04 2.1 
CD59 P13987 Glycoprotein Complement inhibitor 0.033409 1.8 
CD63 P08962 Tetraspanin family Cellular protein localisation 0.049951 1.5 
CD66e (CEA) P06731 Immunoglobulin superfamily Adhesion 0.004495 2.3 
CD104 P16144 Integrin beta chain Adhesion 0.00273 2.5 
CD151 P48509 Tetraspanin family Adhesion 0.101945 2.0 
CD326 (EpCAM) P16422 Cadherin family Adhesion 1.07E-04 2.3 
CD98 Q01650 L-type amino acid transporter Amino acid transporter 0.00697 2.0 
HLA-ABC MHC family MHC class I receptor  Immune response 0.005437 2.1 
 
CD Cluster of differentiation  
HLA Human leukocyte antigen  
CEA Carcinoembryronic antigen 
EpCAM Epithelial cell adhesion molecule  
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Unsupervised hierarchical clustering was applied to the tumour infiltrating T-cell profiles. 
This produced a dendrogram with 4 well-defined clusters (Figure 4.4). The clinico-
pathological properties of each cluster are summarised in Table 4.6. Differentially expressed 
proteins were identified between related clusters generated from the split. The first split 
generated cluster 1 (blue) and cluster 2 (green) consisting of 14 and 28 profiles, respectively. 
Compared to cluster 1, cluster 2 showed elevated levels of 11 antigens and reduction of 6 
antigens (Table 4.7a). Further down the hierarchy, cluster 2 was split into clusters 3 (red) and 
4 (yellow), consisting of 15 and 13 profiles, respectively. Proteins (13) were reduced and 5 
elevated in cluster 3 compared to cluster 4 (Table 4.7b). The clinico-pathological information 
showed that within each cluster the number of metastatic tumours inversely correlated with 
observable peri-tumoural inflammation (Table 4.6). T-cell cluster 3 contained the largest 
number of metastatic tumours but also the least number of CRCs with peri-tumoural 
inflammation (47% and 27%), followed by T-cell cluster 4 (31% and 54%) and cluster 1 
(14% and 57%).   
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Figure 4.4 Hierarchical clustering of the CD3
+
 cell profiles from 42 CRC samples. Each 
sample is labelled with the Tumour ID (T#), Australian clinico-pathological stage (A – D) 
and the neutrophil to lymphocyte ratio (2 – 28). Hierarchical clustering (Euclidean distance, 
complete linkage) split the profiles into 4 clusters (cluster groups 1 – 4).   
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Table 4.6 Patient clinico-pathological and haematological characteristics within CD3
+
 T-cell 
clusters.   
 Cluster 1  
(n=14) 
Cluster 2 
(n=28) 
Cluster 3  
(n=15) 
Cluster 4 
(n=13) 
  No. patients (%) 
Gender     
Male 5 (36%) 17 (61%) 11 (73%) 6 (46%) 
Female 9 (64%) 11 (39%) 4 (27%) 7 (54%) 
Age     
≤ 65 6 (43%) 10 (36%)  4 (27%)  6 (46%) 
> 65 8 (57%) 18 (64%) 11 (73%) 7 (54%) 
Location     
Left (caecum, ascending colon, transverse) 7 (50%) 11 (39%) 6 (40%) 5 (38%) 
Right (descending colon, sigmoid, rectum) 7 (50%) 17 (61%) 9 (60%) 8 (62%) 
Australian clinico-pathological stage (ACPS)     
Adenoma 1 (7%) 0 (0%) 0 (0%) 0 (0%) 
A 5 (36%) 6 (21%) 3 (20%) 3 (23%) 
B 6 (43%) 11 (39%) 5 (33%) 6 (46%) 
C 2 (14%) 8 (29%) 5 (33%) 3 (23%) 
D 0 (0%) 3 (11%) 2 (14%) 1 (8%) 
Infiltration     
Submucosa 4 (29%) 1 (4%) 1 (7%) 0 (0%) 
Muscularis propria 3 (21%) 7 (25%) 2 (13%) 5 (38%) 
Subserosa 5 (36%) 16 (57%) 9 (60%) 7 (54%) 
Serosa 2 (14%) 4 (14%) 3 (20%) 1 (8%) 
Differentiation     
Adenoma 1 (7%) 0 (0%) 0 (0%) 0 (0%) 
Well 0 (0%) 2 (7%) 0 (0%) 2 (15%) 
Moderate 11 (79%) 22 (79%) 12 (80%) 10 (77%) 
Poor 2 (14%) 4 (14%) 3 (20%) 1 (8%) 
Peri-tumoural inflammation      
Present  8 (57%) 11 (39%) 4 (27%) 7 (54%) 
Absent  6 (43%) 17 (61%) 11 (73%) 6 (46%) 
Tumour infiltrating lymphocytes (TIL)     
Present 2 (14%) 3 (11%) 1 (7%) 2 (15%) 
Absent 12 (86%) 25 (89%) 14 (93%) 11 (85%) 
Circulating lymphocytes count     
< 1 × 10
9
/L (low) 4 (29%) 9 (32%) 6 (40%) 3 (23%) 
1.0-3.0 × 10
9
/L (normal) 10 (71%) 19 (68%) 9 (60%) 10 (77%) 
Circulating neutrophil to lymphocyte ratio (NLR)    
≤ 5  6 (43%) 13 (46%) 6 (40%) 7 (54%) 
> 5 8 (57%) 15 (54%) 9 (60%) 6 (46%) 
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Table 4.7 Significantly altered surface proteins between clusters of CD3
+
 tumour cells. Only proteins with 95% confidence interval and over 
1.5-fold change are listed.  
a) Cluster 1 versus 2 
Protein Uniprot ID
a
 Protein family  Function p-value
b,c
 Fold  
Elevated on cluster 2 CRC cells 
CD8 P10966 Immunoglobulin-like protein Cytoxic/ immune suppressor  0.017 2.2 
CD9 P21926 Tretraspanin family Adhesion 0.001 3.1 
CD13 P15144 Peptidase M1 family Aminopeptidase 0.008 2.0 
CD86 P42081 Immunoglobulin-like protein T-lymphocyte activation 0.028 1.9 
CD134 P43489 Tumour necrosis factor receptor 
Lymphocyte proliferation and 
immune response 
1.37E-05 
2.9 
HLA-DR P01903 MHC class II receptor Immune response 0.018 3.2 
CD26 P27487 Peptidase S9B family T-cell activation  0.037 1.9 
CD69 Q07108 C-type lectin domain Lymphocyte proliferation 9.30E-04 3.9 
CD151 P48509 Tretraspanin family Adhesion 0.006 3.0 
CD326 (EpCAM) P16422 Cadherin family Adhesion 4.32E-06 6.1 
CA19-9 (Siglylated Lewis a) Carbohydrate Carbohydrate adhesion molecule Adhesion 1.49E-07 9.5 
Reduced on cluster 2 CRC cells 
CD3 P09693 Immunoglobulin-like protein Signal transduction 0.004681 2.1 
CD31 P16284 Immunoglobulin-like protein Adhesion 7.83E-04 2.3 
CD43 P16150 Glycoprotein T-cell costimulation 0.002468 1.5 
CD49d P13612 Integrin alpha chain Adhesion 0.031068 1.5 
CD57 Q9P2W7 Glycosyltransferase 43 family Carbohydrate metabolism 7.81E-04 3.3 
CD95 P25445 Tumour necrosis factor receptor Caspase recruiter 0.002533 2.0 
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b) Cluster 3 versus 4 
Protein Uniprot ID
a
 Protein family  Function p-value
b,c
 Fold change 
Elevated on cluster 4 CRC cells 
CD5    9.86E-04 1.7 
CD9 P21926 Tetraspanin family Adhesion 0.037 1.9 
CD11a P20701 Integrin alpha chain Adhesion 0.007 1.5 
CD15 Carbohydrate Carbohydrate adhesion molecule Phagocytosis regulation 0.007 4.0 
CD44 P16070 1 link domain protein Adhesion 0.002 1.8 
CD45 P08575 Protein-tyrosine phosphatase family Leukocyte differentiation 0.026 1.5 
CD45RO P08575 Protein-tyrosine phosphatase T-cell activation 3.82E-04 1.8 
CD71 P02786 Peptidase M28 family Transferrin receptor activity 0.013 1.9 
CD47 Q08722 Immunoglobulin-like protein Adhesion 0.023 1.5 
CD59 P13987 Glycoprotein Complement inhibitor 3.79E-04 1.7 
CD63 P08962 Tetraspanin family Cellular protein localisation 0.023 1.9 
CD326 (EpCAM) P16422 Cadherin family Adhesion 0.019 3.3 
CA19-9 (Siglylated Lewis a) Carbohydrate Carbohydrate adhesion molecule Adhesion 2.09E-07 14.0 
Reduced on cluster 4 CRC cells 
CD11c P20702 Integrin alpha chain Adhesion 0.024 2.5 
CD31 P16284 Immunoglobulin-like protein Adhesion 0.018 2.0 
CD66c P40199 Immunoglobulin superfamily Adhesion 0.036 2.6 
CD86 P42081 Immunoglobulin-like protein Stimulate T-cell proliferation 0.009 2.9 
CD95 P25445 Tumour necrosis factor receptor Caspase recruiter 1.68E-05 3.2 
 
CD Cluster of differentiation  
HLA Human leukocyte antigen  
CEA Carcinoembryronic antigen 
EpCAM Epithelial cell adhesion molecule  
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4.2.3 Correlation between CRC cell profiles and T-cell profiles 
There was an association between the EpCAM
+
 CRC profiles and those for the CD3
+
 T-cells 
from the same samples (Figure 4.5). T-cells in cluster 1 tended to associate with cancer cells 
from clusters 3 and 4 (29% and 41%); T-cells with the profile of cluster 3 were associated 
with CRC cells from clusters 3 and 4 (29% and 53%); T-cells of cluster 4 were 
predominantly associated with cancer cells from clusters 1 and 3 (63% and 41%).  
 
Figure 4.5 Association between CD3
+
 tumour-associated T-cell profiles and EpCAM
+
 cancer 
cell profiles. The coloured bars represent individual clusters of each cell type. The coloured 
lines connect clustering positions for each patient on the basis of CD3
+
 and EpCAM
+
 binding 
patterns. The line colour is based on the colour of the corresponding CD3
+
 clusters. 
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4.3 Discussion 
We used a cell capture microarray (DotScan) in conjunction with fluorescence multiplexing 
(Zhou et al., 2010), to simultaneously profile surface antigen expression on EpCAM
+
 CRC 
cells and CD3
+
 T-cells from 97 CRC tumours and normal intestinal mucosa samples resected 
from 50 patients. The original DotScan microarray was designed to allow for the 
investigation of surface markers on leukocytes (Belov et al., 2003) and included markers 
which distinguish between various types of leukocytes (T-cells, B-cells, myeloid cells) as 
well as receptors and adhesion molecules. An additional 40 CRC markers were identified and 
selected through literature searches for CRC cell profiling on the DotScan antibody 
microarray (Zhou et al., 2010, Belov et al., 2010). The antibody selection on DotScan 
allowed us to profile the tumour associated leukocyte population along with the CRC cells. 
The CD3
+
 T-cell population was found to be the most consistently detectable leukocyte 
population in our CRC samples. 
To maintain the optimal number of viable cells (>70%) and the most accurate representation 
of surface antigen levels, the clinical samples were collected and immunophenotyped within 
24 hours of surgical resection. As a result of this narrow time frame, we were only able to 
obtain the corresponding clinico-pathological information a week after the tumours were 
profiled. Hence the sample selection was unbiased and reflected the most frequently 
diagnosed stages of CRC (80% of the samples were moderately differentiated ACPS A3, B1 
or C1). Patients with these intermediate stage CRCs benefit the least from traditional clinico-
pathological staging, largely due to molecular heterogeneity within these tumours. Modern 
clinico-pathological is proficient for predicting the outcomes for very good and very poor 
prognosis patients (ACPS A and D), but not for predicting the long-term outcomes of 
intermediate prognosis patients (ACPS B and C) (Eschrich et al., 2005). There are limited 
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clinico-pathological discriminatory factors for intermediate stage CRCs, where the tumour 
has infiltrated the muscularis propria, but is restricted to local lymph node metastasis, making 
it difficult to determine which patients would benefit from further therapy. It is current 
practice to offer chemotherapy to all ACPS C patients but not all B stage patients. Although 
the majority of ACPS A and B patient will be cured by surgery alone, some patients would 
benefit from further therapy. In addition, at least one third of ACPS C patients are cured by 
surgery and, therefore, undergo unnecessary, and potentially debilitating, further treatment 
(Durrant et al., 2003). 
 
Molecular profiling of cell surface antigens may provide a more accurate representation of 
cancer progression in intermediate stage tumours hence providing additional information for 
improved post-operative treatment and outcomes. Antibodies against 122 cells surface 
markers have been included on the antibody microarray to immunophenotype two sub-
populations of cells derived from primary CRC patients. We were first able to cluster groups 
of cell profiles derived from CRC and normal mucosal tissue (Figures 4.1 and 4.2), validating 
the selection of EpCAM
+
 and CD3
+
 profiles. Subsequently, an unsupervised hierarchical 
clustering of EpCAM
+
 CRC cell profiles identified 3 immunophenotypically distinct groups 
of CRC cells within clinico-pathologically indistinguishable tumours (Figure 4.3).  
We also observed similarly distinct immunophenotypes in the tumour-infiltrating T-cells 
population (Figure 4.4). A strong correlation was observed between the cancer cell profiles 
and the surface profiles of tumour infiltrating T-cells found around them (Figure 4.5), 
suggesting strong mutual influences between tumour cells and immune cells within the 
microenvironment. T-cells with high levels of activation (e.g. HLA-DR and CD71) and 
proliferation markers (e.g. CD5, CD47 and CD59) were found in tumours with CRC cell 
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immunophenotypes associated with reduced invasiveness and well differentiated cells. T-
cells exhibiting low levels of activation markers were indicating tumours with 
immunophenotypes associated with poorer prognosis and higher metastatic potential. The 
immunophenotyping of CRC cells and tumour infiltrating T-lymphocytes was highly 
effective in stratifying clinico-pathologically similar CRCs. Our results for the sub-
stratification of intermediate stage CRC patients on the basis of their cancer cell and T-cell 
surface expression profiles indicated that the DotScan antibody microarray approach may 
provide important additional prognostic and predictive information for this group of patients, 
enabling the identification of patients requiring further therapy after surgery. However, this 
application cannot be validated until the 5-year patient outcome information becomes 
available for analysis against the DotScan profiles.  
 
4.3.1 EpCAM+ CRC cell profile 
Twenty-four proteins showed altered expression between CRC and normal mucosa (Table 
4.2a). The largest group of tumour markers showing reduced expression on CRC cells 
belonged to the adhesion molecule family. Down-regulation of these antigens confers upon 
CRC cells the ability to evade contact inhibition mediated through tight adhesion to 
neighbouring cells and promotes proliferation through loss of cell-cell and cell-matrix 
adhesion (Nigam et al., 1993). 
Adhesion molecules are classified into 4 groups according to their biochemical structures: 
integrins, immunoglobulin-like proteins, cadherins and selectins (Menger and Vollmar, 
1996). Three of these groups showed reduced expression on CRC cells compared to normal 
intestinal mucosa cells (Table 4.2a): integrin subunits (CD49d, CD49f, CD29 and CD104), 
cadherin, (CD324) and immunoglobulin-like proteins (CD66e, CD47 and HLA-ABC). In 
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addition CD15, a member of the group of cell adhesion molecules that bind to selectin, was 
also reduced. Another family of proteins essential to the regulation of cell-cell interactions is 
the claudin family. Claudins play a key role in the construction of tight junctions, and 
reduced claudin-4 expression has been observed in many human malignancies (Ueda et al., 
2007), including the CRC cell surface observed here.  
The integrin family of cell adhesion proteins controls cell attachment to the ECM (Jin and 
Varner, 2004). Decreased CD29, CD49f and CD104 has been reported in CRC (Jin and 
Varner, 2004). Although reduced CD49d has been associated with invasion and metastasis in 
endometrial cancer and melanoma (Lessey et al., 1995, Qian et al., 1994), it has not 
previously been reported for CRC.  
Cadherins are responsible for cell-cell adhesion in epithelial tissues (Dorudi et al., 1993). 
Loss of CD324 (E-cadherin) has been associated with poorly differentiated CRC (Nigam et 
al., 1993), and CD324 is also reported to exhibit a gradual loss during CRC progression from 
adenoma to high grade carcinoma (van der Wurff et al., 1992). 
The immunoglobulin family protein CD66e (CEA) was found reduced on the surface of CRC 
cells (Table 4.2). In contrast, analysis of CRC whole cell lysates revealed elevated levels of 
cytoplasmic CD66e (Chapter 3: Table 3.2). This has been previously reported by in poorly 
differentiated CRC (Goldstein and Mitchell, 2005). The low surface expression of CEA may 
result from shedding of antigen from the cell surface into the circulation, which has been 
associated with higher vascular invasion in late stage CRC patients (Ng et al., 1993). 
Although found in the same family as CD66e, CD66c was found to be over-expressed on all 
tumour samples, and increased with CRC progression (Table 4.2a and 4.2b). In a previous 
study, CD66c up-regulation in colon carcinomas was also found to correlate inversely with 
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the degree of cellular differentiation and overall survival (Jantscheff et al., 2003). Well 
differentiated cancers are associated with better patient prognosis (Jass et al., 1986). 
Another immunoglobulin protein, CD47, was found at lower levels in CRC cells compared to 
normal mucosa. CD47 functions as a “don’t eat me” signal that ensures autologous cells are 
not inappropriately phagocytosed. Tumour cells often display signs of cellular “damage” 
and/or glycosidic variations on their cell surface, and these markers of “stressed self” may 
induce a reduction in CD47 expression and consequent recognition by natural killer (NK) 
cells. Although not observed in this study, some tumour cells have been reported to over-
express CD47 as a general mechanism to evade phagocytosis (Willingham et al., 2012). The 
cause of decreased CD47 expression on tumour cells is unknown, but may be an attempt to 
initiate phagocytosis of neoplastic cells. 
Several members of the immunoglobulin superfamily are involved in T-cell mediated 
responses that are antigen presenting molecules: the MHC class I receptor (including HLA-
ABC) and MHC class II receptor (including HLA-DR). The expression of HLA-ABC on 
tumour cells is essential for cytotoxic T-cell mediated responses and important for 
constraining tumour growth (Zinkernagel and Doherty, 1979). Consistent with its function, 
we found HLA-ABC was lower on tumour cells than normal cells. Down-regulated HLA-
ABC has been correlated with worse clinical outcomes and lower grade of differentiation in 
CRC (Cordon-Cardo et al., 1991, Garrido et al., 1993).  
We found HLA-DR to be elevated on CRC cells compared to normal cells, a trend consistent 
with previous studies (Diederichsen et al., 2003, Matsushita et al., 2006). In addition we 
found HLA-DR to be elevated on early stage CRC (Table 4.2b). The prognostic significance 
of HLA-DR levels remains debatable, as antigen-presenting cells found in CRC often lack 
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co-stimulatory signals, CD80 and CD86 (Schwartz, 1990), thus the interaction between HLA-
DR positive tumour cells and lymphocytes would give rise to anergy.  
 
In addition to adhesion molecules, several other surface molecules were found differentially 
expressed on EpCAM
+
 tumour and normal cells as discussed below. Epithelial cells express a 
variety of surface proteins that regulate cell fate. Two mediators of cell death, CD40 and 
CD95, were reduced on CRC cells, and the complement cofactor protein CD59 was also 
decreased, while the decay accelerating factor CD55 increased (Table 4.2a). The down-
regulation of CD40 and CD95, both members of the tumour necrosis factor family, has been 
documented in CRC (Georgopoulos et al., 2007, Moller et al., 1994). CD40 and CD95 
mediate growth inhibition or apoptosis through immune response and caspase activation, 
respectively.  
CD59 and CD55 protect cells from autologous lysis by complement (Durrant et al., 2003, 
Watson et al., 2006). The current study found that CD59 was reduced on cancer cells, while 
CD55 was elevated. Although elevated CD55 has been consistently observed in CRC 
(Durrant et al., 2003), reports of CD59 levels have been variable. Koretz et al. and Schmitt et 
al. described high CD59 levels in early stage and moderately to well differentiated CRC 
tumours (Koretz et al., 1993, Schmitt et al., 1999), whereas Watson et al. found reduced 
CD59 (Watson et al., 2006) and a correlation between the loss of CD59 and increased CD55 
in low-grade tumours. The differential expression of complement regulatory membrane 
proteins suggests that the over-expression of one or more regulator proteins compensates for 
the absence of others (Koretz et al., 1993).   
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CD98, an L-type amino acid transporter, was elevated on CRC cells (Table 4.2a) as well as 
other cancers (Kaira et al., 2008). CD98 provides a consistent supply of essential amino acids 
with consequent increased CRC tumour size (Ohkame et al., 2001). 
CD38 was reduced on CRC compared to normal cells (Table 4.2a). CD38 may be used as a 
cell differential marker (Mehta et al., 1996). Recently, CD38 negative CRC cells have been 
identified as cancer stem cells (Dalerba et al., 2007a).   
CD13 and CD26 are ectopeptidases that process bioactive peptides. We found CD13 to be 
reduced on CRC cells compared to normal EpCAM
+
 intestinal mucosal cells (Table 4.2a), but 
both were increased in late stage CRC (Table 4.2b). CD13 and CD26 positive cells have been 
associated in CRC with late stage processes, angiogenesis and metastasis (Hashida et al., 
2002, Pang et al., 2010).  
 
 
4.3.2 Hierarchical clustering of EpCAM+ CRC cells 
Unsupervised hierarchical clustering of EpCAM
+
 CRC profiles generated 4 distinct clusters 
(Figure 4.3). Cluster 1 contained slightly more early stage CRC with low levels of tumour 
invasion, while cluster 2 contained most of the metastatic tumours, with tumour infiltration 
beyond the serosa. Despite these differences, most of samples in each cluster were 
moderately differentiated stage B and C tumours (Table 4.4). There were, however, 
significant differences in antigen expression between these clusters (Table 4.5).  
The first split in the dendrogram generated cluster 1, a small group of 11 CRC patients 
distinct from the main group. The clinico-pathological properties of cluster 1 included several 
benign adenomas, several well differentiated tumours (Table 4.4) and no poorly differentiated 
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tumours. Cluster 1 had 20 differentially expressed proteins compared to cluster 2 (Table 
4.5a), 14 of which were previously observed reduced on CRC cells compared with normal 
mucosal cells (discussed in the previous section). Cluster 1 profiles were relatively similar to 
normal mucosal profile, as only 6 differential proteins were observed between them. Cluster 
1 CRC showed higher CD15, CD55, CD66c, CD66e (CEA), and CD98, while the death 
receptor CD95, was reduced. Of particular interest, the levels of CD15, CD66e and CD98 
were highest on cluster 1 samples, compared with samples from the other 3 cluster groups.   
CD15 belongs to a family of cell adhesion molecules that bind to selectin and are involved in 
leukocyte-endothelial adhesion. Elevated expression of CD15 on CRC may indicate adhesion 
to endothelium during metastasis. Elevated CD15 has been associated with poor prognosis in 
metastatic CRC (Hoff et al., 1990); however the majority of cluster 1 tumours were early to 
mid ACPS with metastatic tumours confined to local lymph node infiltration. For low-grade 
CRC (cluster 1) CD15 expression is restricted to cells at the invading front and the periphery 
of the primary tumour mass (Marcial et al., 1993). At these sites, CD15 appears to be 
involved in homotypic aggregation of CRC cells, and in heterotypic aggregation with other 
CD15-positive cells, such as T-cells (Brooks and Leathem, 1995). High CD15 may promote 
tumour invasion, but also encourage interactions with immune cells.   
High levels of surface CD66e have been reported on adenomas and differentiated CRC 
(O'Brien et al., 1981, Denk et al., 1972), consistent with the phenotype of cluster 1 tumours. 
CD66e is lower in moderately differentiated tumours, while poorly differentiated tumours 
may not express surface CD66e (Denk et al., 1972). Up-regulation of CD66e (CEA) on 
tumour cells may contribute to disruption of normal inter-cellular and cell-collagen bonds, 
contributing to disordered histological architecture and facilitating cellular migration 
(Goldstein and Mitchell, 2005).  
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Elevated CD98 on colonic cells has been reported to aggravate intestinal inflammation in a 
mouse model of chronic dextran sulphate sodium (DSS)-induced colitis, with greatly 
increased pro-inflammatory cytokines and chemokines (Nguyen et al., 2011). Therefore, 
within cluster 1, elevated CD98 over-expression may not be limited to CRC cells, but maybe 
also present on normal cells under the influence of inflammation. The link between chronic 
inflammation and tumourigenesis is well established (Mantovani et al., 2008); elevated CD98 
may occur at sites of inflammation before formation of malignant tumours. This proposal is 
supported by the elevated CD98 we observed on benign adenomas and CRC.   
Cluster 2 contains a large group of CRC patients (39), these CRC cells have reduced levels of 
antigens (20) compared with cluster 1 (Table 4.5a). Low levels of these antigens are 
characteristic of cancer cells, and many of them were previously found to be differentially 
abundant between CRC and normal mucosa. The immunophenotypes in cluster 2 can be 
further sub-divided into clusters 3 and 4 (Figure 4.3). Cluster 4 showed reduction expression 
of 13 surface antigens compared to cluster 3, while 2 antigens, CD49d and CD49e, were 
elevated. Cluster 4 showed the lowest levels of CD9, CD15, CD29, CD47, CD49f, CD59, 
CD63, CD66e, CD98, CD104, CD151, CD326 and HLA-ABC (Table 4.4b) and was the most 
immunophenotypically distinct from normal mucosa. The reductions in antigen levels in 
cluster 4 correlated with more poorly differentiated tumours (24%) than clusters 1 (0%) or 3 
(9%). 
Although clusters 3 and 4 shared similar numbers of metastatic CRC (32% and 35%, 
respectively) their immunophenotypes, suggested that cluster 4 may have higher metastatic 
potential and a worse prognosis, supported by over-expression of CD49d and CD49e, which 
correlate with enhanced metastatic activity (Okazaki et al., 1998). The reduced levels of 
HLA-ABC, CD66e and CD326 on CRC cells are associated with lower T-cell activation that 
may assist in CRC escape from the immune system (Nagorsen et al., 2000).   
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Tetraspanin proteins have recently been linked to cancer prognosis and metastasis (Le Naour 
et al., 2006). Although the tetraspanin proteins CD9, CD63 and CD151 were down-regulated 
on all CRC cells in our study, lowest expression was observed in cluster 4 (Table 4.2a,c). 
CD9 and CD63 both function as suppressors of metastasis (Le Naour et al., 2006, Sordat et 
al., 2002), while CD151 in solid tumours is inhibited by elevated hypoxia inducible factor 1 
alpha (HIF-1α) (Chien et al., 2008), a common response to limited oxygen within solid 
tumours. 
The ACPS differentiation grade and immunophenotypic differences between clusters, were 
consistent with other clinico-pathological observations. The proportion of patients over the 
age of 65 decreased as the clusters contained an increasing number of poorly differentiated 
tumours (Table 4.4). Tumour histological features, such as the occurrence of poorly 
differentiated and mucinous/signet ring cell tumours have been associated with CRC of 
young patients (Chung et al., 1998). However, the proposal that CRC in younger patients may 
correlate with poorer prognosis remains controversial (Molnar et al., 1994, Chung et al., 
1998). Cluster 4, that had the most patients with poorly differentiated CRC also contained 
more tumours from the right colon (descending colon, sigmoid and rectum), with a majority 
showing evidence of peri-tumoural inflammation (Table 4.4). Both of these factors have been 
reported to correlate with worse patient outcome (Wolmark et al., 1983, Coussens and Werb, 
2002).    
 
4.3.3 CD3+ tumour-associated T-cell profiles 
For the surface profiling of tumour-infiltrating T-cells, we used the standard 82-antibody 
region of the original DotScan microarray, that recognises a range of lineage-specific 
leukocyte markers, adhesion molecules, receptors and markers of inflammation and immune 
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response (Belov et al., 2003). Previous studies have shown that the presence of tumour-
infiltrating lymphocytes (TIL) in CRC is associated with reduced signs of metastatic invasion 
and prolonged survival (Pages et al., 2005). In this study we have profiled the antigen 
expression of CD3
+
 T-cells within CRC and normal intestinal mucosa to determine 
differences in their immunophenotypes and the possible use of T-cell profiling for CRC 
stratification.  
CD3
+
 profiles were normalised (Log2 transformed, median centre) to allow direct 
comparison between surface protein levels on T-cells in different samples. CD antigens levels 
were compared between CD3
+
 T-cells isolated around and within tumour tissue compared to 
T-cells on normal mucosa: 18 were reduced on tumour-infiltrating T-cells, the majority were 
adhesion molecules (Table 4.3a) and 6 antigens were elevated on tumour-associated T-cells: 
CD11c, CD49e, CD66c, CD71, CD86 and HLA-DR (Table 4.3a). CD71 and HLA-DR are 
associated with late-activated T-cells (Caruso et al., 1997), while CD86 on T-cells is found 
only after T-cell activation (Azuma et al., 1993). The adhesion molecule CD66c has 
previously been reported on T-cells (Singer et al., 2002) but no satisfactory function has yet 
been assigned to this protein.  
CD3 was found reduced on tumour-infiltrating CD3
+
 T-cells compared to T-cells in normal 
mucosa. T-cell signal deregulation in tumours was first described by Mizoguchi et al. and 
Nakagomi et al., where significantly less CD3 was found on T-cells isolated from CRC 
compared with those in the peripheral blood of those patients (Mizoguchi et al., 1992, 
Nakagomi et al., 1993). It was speculated that this reduction in CD3 resulted from local 
production of suppressor factors by CRC cells, deletion of some tumour-specific clones, and 
diminished production of lymphokines. Later studies identified tumour associated 
macrophages (TAM) as one of the factors responsible for the down-regulation of CD3 (Otsuji 
et al., 1996). TAMs induce immune-suppression through oxidative stress induced reduction 
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of CD3 on T lymphocytes, at the same time producing inflammatory cytokines and 
chemokines that contribute to tumour survival and proliferation (Sica et al., 2008). In spite of 
the reduced levels of the costimulation antigen CD3, we found that tumour-infiltrating T-cells 
exhibit higher levels of activation and proliferation markers than T-cells in normal tissue. 
These results suggest that tumour-associated T-cells may be activated through CD3-
independent pathways such as by interleukin-2 induced activation (Clevers et al., 1988).  
CD2, CD7, CD31 and CD44 all have fundamental roles in the regulation of T-cell adhesion 
(Shimizu et al., 1990, Tanaka et al., 1992) and were all reduced on the surface of tumour-
infiltrating T-cells (Table 4.3a).  Adhesion molecules function in two essential aspects of T-
cell physiology: migration and recognition. We found the integrin subunits, CD11c and 
CD49e, to be elevated on tumour-infiltrating T-cells while four others were reduced, CD11a, 
CD29, CD49d and CD103 (Table 4.3a). Integrin alpha subunits CD11a and CD11c can form 
a heterodimeric receptor with CD18 (antibody not on microarray), which is responsible for T-
cell adhesion to the vascular endothelium as well as T-cell activation and proliferation 
(Shelley et al., 2002, Krensky et al., 1983). Similarly, integrin alpha subunits CD49d and 
CD49e, bind to beta subunit CD29 to form very late activation antigen-4 (VLA4) and -5 
(VLA5), respectively. Both VLA4 and VLA5 promote proliferation of naïve and memory T-
cells through binding to fibronectin in the ECM (Davis et al., 1990). In addition, VLA4 and 
VLA5 are responsible for a rapid increase in adhesion to thrombospondin upon T-cell 
activation (Yabkowitz et al., 1993). Thrombospondin is an ECM protein that is transiently 
expressed at high concentrations in damaged and inflamed tissue. Hence the increased 
expression of CD49e on tumour-associated T-cells may reflect this homing potential. Further 
investigation is required to understand the reasons behind the differential expression of 
integrins in tumour-associated T-cells and their roles in tumourigenesis.  
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The reduced levels of CD103 (Integrin αE) on tumour-infiltrating T-cells suggest a decrease 
in the sub-population of intestinal intraepithelial regulatory T-cells. CD103 was reported to 
be necessary for efficient migration of T-cells into inflammatory sites where these cells are 
involved in suppression of peripheral inflammation (Huehn et al., 2004).    
Three tetraspanin proteins, CD9, CD63 and CD151, were reduced on tumour-associated T-
cells (Table 4.3a). CD9 is responsible for CD28-independent T-cell activation and 
proliferation (Tai et al., 1996). Similarly, CD63 is a T-cell activation-induced trans-
membrane protein involved in sustaining and amplifying the ongoing activation 
(Pfistershammer et al., 2004). CD151 directly interacts with integrin α3β1 and facilitates T-
cell migration (Chien et al., 2008). The expression of tetraspanins is not essential to normal 
T-cell function, since CD9- and CD151-deficient mice have normal immune function (Levy 
and Shoham, 2005).  
 
4.3.4 Hierarchical clustering of CD3+ tumour-infiltrating T-cells 
The hierarchical clustering of tumour-associated T-cells generated 3 clusters with different T-
cell characteristics. The first split in the dendrogram generated cluster 1, a small group of 14 
T-cell profiles distinct from the larger cluster 2 (Figure 4.4). Another division in the 
hierarchy, separated cluster 2 into clusters 3 and 4. We found T-cells in cluster 1 to be 
characteristic of T-cell exhaustion, consisting of well differentiated T-cells in the late stages 
of an immune response. Reduced T-cell activation and proliferation suggest prolonged 
exposure to chronic inflammation, which correlates with the relatively high levels of 
inflammation (57%) found around their corresponding tumours (Table 4.6). Cluster 3 T-cells 
exhibited intermediate levels of activation makers but reduced CD3 expression. The reduced 
levels of T-cell markers may reflect a lack of T-cells, as the clinico-pathological and 
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haematological information suggests cluster 3 contains lower than average levels of 
circulating and peri-tumoural lymphocytes (Table 4.6). Cluster 4 T-cells also have reduced 
CD3 but, unlike cluster 3, the members of this group contain much higher levels of activated 
lymphocytes in the circulation and around the tumour.  
 
The T-cell population of cluster 1 is characterised by well differentiated T-cells with low 
levels of activation and proliferation markers. The clinico-pathology data on this cluster 
indicate a high number of tumours with peri-tumoural inflammation (Table 4.6). Similar to 
viral infections, cancers induce functional tumour-specific T-cells; however, they gradually 
lose their function during the course of the cancer and, as a result, show signs of reduced 
activation and proliferation (Wherry, 2011). Evidence for this was observed in the reduction 
in CD8
+
 T-cells and the down-regulation of early- and late-activation markers (CD69 and 
HLA-DR, respectively) (Table 4.3). Several antigens associated with activated T-cells were 
also down-regulated: CD86 (Azuma et al., 1993), CD134 (Taylor and Schwarz, 2001) and 
CD151 (Hasegawa et al., 1996), along with two enzymes (CD13 and CD26) with regulatory 
functions in T-cell activation. Previous studies have shown that the mitogenic activation of 
human peripheral T-cells correlates with a large increase in CD13 mRNA content and the 
presence of CD13 on the surface of these cells (Lendeckel et al., 1996). Similarly, CD26 
molecule is able to transmit an activating signal to the T-cell and is associated with T-cell 
activation and proliferation (Fleischer, 1994).  
CD3, CD31 and CD43 are regulators of T-cell adhesion-induced signalling and were found to 
be over-expressed in cluster 1. They are mediators of integrin dependent-adhesion of T-cells 
to other cells and to the ECM. While integrins are expressed on circulating (“resting”) T-
cells, they do not mediate effective adhesion without induction from specific regulators 
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(Tanaka et al., 1992). CD3 is the critical adhesion inducer in antigen-specific recognition. 
CD3 induces the beta 2 integrin, particularly lymphocyte function-associated antigen 1 (LFA-
1). In turn, LFA-1 mediates binding to ICAM-1 on antigen-presenting cells, and such 
regulated adhesion accounts for many of the adhesive events that accompany antigen-specific 
T-cell recognition (Dustin and Springer, 1989).  
The adhesion-amplifying role for CD3 is analogous to the adhesion-amplifying role played 
by CD31 in T-cell-endothelium interaction. CD31 expression on T-cells induces the function 
of beta 1 integrin (CD29), particularly very late antigen-4 (VLA-4 integrin) (Tanaka et al., 
1992). Evidence for the “adhesion cascade” generated by CD31 is the observed high levels of 
CD49d, the alpha subunit of VLA-4, in cluster 1 (Figure 4.7). Past studies indicate that CD31 
is an amplifier of T-cell-endothelial cell interactions, as a result of the role of VLA-4 (Tanaka 
et al., 1992). In vivo studies in the rat model indicate the contribution of VLA-4 on T-cell 
movement into the gut (Issekutz, 1991). CD49d, may also have a role in gut-homing T-cells, 
as there is another CD49d-containing integrin (α4β7) that interacts with ligands on gut 
endothelium (Holzmann and Weissman, 1989).  
CD43 diminishes T-cell adhesion, irrespective of the adhesion pathway responsible (e.g. 
CD4, β1, or β2 integrins), and provides a general anti-adhesive barrier on cell surfaces, 
impeding the function of several types of receptors (Stockton et al., 1998, Onami et al., 
2002). The over-expression of CD43 by cluster 1 T-cells may prevent promiscuous adhesion 
in vascular beds, where ligand density is too low to override its anti-adhesive effect.  
The net result of increased CD31, CD43 and CD49d could be the enhanced selectivity of T-
cell migration to the gut or tumour site that displays the highest concentrations of homing 
receptor ligands.   
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Evidence of reduced T-cell proliferation in cluster 1 was indicated by the over-expression of 
CD57 and CD95. D’Angeac et al proposed that CD57 expression is a T-cell differentiation 
event during the late immune response on CD3
+
 T-cells (d'Angeac et al., 1994), while a 
similar study reported that CD57
+
 T-cells exert a suppressive effect on other T-cells 
(Brenchley et al., 2003). Although CD57
+
 T-cells could no longer be induced to proliferate, 
they remained efficient producers of cytokines. CD3
+
 CD57
+
 natural killer T-cells produced 
high levels of IFN-γ, that induces HLA-DR expression on a wide variety of cells, including 
tumour-derived cell lines (Trinchieri and Perussia, 1985). IFN-γ may influence HLA-DR 
over-expression on CRC. Similarly, over-expression of CD95 (Fas) helps terminate an 
ongoing immune response by inducing death of activation-mediated T-cells (Ju et al., 1995). 
Naïve T-cells express little or no Fas, whereas activated and memory T-cells show increased 
Fas in both CD4
+
 and CD8
+
 sub-populations (Aggarwal and Gupta, 1998). Some malignant 
tumours express CD95 ligand as a mechanism of inducing apoptosis of T-cells and to mediate 
immune escape (Hahne et al., 1996). Interestingly, both CD57 and CD95 increase on T-cells 
of aging humans (d'Angeac et al., 1994, Aggarwal and Gupta, 1998) but there was no 
correlation between cluster 1 patients and age (Table 4.6).  
This information suggests that cluster 1 T-cells may have been recruited to the tumour as part 
of an immune response. However, most of the T lymphocytes in this cluster also showed 
reduced activation/proliferation markers, correlating with T-cell exhaustion, and a lower 
capability of fighting the cancer compared with those in cluster 2. Clinico-pathologically, 
cluster 1 contains predominantly early stage tumours (86%) with a majority showing signs of 
peri-tumour inflammation (Table 4.6). This supports the proposal that inflammation plays an 
important role in early tumourigenesis, either as an initiator of CRC development or as a 
mediator of tumourigenesis once the tumour has formed (Hofseth and Ying, 2006). 
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Further down the hierarchy, the next division separated cluster 2 into two distinct groups 
(Figure 4.4). The phenotypic differences between clusters 3 and 4 showed increases in 
CD11c, CD31, CD66c, CD86 and CD95 in cluster 3, while cluster 4 had elevated CD5, CD9, 
CD11a, CD15, CD44, CD45, CD45RO, CD47, CD59, CD63, CD71, CD326 and CA19-9. 
Cluster 3 is characterised by intermediate levels of antigens. It shows higher levels of 
activation markers than cluster 1, but lower levels than cluster 4 (CD69, CD71 and HLA-
DR). T-cells in cluster 3 contain the highest levels of CD11c, CD66c and CD86, but the 
lowest levels of CD44 and CD45. CD11c and CD66c are endothelial adhesion markers, while 
CD86 expression has been associated with activated T-cells (Azuma et al., 1993). The 
reduced levels of CD44 and CD45 suggest a larger population of naïve T-cells within cluster 
3. Clinico-pathological information indicates that cluster 3 contains the largest number of 
metastatic tumours (47%) but the lowest levels of peri-tumour inflammation (27%), and 
lowest levels of circulating- and tumour infiltrating- lymphocytes, at 60% and 7% 
respectively (Table 4.6). These factors may contribute towards fewer T-lymphocytes in 
cluster 3 patients and the below average CD3 levels.  
The T-cell population in cluster 4 is characterised by elevated expression of the memory T-
cell markers, CD11a, CD44 and CD45RO (Sanders et al., 1988, Lee and Vitetta, 1991, 
Clement, 1992), and “classic” markers of T-cell activation and proliferation, CD44, CD45 
and CD71 (DeGrendele et al., 1997, Janeway, 1992, Brekelmans et al., 1994). CD15, 
increased in cluster 4 T-cells, may also be associated with T-cell activation (Chadburn et al., 
1992) and has been found elevated on tumour TILs isolated from various human cancers 
(Roussel et al., 1996). 
Cluster 4 T-cells show low levels of CD3, despite having relatively high levels of both 
circulating T-cells and TILs (Table 4.6). The presence of peri-tumoural inflammation may 
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reduce CD3 levels on T-cells, resulting from TAM mediated immune-suppression. However, 
activation markers are present on these T-cells, suggesting that alternative signalling 
pathways are involved. T-cells in cluster 4 also show elevation of the tetraspanin proteins 
CD9 and CD63, both associated with T-cell stimulation and activation. CD9 can induce 
stimulation of naïve T-cells independently of the co-stimulatory molecules CD28 and, CD80 
and CD86 on the surface of antigen presenting cells, which are generally considered to be the 
primary co-stimulatory pathway of T-cells (Tai et al., 1996). Similarly, the CD63 can induce 
T-cell activation independent of CD28, but relies on antigen presenting cells. Following 
antigen presenting cell co-stimulatory signal to T-cells, CD63 further sustains and amplifies 
the ongoing activation, resulting in efficiently stimulated T-cells (Pfistershammer et al., 
2004).  
The antigens CD5, CD47 and CD59, up-regulated on T-cells in cluster 4, have roles in T-cell 
survival. Recent reports have suggested CD47 to function in T-cell co-stimulation (Reinhold 
et al., 1997, Seiffert et al., 2001) and the active protection of T-cells from phagocytosis 
(Blazar et al., 2001). Elevated CD47 has been observed on haematopoietic stem cells as 
protection during migration to the periphery after a strong mobilisation or inflammatory 
stimulus (Jaiswal et al., 2009), and could also apply to migrating T-cells seeking out tumour 
targets. CD59 has also been implicated in T-cell activation (Korty et al., 1991) and the 
inhibition of complement-mediated lysis (Davies et al., 1989). CD59-mediated T-cell 
activation induces internalisation of the molecule and results in diminished surface CD59. As 
a result, active T-cells with decreased CD59 expression are susceptible to in vitro apoptosis 
by autologous complement as a means to control hyper-reactivity of T-cells (Tsunoda et al., 
2000). The up-regulation of CD59 may prolong the immune response by avoiding activation-
induced cell death. CD5 is expressed on the surface of all mature T-cells (Van de Velde et al., 
1991) and is elevated on TILs isolated from various human tumours (Dalloul, 2009). Over-
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expression of CD5 protects TILs from apoptosis mediated by uncontrolled over-reactivity to 
self-antigens (Friedlein et al., 2007). 
The immunophenotype of cluster 4 suggests these T-cells to be highly active and 
proliferative. T-cell activation is induced via a variety of stimulation pathways and sustained 
through the expression of multiple antigens (CD9 and CD63). In contrast to cluster 1 T-cells, 
cluster 4 T-cells show no sign of activation-induced apoptosis, with several antigens over-
expressed to ensure T-cell survival (CD5, CD47 and CD59).  
An interesting finding was the cell binding on antibody dots for CD326 (EpCAM) and CA19-
9 by cluster 4 T-cells. Both of these antigens are CRC markers (Nakayama et al., 1997a, 
Munz et al., 2009) and found on CRC cells, microvesicles and in serum. We speculate that 
the positive results for CD326 and CA19-9 may be due to the capture of T-cells on these 
antibody dots by virtue of adhering membrane fragments from damaged CRC cells on their 
surface. This is supported by the finding that positive CD326 and CA19-9 results were 
limited to the profiles of highly activated T-cells expressing high levels of adhesion 
molecules found within cluster group 4. While the large cancer cells were easily damaged 
during tumour disaggregation, T-cells remained intact, and no T-cell markers were detected 
in the EpCAM
+
 CRC profiles.  
 
4.3.5 Correlation between CRC cells profiles and T-cell profiles 
Tumour progression is a complex process that depends on interactions between CRC and 
normal cells (Hart and Saini, 1992). One aspect of the host response, the presence of 
infiltrating T-lymphocytes, is of particular interest, because signs of an immune response 
within CRC are associated with reduced tumour invasion and prolonged survival (Pages et 
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al., 2005). We found this to be the case, as T-cells with elevated activation and proliferation 
markers (T-cell cluster 4) were associated with well differentiated tumours with low 
metastatic potential (CRC cluster 1). The immunophenotype of the CRC cells within these 
tumours was similar to that of normal mucosa. This group of cancer cells, unlike those of 
clusters 3 and 4, retained the expression of several antigens that make them susceptible to an 
immune response, e.g., normal levels of HLA-ABC and CD95. HLA-A and B are essential 
for the presentation of antigens from within the cancer cell to T-cells (Zinkernagel and 
Doherty, 1979), while CD95 acts as a receptor for CD95 ligand on cytotoxic T-cells 
expressing CD95 (Moller et al., 1994).  
CRC cells in cluster 3 are characterised by moderate expression of tumour associated 
antigens and consist of infiltrating T-cells from all immune-phenotypic clusters (Figure 4.5). 
Within cluster 3, subsequent hierarchical divisions further stratify the CRC samples into sub-
groups that correlate with the distribution of T-cell cluster profiles. Metastatic tumours in 
cluster 3 are more likely to be associated with the activated T-cells from cluster 4, while non-
metastatic tumours are found with less activated T-cells from clusters 1 and 3. Interactions 
between CRC and associated T-cells may be responsible for the clustering of surface profiles 
and may provide additional information for the sub-classification of clinico-pathologically 
similar CRC. Further investigation is required to determine if the similarities in 
immunophenotype translates to similar patient outcomes.    
The immunophenotype of CRC cells in cluster 4 is associated with more aggressive tumours, 
with high metastatic potential. Subsequent divisions further down the hierarchy consist of 
samples corresponding to clusters 1 and 3 of the tumour-infiltrating T-cells. T-cell cluster 3, 
with low levels of moderately activated T-cells, contains samples corresponding to the 
metastatic tumours in cluster 4, while T-cell cluster 1, characteristic of T-cell exhaustion, 
corresponds to the non-metastatic tumours in cluster 3 (Figure 4.5). The immunophenotype of 
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this CRC cluster represents cells associated with a diminished or low level immune response. 
The down-regulation of HLA-ABC and the tumour-associated antigens, CD66e and CD326, 
on CRC cells in cluster 4 correlates with the reduction in activation markers on tumour-
infiltrating T-cells. In addition, these T-cells show high levels of surface CD95, while the 
corresponding CRC has reduced CD95. Previous studies reported that melanoma cells 
express CD95 ligand in order to escape immune surveillance by inducing apoptosis in CD95
+
 
T-cells, while also down-regulating their own CD95 (Hahne et al., 1996).  
This strong interrelationship between the immunophenotypes of CRC cells and T-cells from 
the same tumour illustrate the mutual influences between cancer cells and the various cells 
within their microenvironment. We have shown that surface profiling of CRC cells and 
tumour-infiltrating T-cells provides more discrimination between intermediate stage CRC 
than traditional clinico-pathological staging by ACPS.  
 
4.3.6 Conclusions and future studies 
The next logical step for this project would be to correlate the immunophenotypes with 5-
year patient survival data. The surface profiles for CRC and tumour infiltrating T-cells have 
clustered with good and poor prognosis. When information on 5-year patient outcome 
becomes available, these findings can be confirmed, and surface antigen profiles can be 
validated with a larger group of patients as a prognostic assay. In addition, we wish to 
correlate these profiles with cancer recurrence and response to therapy. The use of a training 
data set as established here coupled with an independent validation cohort is required to 
determine clinical utility.     
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Gene expression profiles and individual tumour markers (e.g., CEA or CD66e) have shown 
promise in predicting long-term outcomes in CRC patients, especially for intermediate ACPS 
B and C, where prognosis is problematic (Durrant et al., 2003, Eschrich et al., 2005). It has 
been suggested that multiple markers will be required to enable reliable sub-classification of 
cancers (Simpson and Dorow, 2001). The results presented here support this hypothesis, the 
profiling of CRC and infiltrating T-cells using DotScan microarrays may produce “disease 
signatures” that would provide a more accurate measurement of tumour progression and 
enable better prediction of patient survival. Hierarchical clustering generated clusters with 
surface profiles of CD antigens associated with good or poor prognosis. Clinico-pathological 
data from the extreme stages of CRC (early stage/ ACPS A versus metastatic/ stage D) and 
histological assessment (differentiation, tumour location, inflammation) supported the patient 
survival prediction for each cluster. Intermediate stage CRCs (ACPS B and C) were 
distributed within all cluster groups and showed various immunophenotypes. Surface profiles 
may enable distinction between intermediate-stage CRC patients that would benefit from 
adjuvant therapy, and those that would be cured from surgery alone. In addition, surface 
profiling enabled correlation between cancer cells and infiltrating T-lymphocytes. The 
correlation between activated T-cells and a favourable CRC immunophenotype shows that 
strong mutual influences shape the surface proteomes of CRC and T-cells within the 
microenvironment. Surface profiling detects molecular heterogeneity within ACPS B and C 
CRC with similar histology. DotScan analysis, in conjunction with clinico-pathological data, 
should enhance prognosis and enable more effective personalised treatment of CRC patients.    
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5.1 Proteomic techniques 
The proteomic techniques, saturation-DIGE and antibody microarrays, were used to identify 
differentially abundant proteins between whole cell lysates of CRC and matching normal 
intestinal mucosal cells. Although each technique yielded a substantial number of 
differentially abundant proteins (58 by Saturation-DIGE and 64 by antibody microarrays), 
there was no overlap between them. These results suggest that each method may only capture 
a specific subset of the proteomic changes. Interestingly, many of the differential protein 
changes between tumour stages were observed between Stage A and Stage C, but not for 
Stage B (e.g. proliferation markers, growth factors, suppressors of regulators). These results 
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may be the result of technical artefacts. However, precautions were taken in the experiment 
design to avoid data bias, such as running samples in random.   
Saturation-DIGE improves upon normal DIGE by significantly reducing the amount of 
protein required (5 µg per gel) because of label saturation on cysteine residues, and increased 
reproducibility with an internal control. However, the major limitation associated with 2D gel 
based techniques remains that low abundance proteins are not easily detected by 2D 
electrophoresis/MS proteomics (Gygi et al., 1999), because high abundance proteins often 
mask their detection. This was evident from our results; the majority of differential proteins 
detected by saturation-DIGE were relatively high abundance and involved in glycolysis (e.g., 
enolase, ATP synthase, aconitate hydratase) or stress response (e.g. Hsp60, peroxiredoxin, 
superoxide dismutase). This is unfortunate, since it is often the less abundant proteins that 
respond in interesting ways to various stimuli (Gygi et al., 2000).  
Antibody microarrays have been applied to cancer research for protein identification. 
Microarrays can simultaneously measure hundreds of proteins in a rapid, low volume assay. 
The major challenge with antibody microarrays is acquiring the desired set of antibodies. 
Consequently, many microarrays are limited to specific pathways or diseases (Huang et al., 
2001, Paweletz et al., 2001). Even a large-scale discovery focused microarray, such as the 
Explorer microarray, has only 656 antibodies. Selection bias can be inadvertently introduced 
as a result of antibody availability. Although many monoclonal and polyclonal antibodies are 
commercially available, it may not be financially feasible to incorporate multiple antibodies 
with redundant antigen specificities in an array. Several attempts have been made to replace 
expensive antibody production in hybridomas with scFvs or Fabs by phage display (Hallborn 
and Carlsson, 2002) or ribosomal display (Hanes et al., 2000), but this approach has not yet 
been widely used for microarray analysis. 
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In this study, the Explorer antibody microarray was able to detect changes in some relatively 
low abundance proteins (e.g., p73, chemokine receptor type 4), but displayed only weak 
binding for some of the proteins identified by saturation-DIGE/MS analysis (Hsp60, 
superoxide dismutase and glyceraldehyde-3-phosphate dehydrogenase). We speculate that the 
relatively low binding density of manganese superoxide dismutase (MnSOD)  on the 
microarray may be due to reduced affinity of the corresponding antibody with the mutant 
form of the protein (MnSOD Q143N mutant) identified by saturation-DIGE/MS (Table 3.2). 
This mutant contains a replacement of 143Gln→Asn, resulting in a slight conformational 
change (Hsieh et al., 1998). This mutation may alter the antibody binding site (antibody clone 
30F11 recognises MnSOD epitope N-terminal domains I-V), resulting in reduced detection 
by antibody microarrays. For GAPDH and Hsp60, no mutants were identified by MS but we 
did observe multiple charged isoforms of these proteins on the gel, some of which may lack 
the epitope recognised by the antibody clone used on the microarray. Proteins often undergo 
numerous post-translational modifications that may be crucial to their functions, but some of 
these modifications may render the protein undetectable by an antibody that recognises a 
specific isoform of the protein.  
Another source of inconsistencies in antibody microarray data is the variation in affinity and 
performance of different antibodies on the array, due to conformational changes after 
application on the solid phase. Heterogeneity in antibody affinity can span orders of 
magnitude. The performance of each individual antibody can depend on the chemistry of the 
solid surface to which it is applied, the buffer, the storage conditions and storage time. The 
shelf-lives of different antibodies vary in solution, and in the solid phase.  
The DotScan antibody microarray screens for known CD markers to classify CRC cells and 
infiltrating T-cells. Live cells are captured on the microarray via their surface antigens, 
recognised by antibodies of corresponding specificity on the microarray. This procedure 
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provides a profile of the cell surface proteome, with minimal chemical/physical alterations to 
protein integrity. The main challenge associated with this method is to profile cells under 
consistent conditions for all microarrays. The pairs of CRC tumour and mucosa samples 
contain a variety of cell types, of variable relative abundance. While we aim to use 6×10
6
 
total cells per microarray, the final number of cells profiled may vary with a heterogeneous 
cell population. Subtraction of background and normalisation of DotScan microarray data is 
critical for the comparison of different samples.   
Median normalisation was selected as the global normalisation technique, in preference to 
LOESS normalisation or normalisation relative to housekeeping proteins. Median 
normalisation is the simplest and most widely used global normalization technique for 
antibody microarray data. In cases where a large number of outliers in the sample data may 
provide an inaccurate estimate of the true centre of distribution, median centring can be 
employed. The advantage of median normalisation is its mathematical simplicity, enabling 
quick and easy implementation. Median centring, and its variations, have proven to be a 
reliable method of minimising technical variance for large-scale high-throughput data 
(Mestdagh et al., 2009, Wylie et al., 2011). The main issue with this normalisation method is 
that it implicitly assumes that differences between arrays and/or samples are of a linear 
nature. Despite these short-comings, median centring remains the preferred normalisation 
approach for antibody microarray analysis. It is hoped that a normalisation method capable of 
handling non-linear signals may be developed in the future, enabling the standardisation of 
antibody microarray normalisation. 
Direct implementation of LOESS normalisation to antibody microarray data has been shown 
to lower reproducibility and reduces correlation between data (Hamelinck et al., 2005). The 
main reason for this is that the LOESS method was developed for DNA microarray data and 
relies on having a large number of data points to produce an accurate measure of intensity-
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based differences between two samples. Generally antibody microarrays have fewer data 
points, often less than a thousand different antibodies, compared to 5,000 genes on DNA 
microarrays. Therefore, without compensation for fewer data points, direct translation of this 
normalisation method may add noise to the data and reduce the detection of true biological 
variation. 
Sets of housekeeping genes are often used to normalise DNA microarray data, but 
corresponding “house-keeping” proteins are more difficult to find for antibody microarrays, 
due to the dynamic nature of protein expression. Currently, there are no known proteins 
expressed at consistent levels on the surface of CRC cells and normal mucosa.   
 
5.2 Cancer markers: intracellular versus surface proteomics 
Alterations in the intracellular and surface proteomes of CRC cells, compared to normal 
intestinal mucosa, were investigated. The expression profiles of intracellular and surface 
proteins differentiated between cancer cells and normal mucosa (Table 3.2a, 3.3a and 4.2). 
Changes in the intracellular proteome reflected functional changes found in most cancer cells 
(e.g., elevation of glycolysis, proliferation signalling and stress-response proteins). These 
changes correlated with tumour progression and the availability of resources (such as space, 
oxygen and nutrient; Table 3.2b and 3.3b). Many of the changes in intracellular proteins 
correlated with disease stage and showed little variation between patients with histologically 
similar tumours. By contrast, the surface proteome showed greater diversity between same-
stage tumours, often correlating with external factors such as inflammation, circulating 
lymphocyte counts and the expression profiles of non-cancerous cells, such as tumour-
infiltrating T-cells (Table 4.2b and 4.4). 
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The differences in expression between intracellular and surface proteins may provide a guide 
to their application in CRC treatment. The characteristics of intracellular markers make them 
better anti-cancer drug targets; many are essential in tumourigenesis and remain relatively 
consistent within clinico-pathological stages. Our results also show that the CRC proteome is 
highly dynamic during CRC progression. These fluctuations in protein levels could be used to 
guide selection of the most effective drugs for a particular stage of CRC. Many of the 
proteins whose levels change are potential therapeutic targets, such as proteins involved in 
the Ras signalling pathway (Downward, 2003), glycolytic metabolism (Gatenby and Gillies, 
2007) and redox regulation (Trachootham et al., 2009). The effectiveness of these therapeutic 
interventions may be increased if they are tailored for the appropriate protein, for example 
Ras and its downstream Raf kinase are elevated in early CRC stage A patients (Table 3.3c). 
The proteins driving glycolysis (alpha-enolase, GAPDH, phosphoglycerate kinase 1 and L-
lactate dehydrogenase) were most abundant during intermediate CRC stage B and C (Table 
3.2b), or redox proteins (MnSOD and peroxiredoxins) elevated only in late metastatic C and 
D CRC (Table 3.2b and c).     
The immuno-phenotypes of cancer cells were highly variable within same-stage CRC (Figure 
4.3). Differences in surface antigen expression are dependent on the patient’s immune 
response, the microenvironment and on tumour progression. This variation between patients 
may enable sub-classification of CRC and indicate the patient-specific immune response to 
CRC. For example, the presence of the one or all HLA-A,B and C antigens on the surface of 
tumour cells indicate the presence of antigen presentation machinery able to initiate an 
immune response (Romero et al., 2005). Our data confirm that, CRC cells with high levels of 
HLA-ABC were more likely to be associated with activated TILs (Figure 4.5). There was a 
correlation between the immuno-phenotypes of CRC cells and their tumour-infiltrating T-
cells. This relationship shows that interactions between CRC cells and immune cells are 
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variable within CRC stages, especially for intermediate B and C CRC. Histologically similar 
CRC can be sub-classified by the level of local tumour infiltrating T-cells. An assay that 
could determine the positive or negative influences of these interactions with TILs could be 
used to determine the course of treatment and overall survival.      
 
5.3 Future research 
The direction of this study is to apply the DotScan™ CRC microarray as a rapid approach 
(workflow 3 hr) to antigen profiling of cells isolated from clinical samples. It can be adapted 
to contain small number of antibodies that detect only the signature antigens, to reduce costs. 
While the current results obtained are promising, the survival data and validation with a 
larger independent cohort is required to confirm the surface signatures. There is implicit bias 
in the results presented here as, due to the small sample size, no validation could be 
performed. These limitations are part of the inherent challenges associated with using fresh 
clinical CRC: the limited availability of samples and the 3-year waiting period for outcome 
data. Surface profiling may focus attention on the association between tumor spread and 
patient survival, and the influence of the host immune response on patient outcome. 
Application of prognostic antigen signatures may aid in the identification of interactions 
between cancer cells and T-cells, and together with traditional clinico-pathologic staging, 
may improve the selection of high-risk CRC patients who could benefit most from adjuvant 
therapy.    
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5.4 Conclusions 
Expression patterns of biomarkers have enormous potential to improve diagnosis, guide 
molecularly targeted therapy and monitor proliferative activity and therapeutic response of 
CRC. As cancer therapies become increasingly patient specific, biomarkers play greater roles 
in cancer staging and treatment. The evolution of powerful proteomic methods for high 
throughput analysis has facilitated biomarker discovery. In this project, saturation-DIGE and 
Explorer antibody microarrays have provided extensive profiles of proteins that are 
modulated during CRC progression. These protein changes offer a proteomic approach to 
CRC stratification and insight into the tumour microenvironment. Essential processes in CRC 
progression, such as glycolysis, ER stress response, angiogenesis and the redox response, 
offer molecular landmarks for CRC progression and novel targets for therapy. The sequential 
nature in which these protein changes occur may also allow clinicians to predict 
physiological events occurring within the cancer cells and tailor treatments accordingly.    
The cancer surface proteome offers a unique perspective of the interactions between cancer 
cells and normal cells in the microenvironment. The DotScan antibody microarray enables 
the profiling of surface antigens on viable cells and utilises cell specific panels of antibodies 
to profile the immunophenotype of CRC cells and tumour-infiltrating T-cells. We have 
identified distinct groups of cancer cells and infiltrating T-cells from histologically similar 
tumours. These differences in antigen expression correlate with CRC cell differentiation, 
peri-tumoural inflammation and T-cell stimulation. The application of surface profiling 
enables more accurate prediction of survival in same stage tumours. We have also found that 
CRC cell profiles correlate with the pattern of surface proteins of their tumour-infiltrating T-
cells. This finding proves that cancer antigens are actively influencing the surface protein 
expression of neighbouring cells and vice versa. This degree of mutual influence suggests 
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that patient survival is dependent on cancer progression permitted by surrounding 
microenvironment. 
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Appendix  
 
6.1 Explorer antibody microarray  
 
 
Figure 6.1 The Explorer antibody microarray consisted of 656 antibodies arranged over 5 
duplicate panels (1-5). Panels 1 – 4 consist of 128 antibodies while panel 5 contains 144 
antibodies. The antibody are listed in table 6.1 below.  
 
 
 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
A 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
B 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
C 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48
D 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64
E 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80
F 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96
G 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112
H 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
A 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144
B 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160
C 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176
D 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192
E 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208
F 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224
G 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240
H 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
A 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272
B 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288
C 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304
D 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320
E 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336
F 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352
G 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368
H 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
A 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400
B 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416
C 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432
D 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448
E 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464
F 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480
G 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496
H 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
A 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528
B 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544
C 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560
D 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576
E 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592
F 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608
G 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624
H 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640
I 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656
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Table 6.1 Explorer microarray antibody list.  
ID Antibody Name Reactivity IG Isotype Epitope Source 
1 p18INK4c HM N/A aa 155-168 Rabbit 
2 Cyclin B1 HMR N/A C-terminal Rabbit 
3 Cyclin C HMRD N/A aa 290-303 Rabbit 
4 Cyclin E HMR N/A C-terminal Rabbit 
5 Cdk3 HMR 
 
aa 290-305 Rabbit 
6 Cdk8 HMR N/A aa 451-464 Rabbit 
7 BRCA2 (aa 1323-1346) H N/A aa1324-1347 Rabbit 
8 Nck HMR N/A Not determined Rabbit 
9 CDC37 HM N/A aa 369-379 Rabbit 
10 p19Skp1 HM N/A aa 152-163 Rabbit 
11 CDC47 HMRDX IgG1 / κ Not determined Rabbit 
12 Cullin-1 (CUL-1) HM N/A aa 742-752 Rabbit 
13 CDC34 H N/A aa285-298 Rabbit 
14 p14ARF H N/A aa 119-132 Rabbit 
15 Cullin-2 (CUL-2) HM N/A aa 733-745 Rabbit 
16 Cyclin E2 H N/A aa 391-404 Rabbit 
17 GSTmu H N/A Not determined Rabbit 
18 DNA Polymerase Gamma HM N/A aa714-1061 Rabbit 
19 Gab-1 HMRY N/A aa 675-694 Rabbit 
20 SIRP a1 HY N/A aa476-503 Rabbit 
21 DNA Primase (p49) HM N/A Not determined Rabbit 
22 DNA Primase (p58) HM N/A Not determined Rabbit 
23 APC11 HM N/A aa 76-84 Rabbit 
24 APC2 HM N/A aa 76-84 Rabbit 
25 ROC HM N/A aa 97-108 Rabbit 
26 Endostatin H N/A Not determined Rabbit 
27 Caspase 5 HMRSTWY N/A Middle region Rabbit 
28 FGF-1 H N/A Not determined Rabbit 
29 Catenin alpha HM N/A Not determined Rabbit 
30 Catenin beta HM N/A Not determined Rabbit 
31 Stat-1 H N/A C-terminal Rabbit 
32 Stat3 HMR N/A C-terminal Rabbit 
33 Stat5a HMR N/A C-terminal Rabbit 
34 Stat5b HMR N/A C-terminal Rabbit 
35 Stat6 HMR N/A C-terminal Rabbit 
36 Negative Control for Rabbit IgG All N/A Not determined Rabbit 
37 Heat Shock Protein 27/hsp27 HY IgG1 Not determined Mouse 
38 Glucose-Regulated Protein 94 HMRDEGpKPSTX IgG2a Not determined Rat 
39 c-erbB-2/HER-2/neu Ab-1 (21N) HMRY N/A C-terminal Rabbit 
40 p53 H IgG1 aa 212-217 Mouse 
41 PCNA HMR IgG2a / κ Not determined Mouse 
42 Retinoblastoma H IgG1 aa703-722 Mouse 
43 Cdk1/p34cdc2 HMRGKX IgG2a aa220-227 Mouse 
44 pS2 H IgG1 Not determined Mouse 
45 CD45RO HM IgG2a / κ Not determined Mouse 
46 FGF-2 H N/A Not determined Rabbit 
47 CD54/ICAM-1 
H IgG1 / κ 
Extracellular (close to 
transmembrane domain) 
Mouse 
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48 Keratin 14 HR IgG3 C-terminal Mouse 
49 nm23 H N/A aa 86-102 Rabbit 
50 Topoisomerase IIa H N/A aa 1513-1530 Rabbit 
51 Heat Shock Protein 90b/hsp84 HMR N/A aa 2-13 Rabbit 
52 claudin 11 HMR N/A C-terminal Rabbit 
53 Heat Shock Protein 60/hsp60 HMRKS IgG1 aa 383-447 Mouse 
54 DJ-1 H N/A C-terminal Rabbit 
55 bcl-2a 
H IgG1 / κ 
GAAPAPGIFSSQPG-
Cys 
Mouse 
56 Involucrin HRDP IgG1 Codon 421-568 Mouse 
57 SIM Ag (SIMA-4D3) H N/A Not determined Mouse 
58 Tenascin H IgG1 Not determined Mouse 
59 Vimentin HMRCDKSTY IgG1 / κ Not determined Mouse 
60 CDw75 H IgM / κ Not determined Mouse 
61 E3-binding protein (ARM1) H N/A Not determined Mouse 
62 Myeloid Specific Marker H IgG1 Not determined Mouse 
63 MHC II (HLA-DR) Ia H IgG2b Not determined Mouse 
64 CD57 H IgM / κ Not determined Mouse 
65 TAG-72 
HRDSW IgG1 / κ 
Mucin-carried-
sialylated-Tn epitope 
Mouse 
66 Keratin 18 H IgG1 Not determined Mouse 
67 Kappa Light Chain H IgG1 / κ Not determined Mouse 
68 Epithelial Specific Antigen H IgG1 / κ Not determined Mouse 
69 Mucin 5AC 
MRCPTK IgG1 / κ 
Destroyed by β-
mercaptoethanol and 
proteases but not by 
periodate treatment 
Mouse 
70 CD43 H IgG1 Not determined Mouse 
71 Macrophage HMRCDGpY IgG1 Not determined Mouse 
72 Keratin, Multi HMRW IgG1 Not determined Mouse 
73 EMA/CA15-3/MUC-1 
H IgG1 / κ 
APDTR in tandem 
repeats 
Mouse 
74 Keratin 5/8 H IgG1 / κ Not determined Mouse 
75 Keratin 10/13 HRC IgG2a Not determined Mouse 
76 MHC II (HLA-DP) H IgG2b Not determined Mouse 
77 MHC II (HLA-DQ) HP IgG2a Not determined Mouse 
78 Lck HMR IgG2b / κ aa 1-225 Mouse 
79 Fibronectin H IgG1 Peptide core Mouse 
80 Estrogen Receptor HMRTW IgG1 / λ aa 125-165 Mouse 
81 Inhibin alpha H IgG2a / κ aa 1-32 Mouse 
82 IL-8 H N/A Not determined Mouse 
83 Lambda Light Chain H IgG2a / k Not determined Mouse 
84 Granulocyte H IgG1 Not determined Mouse 
85 p170 / MDR-1 Ch IgG1 / κ Not determined Mouse 
86 Progesterone Receptor 
HKTW IgG1 / κ 
N-terminal half of 
human progesterone 
Mouse 
87 Keratin 19 H IgG2a / λ aa 312-335 Mouse 
88 Helicobacter pylori Helicobacter pylori N/A Not determined Rabbit 
89 CD25/IL-2 Receptor a H IgG1 / κ Not determined Mouse 
90 CD56/NCAM-1 
H IgG1 / κ 
Extracellular (close to 
transmembrane domain) 
Mouse 
91 FITC All IgG1 / κ Not determined Mouse 
92 PLAP H IgG2a / κ Not determined Mouse 
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93 Cyclin D1 HMR N/A C-terminus Rabbit 
94 Integrin beta5 HMRS N/A Not determined Mouse 
95 Cyclin D3 HMRY IgG1 / κ Not determined Mouse 
96 p16INK4a H IgG1 Not determined Mouse 
97 Cdk7 
HR IgG2b 
221 amino acid fragment 
of C-terminus 
Mouse 
98 Transglutaminase II HDT IgG1 / κ aa 447-478 Mouse 
99 HDJ-2/DNAJ HMRPSTY IgG1 aa 1-179 Mouse 
100 Alpha Fetoprotein (AFP) HDP IgG2a Not determined Mouse 
101 p21WAF1 H IgG2a Not determined Mouse 
102 Fibrillin-1 HW IgG1 / κ aa 451-909 Mouse 
103 Collagen II 
HMRKW IgG2a / κ 
Carboxyl-terminal one 
quarter of the type 
Mouse 
104 CD35/CR1 H IgG1 Not determined Mouse 
105 CD4 H IgG1 Not determined Mouse 
106 Mucin 2 H IgG1 Not determined Mouse 
107 CD45/T200/LCA H IgG1 Not determined Mouse 
108 Ga0 HRGpW IgG1 Not determined Mouse 
109 Gai1 HMRGpW IgG2b Not determined Mouse 
110 Myelin / Oligodendrocyte HMRCKY IgM Not determined Mouse 
111 tau HMRW IgG1 Middle of Tau Mouse 
112 MAP1B HRW IgG1 Not determined Mouse 
113 MAP2a,b HMRKW IgG1 aa 997-1332 Mouse 
114 IL-6 H N/A Not determined Rat 
115 Tubulin-b HMRW IgM Not determined Mouse 
116 E2F-2 HR IgG1 aa 1-85 Mouse 
117 p27Kip1 HMRD IgG1 / κ aa 83-197 Mouse 
118 Amphiregulin HM N/A aa 8-26 Rabbit 
119 Laminin Receptor H IgM Not determined Mouse 
120 Prostate Specific Antigen H IgG1 / κ Not determined Mouse 
121 Prohibitin HMRKP IgG1 Not determined Mouse 
122 E2F-3 HR IgG2b aa 1-132 Mouse 
123 UCP3 HRM N/A C-terminal Rabbit 
124 Heregulin HMR IgG2a Not determined Mouse 
125 MyoD1 HMRK IgG1 / κ aa 180-189 Mouse 
126 GFAP HRKP IgG1 / κ Not determined Mouse 
127 CLAUDIN 7 HMR N/A C-terminal Rabbit 
128 Ku (p80) HY IgG1 / κ aa 610-705 Mouse 
129 Ku (p70/p80) 
HMXY IgG2a 
A conformational 
epitope of p70/p80 dimer 
Mouse 
130 MDM2 HMR IgG1 / κ aa 154-167 Mouse 
131 MLH1 H N/A aa 557-756 Rabbit 
132 Bcl-6 H N/A aa 1-150 Rabbit 
133 S100 HMRW IgG2a Not determined Mouse 
134 Cdk4 HMRP IgG 1 / κ aa 1-20 Mouse 
135 c-erbB-4/HER-4 HMRW IgG2a/κ aa1295-1323 Mouse 
136 EGFR 
H N/A 
aa 985-996 (Cytoplasmic 
domain) 
Mouse 
137 Prostate Specific Acid Phosphatase H IgG1 Not determined Mouse 
138 Syk H N/A aa 313-339 Mouse 
139 Caspase 6 (Mch 2) H N/A N-terminal Rabbit 
140 Chromogranin A HRPTY IgG1 / κ Not determined Mouse 
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141 Mekk-1 HMR N/A Near C-terminus Rabbit 
142 ER beta HR N/A N-terminus Rabbit 
143 Neuron Specific Enolase H IgG1 Not determined Mouse 
144 IL-2 H N/A Not determined Rat 
145 Fyn HMR IgG1 / κ aa 26-75 Mouse 
146 Keratin, LMW HMRKTW IgG1 Not determined Mouse 
147 GM-CSF H N/A Not determined Rat 
148 Keratin, Pan 
HMRKTW 
IgG1 + 
IgG1 Not determined 
Mouse 
149 Collagen IX 
KQ IgG1 / κ 
Close to the C-terminus 
(COL2) of the HMW 
fragment, which is 
present in both the long- 
and short-form type IX 
collagens 
Mouse 
150 CNPase HMRCDEGPTWY IgG1 Not determined Mouse 
151 CD79a mb-1 HMRGpKPTWY IgG1 / κ GTYQDVGSLNIADVQ Mouse 
152 Neurofilament HMRCT IgG1 / κ Not determined Mouse 
153 TNF alpha H N/A Not determined Rat 
154 DNA-PKcs HR IgG1 aa 1-2713 Mouse 
155 Myeloperoxidase HMR N/A Not determined Mouse 
156 CA19-9 H IgM Not determined Mouse 
157 CD45RB H IgG1 Not determined Mouse 
158 Keratin 5/6/18 HRW IgG1 / κ Not determined Mouse 
159 NGF-Receptor (p75NGFR) HCT IgG1 / κ aa 1-160 Mouse 
160 Streptavidin 
Bacterium 
Streptomyces avidinii N/A Not determined 
Rabbit 
161 CD68 HRCY IgG1 / κ Not determined Mouse 
162 IL-1 alpha H N/A Not determined Rabbit 
163 Paxillin HR IgG1 / κ Not determined Mouse 
164 Heat Shock Factor 1 
HMR IgG1 
aa 425-439 of mouse 
HSF1 
Rat 
165 Heat Shock Factor 2 HMK IgG1 Not determined Rat 
166 Renal Cell Carcinoma HR IgG1 / κ Carbohydrate domain Mouse 
167 TNFa H IgG1 Not determined Mouse 
168 p95VAV HM IgG1 Not determined Mouse 
169 Thrombospondin 
HMRWDP IgG1 
Calcium-binding domain 
of TSP (Cterminal 
50kDa piece of the 
120kDa fragment) 
Mouse 
170 IL-1 beta H IgG1 Not determined Mouse 
171 Retinol Binding Protein HMRGTY IgG1 / κ aa 74-182 Mouse 
172 CD6 H IgG1 / κ Not determined Mouse 
173 CD15 H IgM Not determined Mouse 
174 CD20 H IgG2a / κ Extracellular domain Mouse 
175 XRCC1 HR IgG2b Not determined Mouse 
176 Interferon-g H IgG1 / κ Not determined Mouse 
177 DFF45 / ICAD H N/A Not determined Rabbit 
178 b-2-Microglobulin H IgG2a / κ Not determined Mouse 
179 Erk1 HMR N/A N-terminal Rabbit 
180 Androgen Receptor HD IgG1 aa 299-315 Mouse 
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181 Collagen VII 
HEGpGtPWY IgG1 / κ 
On non-helical (non-
collagenous) Cterminal 
region of collagen VII 
and is resistant to 
collagenase, trypsin, 
pronase, neuraminidase, 
chondroitinase, and 
hyaluronidase. However, 
it is lost by digestion of 
collagen VII with 
pepsin. 
Mouse 
182 Phosphotyrosine All IgG2b Not determined Mouse 
183 Filaggrin H IgG1 / κ Not determined Mouse 
184 sm HRPT IgG3 / κ Not determined Mouse 
185 Adrenocorticotrophic Hormone H IgG1 aa 1-24 Mouse 
186 Thomsen-Friedenreich Antigen HR IgM / κ Galβ1-3GalNAc Mouse 
187 Cdk2 HMR IgG2b Not determined Mouse 
188 Ornithine Decarboxylase HMR IgG1 aa 355-360 (-IWGPTC-) Mouse 
189 CD155/PVR (Polio Virus Receptor) HY IgG1 aa 35-50 Mouse 
190 CD36GPIIIb/GPIV H N/A Not determined Mouse 
191 GAD65 HR N/A C-terminal Rabbit 
192 MGMT H IgG1 aa 8-221 Mouse 
193 Thymidylate Synthase H IgG1 / κ Not determined Mouse 
194 Xanthine Oxidase 
HMRT IgG1 
C-terminal 358 amino 
acids 
Mouse 
195 Golgi Complex N/A N/A Not determined Mouse 
196 Perforin H IgG2b / κ Not determined Mouse 
197 Keratin 10 HRP IgG1 / κ Not determined Mouse 
198 Heat Shock Protein 70/hsp70 HKW IgG2a Not determined Mouse 
199 Dystrophin HMRKX IgG1 Not determined Mouse 
200 Plasma Cell Marker H IgG2a Not determined Mouse 
201 GnRH Receptor H IgG1 aa 1-29 Mouse 
202 LewisA 
H IgG1 / κ 
Gal β1-3(Fuc α1-4) 
GlcNAc 
Mouse 
203 NuMA H IgM / κ Not determined Mouse 
204 Thymidine Phosphorylase HMR IgG1 Not determined Mouse 
205 CD81/TAPA-1 H IgG1 / κ Not determined Mouse 
206 CD5 H IgG1 Not determined Mouse 
207 CD59 / MACIF / MIRL / Protectin H IgG1 / κ Not determined Mouse 
208 B-cell Linker Protein (BLNK) H IgG1 aa 4-205 Mouse 
209 mGluR5 HRT N/A C-terminal Rabbit 
210 
Milk Fat Globule Membrane 
Protein H IgG1 / κ Not determined 
Mouse 
211 CD1 H IgG2a / κ Not determined Mouse 
212 CD2 H N/A Not determined Rabbit 
213 CD1b H IgM / κ Not determined Mouse 
214 GABA a Receptor 1 HMR N/A N-terminal Rabbit 
215 CD14 H IgG1 / κ Not determined Mouse 
216 CD16 H IgG2a / κ Not determined Mouse 
217 CDw17 H IgM / κ Not determined Mouse 
218 CD26/DPP IV HR IgG2b / κ Not determined Mouse 
219 CD32/Fcg Receptor II 
H IgG1 / κ 
Second Ig-like domain 
(D2γ) 
Mouse 
220 mGluR1 HMRKY N/A C-terminal Rabbit 
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221 CD8 H IgG1 / κ Not determined Mouse 
222 CD21 
H IgG1 / κ 
5-8 short consensus 
repeats 
Mouse 
223 alpha-1-antichymotrypsin H N/A Not determined Rabbit 
224 Cadherin-E H N/A 600-707aa Rabbit 
225 Oct-2/ HMR N/A C-terminal Rabbit 
226 CD53 
H IgG1 / κ 
Extracellular (close to 
transmembrane domain) 
Mouse 
227 CDw78 H IgG1 / κ Not determined Mouse 
228 CD98 H IgM / κ Not determined Mouse 
229 CD100/Leukocyte Semaphorin H N/A Not determined Mouse 
230 Rabies Virus H IgG2a / κ Not determined Mouse 
231 MHC I (HLA-A,B,C) H+Primates IgG2a / κ Not determined Mouse 
232 MHC II (HLA-DR) HP IgG2a / κ Not determined Mouse 
233 MHC II (HLA-DP and DR) 
H IgG3 / κ 
Epitope common to 
human major 
histocompatibility 
(MHC) class II antigens, 
HLA-DR and DP 
Mouse 
234 MMP-2 (72kDa Collagenase IV) 
HMR IgG1 
N-terminal 
(APSPIIKFPGD-
VAPKTDK) 
Mouse 
235 MMP-9 (92kDa Collagenase IV) H IgG1 Not determined Mouse 
236 TIMP-1 HR IgG1 Not determined Mouse 
237 TIMP-2 H IgG1 aa 111-126 Mouse 
238 Bovine Serum Albumin W IgG1 / κ Not determined Mouse 
239 Interferon-a(II) H IgG1 / κ aa 43-53 Mouse 
240 Tubulin-a HMRGpKPW IgG1 / κ aa 426-450 Mouse 
241 p300 / CBP HMRKY IgG2b / κ aa 2071-2091 Mouse 
242 Adenovirus Type 5 E1A A IgG2a / κ Not determined Mouse 
243 Adenovirus Type 2 E1A A IgG2a / κ Not determined Mouse 
244 CD29 HP IgG1 / κ Not determined Mouse 
245 CD115/c-fms/CSF-1R/M-CSFR H IgG2b Not determined Rat 
246 MART-1/Melan-A H IgG2b / κ Not determined Mouse 
247 Keratin 16 H IgG1 C-terminal Mouse 
248 CD137 (4-1BB) H IgG1/ κ Ectodomain Mouse 
249 Cryptococcus neoformans All strains of C. 
neoformans IgG2b 
Carbohydrate moiety 
occuring on one or two 
glycoproteins. 
Mouse 
250 CD50/ICAM-3 H N/A Not determined Mouse 
251 Histone H1 H IgG2a Not determined Mouse 
252 Insulin Receptor Substrate-1 HMR IgG1 aa 1221-1235 Mouse 
253 Insulin Receptor H IgG2a / κ aa 469-592 (exon 7/8) Mouse 
254 Actin beta HMRCDGpKPST N/A N-terminus Rabbit 
255 IGF-1R H IgG1 aa 283-440 (exon 4-6) Mouse 
256 ERCC1 H IgG2a / κ Not determined Mouse 
257 XPA H IgG2a / k Not determined Mouse 
258 Hepatocyte Growth Factor H IgG2b Not determined Mouse 
259 IL-10 H N/A Not determined Rat 
260 CD18 H IgG2a Not determined Mouse 
261 Ruv A E. Coli IgG1 / κ Not determined Mouse 
262 Ruv B E. Coli IgG1 / κ Not determined Mouse 
263 Ruv C E. Coli IgG2b / κ Not determined Mouse 
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264 Plasminogen H IgG1 / κ Not determined Mouse 
265 Ezrin/p81/80K/Cytovillin HMRSTWY IgG1 aa 362-585 Mouse 
266 LRP / MVP HR IgG1 / κ Not determined Mouse 
267 6-Histidine All IgG2a / κ HHHHHHGS Mouse 
268 Transforming Growth Factor a HMRW IgG1 / κ C-terminal Mouse 
269 Maltose Binding Protein Bacteria IgM Not determined Mouse 
270 XPG H IgG2a / k Not determined Mouse 
271 IL-30 H N/A Not determined Rat 
272 Activin Receptor Type II H IgG1 Tyrosine kinase domain Mouse 
273 Mcl-1 H IgG1 / κ aa 1-327 Mouse 
274 Melanoma (gp100) H IgG2a Not determined Mouse 
275 von Hippel-Lindau Protein HM IgG1 / κ aa 1-54 Mouse 
276 RPA/p32 H IgG1 / κ Not determined Mouse 
277 RPA/p70 H IgG1 / κ Not determined Mouse 
278 CREB-Binding Protein HR IgG1 / κ Not determined Mouse 
279 TTF-1 HMR IgG1 / κ Not determined Mouse 
280 HIF-1a H IgG1 / κ aa 530-826 Mouse 
281 Surfactant Protein A H IgG2b / κ Not determined Mouse 
282 Surfactant Protein B (Pro) HR IgG2a / κ Not determined Mouse 
283 DR3 H IgG2a Not determined Mouse 
284 GST All IgG1 Not determined Mouse 
285 TR2 H IgG1 Not determined Mouse 
286 Bax H IgG1 / k aa 3-16 Mouse 
287 bcl-X HMPR IgG2a Cys-QSNRELVVDFLS Mouse 
288 Tubulin H N/A Not determined Mouse 
289 F.VIII/VWF H IgG1 / κ Not determined Mouse 
290 Factor VIII Related Antigen H N/A Not determined Rabbit 
291 IPO-38 Proliferation Marker HMR IgM / κ Not determined Mouse 
292 Moesin HRW IgG1 / κ Not determined Mouse 
293 Collagen IV H IgG1+ IgG1 Not determined Mouse 
294 Negative Control for Mouse IgG1 All IgG1 / κ Not determined Mouse 
295 CDC25C H IgG1 / κ aa 1-150 Mouse 
296 p73a HY IgG1 aa380-637 (p73α) Mouse 
297 p73a/b HY IgG1 / κ aa380-637 (p73α) Mouse 
298 Ang-1 HM N/A Not determined Rabbit 
299 HPV 16-E7 HPV-16 IgG2a / κ Not determined Mouse 
300 HPV 16 HPV-16 IgG2a Not determined Mouse 
301 L1 Cell Adhesion Molecule H IgG1 / κ Not determined Mouse 
302 Microphthalmia HMRD IgG1 / κ N-terminal Mouse 
303 DNA Ligase I HW IgG1 Not determined Mouse 
304 Ang-2 HM N/A Not determined Rabbit 
305 CD46 
H IgG2a / κ 
Four immunogenic short 
consensus repeat (SCR) 
domains at N-terminus 
of the protein 
Mouse 
306 B7-H2 H IgG2b / κ Extracellular Mouse 
307 CD84 H IgG1 / κ Not determined Mouse 
308 Heparan Sulfate Proteoglycan HMWP IgG2a / κ Not determined Rat 
309 Laminin B2/g1 HM IgG2a / κ Not determined Rat 
310 Laminin B1/b1 HMPS IgG1 / κ Not determined Rat 
311 Tyrosinase HCD IgG2a aa 1-433 Mouse 
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312 MMP-1 (Collagenase-I) 
H IgG1 / κ 
aa 1-81 of the pro-form 
of MMP-1 
Mouse 
313 A-Raf HMR N/A C-terminal Rabbit 
314 MMP-7 (Matrilysin) H IgG2b / κ Not determined Mouse 
315 MMP-10 (Stromilysin-2) H IgG2b Not determined Mouse 
316 MMP-13 (Collagenase-3) H IgG1 / κ Not determined Mouse 
317 uPA H IgG1 / κ Not determined Mouse 
318 BAG-1 H IgG1 Not determined Mouse 
319 MAGE-1 H IgG2a aa 37-44 Mouse 
320 S100A6 HMRCD N/A Not determined Rabbit 
321 Thymine Glycols All IgM / κ Not determined Mouse 
322 p130cas HR IgG1 / κ Not determined Mouse 
323 p130 H IgG1 aa 878-913 Mouse 
324 Claudin-1 HMRDY N/A C-terminal Rabbit 
325 CDC6 H IgG1 Not determined Mouse 
326 E2F-1 HMR IgG2a / κ aa1-89 Mouse 
327 p15INK4b HD IgG1 / κ Not determined Mouse 
328 p35nck5a H IgG2b / κ Not determined Mouse 
329 
DFF40 (DNA Fragmentation Factor 
40) / CAD H N/A N-terminal 
Rabbit 
330 IRAK HMR N/A C-terminal Rabbit 
331 PCTAIRE2 H N/A Not determined Mouse 
332 Cdk5 HMR IgG1 Not determined Mouse 
333 p19ARF M N/A Middle of p19ARF Rabbit 
334 CD106 / VCAM H N/A Not determined Mouse 
335 MHC I (HLA-A) 
H IgG1 / κ 
aa65-to-aa80 of the α1 
domain of the HLA-A 
Mouse 
336 MHC I (HLA25 and HLA-Aw32) H IgG2a / κ Not determined Mouse 
337 MHC I (HLA-B) 
H IgG1 / κ 
Intralocus determinant 
present on HLA-B locus-
encoded gene products 
Mouse 
338 Casein H IgG1 Not determined Mouse 
339 Alpha Lactalbumin H IgM Not determined Mouse 
340 c-Abl HM IgG1 / γ SH2 domain Mouse 
341 CD95 / Fas H IgG1 Not determined Mouse 
342 Parkin HMR N/A N-terminal Rabbit 
343 CD10 H N/A Not determined Rabbit 
344 Rad51 HMR IgG1 / κ Not determined Mouse 
345 CD1a H IgG1 / κ Not determined Mouse 
346 Keratin 8 H IgG1 / κ aa 343-357 Mouse 
347 IgA 
H IgG1 / κ 
Third constant domain 
(CH3) of the alpha chain 
of IgA 
Mouse 
348 Alkaline Phosphatase (AP) H IgG1 / κ Not determined Mouse 
349 Presenillin H N/A N-terminal Rabbit 
350 APC HMR N/A C-terminus Rabbit 
351 LewisB H IgG1 / κ Not determined Mouse 
352 Adenovirus Fiber A IgG2a / κ Not determined Mouse 
353 Negative Control for Mouse IgM All IgM Not determined Mouse 
354 MMP-11 (Stromelysin-3) H IgG1 / κ Not determined Mouse 
355 
Chorionic Gonadotropin beta 
(hCG-beta) H IgG2b / κ Not determined 
Mouse 
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356 Progesterone All IgG1 / κ Not determined Mouse 
357 Testosterone All IgG1 Not determined Mouse 
358 FSH-b H IgG1 / κ Not determined Mouse 
359 Estriol All IgG1 Not determined Rat 
360 Leukotriene (C4, D4, E4) H IgG1 Not determined Rat 
361 
Medroxyprogesterone Acetate 
(MPA) H IgG1 Not determined 
Rat 
362 Biotin All IgG1 / κ Not determined Mouse 
363 Estradiol All IgG2a / κ Not determined Mouse 
364 Growth Hormone (hGH) H IgG1 / κ Not determined Mouse 
365 IL-3 H N/A Not determined Rat 
366 E2F-4 HR IgG1 Not determined Mouse 
367 BrdU All IgG1 Not determined Mouse 
368 Keratin 15 HMRW IgG2a / κ C-terminal Mouse 
369 Adenovirus 
A 
IgG2a / κ + 
IgG2a / κ Not determined 
Mouse 
370 Glycophorin A H IgM / κ N-terminal Mouse 
371 p63 (p53 Family Member) HMR IgG2a / κ aa 1-205 Mouse 
372 TdT H IgG2a N-terminal Mouse 
373 Fascin HR IgG1 Not determined Mouse 
374 Myogenin HMRC IgG1 / κ aa 138-158 Mouse 
375 cdh1 H IgG1 / κ Not determined Mouse 
376 CD63 H IgG1 / κ Not determined Mouse 
377 Ret Oncoprotein H IgG1 C-terminal Mouse 
378 Caspase 3 H IgG2a Not determined Mouse 
379 
SRC1 (Steroid Receptor 
Coactivator-1) Ab-1 H IgG1 / κ Not 
Mouse 
380 GRIP1 H IgG1 / κ Not determined Mouse 
381 Caspase 9 HM IgG1 / κ Caspase 9 prodomain Mouse 
382 CA125 H IgG1 Not determined Mouse 
383 Heat Shock Protein 90a/hsp86 HMR N/A aa 2-12 Rabbit 
384 Calponin HR IgG1 / κ Not determined Mouse 
385 Caldesmon H IgG1 / k Not determined Mouse 
386 GCDFP-15 HR IgG2a / k Not determined Mouse 
387 CD42b H IgG1 Not determined Mouse 
388 
Myosin Smooth Muscle Heavy 
Chain H IgG1 / κ Not determined 
Mouse 
389 ER Ca+2 ATPase2 H N/A Not determined Mouse 
390 IL-10R H N/A Not determined Rat 
391 G-CSF H N/A Not determined Rat 
392 SHP-1 H IgG2b / κ Not determined Mouse 
393 CD40 H IgG1 / κ Not determined Mouse 
394 ATM H IgG1 C-terminal Mouse 
395 Survivin HR IgG1 / κ aa 1-99 Mouse 
396 
SREBP-1 (Sterol Regulatory 
Element Binding Protein-1) HS IgG1 / κ aa 301-407 
Mouse 
397 Vinculin H IgG1 Not determined Mouse 
398 Filamin HRGpKT IgG1 Not determined Mouse 
399 Mast Cell Chymase H IgG1 Not determined Mouse 
400 Amyloid A H IgG2a / κ Not determined Mouse 
401 CDw60 H IgM Not determined Mouse 
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402 Synaptophysin H IgG1 Near C-terminus Mouse 
403 Axonal Growth Cones H IgG1 Not determined Mouse 
404 Neurofilament (68kDa) H IgG1 Not determined Mouse 
405 Neurofilament (160kDa) H IgG1 Not determined Mouse 
406 Neurofilament (200kDa) H IgM Not determined Mouse 
407 Rhodopsin (Opsin) HMR IgG1 Not determined Mouse 
408 HRP Not determined N/A Not determined Rabbit 
409 IgG H IgG1 / κ Not determined Mouse 
410 Keratin 8 (phospho-specific Ser73) HM IgG2a LLpS/TPL Mouse 
411 Ferritin H IgG1 Not determined Mouse 
412 
Cystic Fibrosis Transmembrane 
Regulator H IgG1a / κ N-terminus 
Mouse 
413 GAPDH HMRChKTY IgM Not determined Mouse 
414 Tropomyosin HRK IgG1 / κ Not determined Mouse 
415 Calmodulin HRKW IgG1 Not determined Mouse 
416 ADP-ribosylation Factor (ARF-6) H IgG1 / κ Not determined Mouse 
417 
Parathyroid Hormone Receptor 
Type 1 H IgG1 / κ aa 146-169 
Mouse 
418 SRF (Serum Response Factor) H N/A Not determined Mouse 
419 
Gamma Glutamyl Transferase 
(gGT) H IgG1 Not determined 
Mouse 
420 Cytochrome c HDW IgG2a / κ Not determined Mouse 
421 CD9 H IgG1 / κ Not determined Mouse 
422 CD24 H IgG1 / κ Not determined Mouse 
423 CD79b H IgG1 / κ Extracellular domain Mouse 
424 CD165 H IgG1 / κ Not determined Mouse 
425 CD231 H IgG1 / k Not determined Mouse 
426 Green Fluorescent Protein (GFP) All IgG1 / κ Not determined Mouse 
427 CD3zeta 
HMR IgG1 
aa 36-54 of T Cell 
Receptor ζ Chain 
Mouse 
428 CD105 H IgG1 / κ Not determined Mouse 
429 Clathrin HW IgG2b / κ aa23-44 Mouse 
430 PMP-22 H IgM / κ aa 118-132 Mouse 
431 Luciferase All IgG1 / κ Not determined Mouse 
432 Actin, Pan HMRDKPTW IgG1 / κ Not determined Mouse 
433 Actin, Muscle Specific HMRDPW IgG1 / κ Not determined Mouse 
434 Hepatocyte Factor Homologue-4 HR IgG1 / κ Not determined Mouse 
435 Hepatic Nuclear Factor-3B H IgG2a / κ Not determined Mouse 
436 Surfactant Protein B H IgG2a / κ Not determined Mouse 
437 Ras HMRW N/A aa 31-43 Rabbit 
438 Calcium Pump ATPase H IgG1 / κ aa 1156-1180 Mouse 
439 Heat Shock Protein 75/hsp75 H IgG Not determined Mouse 
440 B-Cell M IgG2b / κ Not determined Rat 
441 
Thyroid Hormone Receptor, 
Human HMRP IgG2a / κ aa 13-32 
Mouse 
442 
Thyroid Hormone Receptor beta, 
human HD IgG1 / κ aa31-50 
Mouse 
443 Laminin-s HGpRKTW IgG1 Not determined Mouse 
444 L-Plastin H IgG1 Headpiece region Mouse 
445 b Galactosidase All IgG1 Not determined Mouse 
446 Progesterone Receptor (phospho- H IgG1 / κ aa184-196 Mouse 
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specific) - Serine 190 
447 
Progesterone Receptor (phospho-
specific) - Serine 294 H IgG1 / κ aa 288-300 
Mouse 
448 PR3 (Proteinase 3) H IgG1 / κ Not determined Mouse 
449 bcl-XL HM IgG2a TEAPEETEAERETPSA Mouse 
450 Prolactin Receptor H IgG1 Not determined Mouse 
451 Notch HM IgG2b Ligand binding region Mouse 
452 Retinoic Acid Receptor (b) H IgG1 / κ aa 11-25 Mouse 
453 Retinoid X Receptor (hRXR) 
H IgG2a / κ 
aa 213-226 (Hinge 
region) 
Mouse 
454 MCM2 H IgG1 Not determined Mouse 
455 Negative Control for Mouse IgG3 All IgG3 / κ Not determined Mouse 
456 Prolactin H IgG1 / κ Not determined Mouse 
457 Thyroglobulin HMRD IgG1 Not determined Mouse 
458 Mitochondria H IgG1 Not determined Mouse 
459 c-Src HMR N/A N-terminal Rabbit 
460 Insulin HRPTW IgG1 / κ Not determined Mouse 
461 XPF H IgG2 / κ Not determined Mouse 
462 Negative Control for Mouse IgG2a All IgG2a / κ Not determined Mouse 
463 MCM5 H IgG2b Not determined Mouse 
464 RAD1 H IgG2a / κ Not determined Mouse 
465 DNA Polymerase Beta H IgG2a Not determined Mouse 
466 c-fos H IgG2a Extracellular domain Mouse 
467 c-jun H N/A Not determined Rabbit 
468 DP-2 HMR N/A C-terminus Rabbit 
469 E2F-5 HMR N/A N-terminal Rabbit 
470 Glucagon HMR N/A Not determined Rabbit 
471 Pneumocystis jiroveci Pneumocystis jiroveci IgM / κ Not determined Mouse 
472 Topo II beta H N/A C-terminal 300 aa Rabbit 
473 Fli-1 HMR N/A C-terminal Rabbit 
474 ITK HM IgG1 / κ N-terminal Mouse 
475 LH H IgG1 / κ Not determined Mouse 
476 FSH HW IgG1 / κ Not determined Mouse 
477 
Thyroid Stimulating Hormone 
(TSH) H IgG1 / κ Not determined 
Mouse 
478 Grb2 HMRW IgG1 / κ aa 54-62 Mouse 
479 CXCR4 / Fusin H IgG2a / κ Not determined Mouse 
480 
Vacular Endothelial Growth 
Factor(VEGF) H IgG1 / κ Not determined 
Mouse 
481 14.3.3 gamma H IgG1 / κ Not determined Mouse 
482 14.3.3, Pan H IgG1 / κ Not determined Mouse 
483 IL-4 H N/A Not determined Rat 
484 Ki67 HR N/A Middle of Ki67 protein Rabbit 
485 Pds1 H IgG2a / κ Not determined Mouse 
486 Chk1 H N/A Not determined Rabbit 
487 IL-5 H N/A Not determined Rat 
488 PARP HMR N/A N-terminal Rabbit 
489 Calcitonin HMRDEPY N/A Not determined Rabbit 
490 Bak HMS N/A N-terminal Rabbit 
491 Cadherin, (Pan) HMRDKWXY N/A C-terminal Rabbit 
492 Flk-1 / KDR / VEGFR2 HMR Synthetic C-terminal Rabbit 
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peptide 
493 Flt-1 / VEGFR1 HMR N/A C-terminal Rabbit 
494 TRADD H N/A C-terminal Rabbit 
495 Exo1 HM IgG1 / κ Not determined Mouse 
496 MMP-23 H N/A Not determined Rabbit 
497 MMP-14 / MT1-MMP 
H N/A 
Second quarter of MMP-
14 
Rabbit 
498 MMP-15 / MT2-MMP 
HM N/A 
Catalytic domain of 
mouse MMP-15 
Rabbit 
499 MMP-16 / MT3-MMP HMR N/A Catalytic domain Rabbit 
500 I-FLICE / CASPER H N/A C-terminal Rabbit 
501 TID-1 HMR IgG1 / κ Not determined Mouse 
502 Somatostatin Receptor-I HMR N/A C-terminal Rabbit 
503 NOS-u HMRPW N/A C-terminal Rabbit 
504 Fra2 H N/A C-terminal Rabbit 
505 Synuclein H IgG2a / κ Not determined Mouse 
506 ERK2 HMR N/A Not determined Rabbit 
507 Cullin-3 (CUL-3) HM N/A N-terminal Rabbit 
508 p73 H N/A aa1-15 Rabbit 
509 RAIDD H N/A C-terminal Rabbit 
510 MADD 
H N/A 
Second half of MADD 
protein 
Rabbit 
511 XRCC2 H N/A N-terminal Rabbit 
512 
Glycogen Synthase Kinase 3b 
(GSK3b) HMRW N/A 
Kinase subdomain XI 
region 
Rabbit 
513 Granzyme B HR N/A aa 139-157 Rabbit 
514 Keratin 8/18 
H 
IgG1 / κ + 
IgG1 Not determined 
Mouse 
515 NOS-i HMR N/A C-terminal Rabbit 
516 Caspase 1 
HMR N/A 
Second quarter of 
Caspase 1 
Rabbit 
517 D4-GDI HW N/A N-terminal Rabbit 
518 Bim (BOD) HMR N/A N-terminal Rabbit 
519 PLC gamma 1 HRW N/A C-terminal Rabbit 
520 PHAS-I HMR N/A C-terminal Rabbit 
521 TRP75 / gp75 H IgG2a Not determined Mouse 
522 p57
Kip2 
Ab-7 HMW N/A Near C-terminus Rabbit 
523 NF kappa B / p65 (Rel A) HDMPRSTW N/A C-terminal Mouse 
524 Amyloid A4 Protein Precursor HMR N/A Extreme C–terminus Rabbit 
525 Amyloid Beta (APP) 
HMR N/A 
aa653-662 
(DAEFRHDSGY) 
Rabbit 
526 ARC H N/A C-terminal Rabbit 
527 NF kappa B / p50 H N/A aa44-61 Rabbit 
528 Lck (p56lck) H N/A Near the N-terminus Rabbit 
529 AIF (Apoptosis Inducing Factor) H N/A N-terminal Rabbit 
530 
Human Sodium Iodide Symporter 
(hNIS) H IgG1 / κ aa625-643 
Mouse 
531 Caspase 7 (Mch 3) H N/A Not determined Rabbit 
532 Ask1 / MAPKKK5 H N/A C-terminal Rabbit 
533 
TACE (TNF-alpha converting 
enzyme) / ADAM17 HMR N/A C-terminal 
Rabbit 
534 Zip kinase HMR N/A Not determined Rabbit 
535 Mek1 HMR N/A N-terminal Rabbit 
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536 Mek2 HMR N/A N-terminal Rabbit 
537 Mek6 HMR N/A N-terminal Rabbit 
538 I-Kappa-B Kinase b (IKKb) HMR N/A Near C-terminus Rabbit 
539 JNK Activating kinase (JKK1) HMR N/A Near C-terminus Rabbit 
540 FLIP HM N/A C-terminal Rabbit 
541 Raf1 HMRF N/A Middle of Raf1 Rabbit 
542 
PARP (Poly ADP-Ribose 
Polymerase) HMRW N/A C-terminal 
Rabbit 
543 Bonzo / STRL33 / TYMSTR H N/A Near the C-terminus Rabbit 
544 
FADD (FAS-Associated death 
domain-containing protein) HM N/A Middle of mouse FADD 
Rabbit 
545 SODD (Silencer of Death Domain) H N/A C terminal Rabbit 
546 Vitamin D Receptor (VDR) H N/A C-terminal Rabbit 
547 PDGFR, alpha HMR N/A C-terminal Rabbit 
548 PDGFR, beta HM N/A Near C-terminal Rabbit 
549 Daxx HKM N/A C-terminal Rabbit 
550 Caspase 8 (FLICE) HMRW N/A Not determined Rabbit 
551 
Gamma Glutamylcysteine 
Synthetase(GCS)/Glutamate-
cysteine Ligase HMR IgG1 aa 295-313 of rat GCLC 
Rabbit 
552 DcR2 / TRAIL-R4 / TRUNDD H N/A Intracellular Rabbit 
553 Caspase 2 HMRK N/A C-terminal Rabbit 
554 CREB HMR N/A Middle region Rabbit 
555 
Nitric Oxide Synthase, brain 
(bNOS) HR N/A Near N-terminal 
Rabbit 
556 Acinus 
HM N/A 
Present in AcinusL, 
AcinusS’ and AcinusS 
Rabbit 
557 CIDE-A H N/A C-terminal Rabbit 
558 CIDE-B M N/A C-terminal Rabbit 
559 Bcl10 / CIPER / CLAP / mE10 HMR N/A N-terminal Rabbit 
560 
Nitric Oxide Synthase, endothelial 
(eNOS) HMRDPW N/A C-terminal 
Rabbit 
561 Int-2 Oncoprotein HM IgG2a / κ Not determined Mouse 
562 CEA / CD66e H IgG1 Not determined Mouse 
563 
Epithelial Membrane Antigen 
(EMA / CA15-3 / MUC-1) H IgG1 / κ Not determined 
Mouse 
564 Raf-1 (Phospho-specific) 
H IgG1 
GQRDS*SYY*WEIEA
S 
Rat 
565 Mucin 3 (MUC3) 
H IgG2a 
Tandem repeats of the 
human MUC3 
Mouse 
566 MyD88 HM N/A Near C-terminus Rabbit 
567 Cadherin-P H IgG1 External domain Mouse 
568 Glicentin HRP N/A Not determined Rabbit 
569 Superoxide Dismutase H IgG1 N-terminal domains I-V Mouse 
570 TRAP H IgG2b N-terminal Mouse 
571 p170 H IgG2a C-terminal cytoplasmic Mouse 
572 CD138 H IgG1 Not determined Mouse 
573 Hepatocyte H IgG1 / κ Not determined Mouse 
574 SV40 Large T Antigen SV40 virus IgG2a IgG2a Mouse 
575 Apolipoprotein D HM N/A aa 810-822 Rabbit 
576 Neutrophil Elastase H IgG1 / κ Not determined Mouse 
577 CD61 / Platelet Glycoprotein IIIA H IgG1 / κ Not determined Mouse 
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578 Bromodeoxyuridine (BrdU) All IgG1 / κ Not determined Mouse 
579 Nucleophosmin (NPM) H IgG / κ N-terminal Mouse 
580 Keratin 20 H IgG1 Not determined Mouse 
581 
Retinoblastoma (Rb) (Phospho-
specific Serine608) HM IgG1 Not determined 
Mouse 
582 CDC14A Phosphatase H IgG1 C-terminal Mouse 
583 CD71 / Transferrin Receptor H IgG1 Not determined Mouse 
584 IgM (m-Heavy Chain) H IgG1 / κ Not determined Mouse 
585 PHAS-II 
H N/A 
Amino acids 99-120 of 
human PHAS-II 
Rabbit 
586 DcR1 
H N/A 
Amino acids 111-123 of 
human DcR1 
Rabbit 
587 Rad18 
H N/A 
Amino acids 402-414 of 
human Rad18 
Rabbit 
588 DR5 
HR N/A 
Amino acids 255-270 of 
rat DR5 
Rabbit 
589 Stat5 
H N/A 
Amino acids 371-389 of 
human Stat5 
Rabbit 
590 Calretinin HMR N/A Not determined Rabbit 
591 Desmin HMR N/A Near C-terminus Rabbit 
592 
CD30 (Reed-Sternberg Cell 
Marker) H IgG1 Extracellular domain 
Mouse 
593 Dysferlin H N/A C-terminus Rabbit 
594 Fas-ligand HMR N/A N-terminus Rabbit 
595 Connexin 43 HMR N/A 3rd cytoplasmic Mouse 
596 Synuclein beta HR N/A Near C-terminus Rabbit 
597 Parathyroid Hormone HM N/A N-terminus Rabbit 
598 Synuclein pan HR N/A Near C-terminus Rabbit 
599 Cathepsin D H N/A Not determined Rabbit 
600 GLUT-1 HR N/A C-terminal Rabbit 
601 GluR4 HMRKY N/A C-terminal Rabbit 
602 GSK-3 HMRKY N/A C-terminal Rabbit 
603 14-3-3 beta HMR N/A N-terminal Rabbit 
604 GluR6/7 HMRKY N/A C-terminal Rabbit 
605 hPL H N/A Not determined Rabbit 
606 Myoglobin H N/A Not determined Rabbit 
607 GluR 2/3 HMRY N/A C-terminal Rabbit 
608 H.Pylori Helicobacter pylori N/A Not determined Rabbit 
609 CD23 H N/A 48-248aa Rabbit 
610 COX2 HMR N/A C-terminus Rabbit 
611 GluR1 HR N/A C-terminal Rabbit 
612 Phospho-Ser/Thr/Tyr All IgG1 Not determined Mouse 
613 GLUT-3 H N/A C-terminal Rabbit 
614 Osteopontin HDP N/A Internal domain Rabbit 
615 PSCA H N/A Extracellular Rabbit 
616 PGP9.5 H N/A Not determined Rabbit 
617 Ubiquitin H N/A Not determined Rabbit 
618 Amylin Peptide H N/A N-terminal Rabbit 
619 
Prostate Apoptosis Response 
Protein-4 HMR N/A C-terminus 
Rabbit 
620 alpha-1-antitrypsin H N/A Not determined Rabbit 
621 CITED1 H N/A Not determined Rabbit 
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622 Muc-1 HM N/A aa 239-255 Rabbit 
623 HDAC1 HMR N/A C-terminus Rabbit 
624 TrxR2 HR N/A C-terminus Rabbit 
625 FHIT H N/A Not determined Rabbit 
626 Catenin gamma HMR N/A C-terminal Rabbit 
627 IGF-I HMR N/A Not determined Rabbit 
628 Claudin 5 HM N/A C-terminal Rabbit 
629 a-B-Crystallin H N/A Not determined Rabbit 
630 TGF-beta 2 HMR N/A C-terminal Rabbit 
631 Claudin 3 HMR N/A C-terminal Rabbit 
632 O ct-1 HMR N/A C-terminal Rabbit 
633 Flt-4 HMR N/A C-terminus Rabbit 
634 Actin, skeletal muscle HREGpT N/A N-terminus Rabbit 
635 PDGF HR N/A 101-116aa Rabbit 
636 Claudin 2 HM N/A C-terminal Rabbit 
637 TGF beta 3 HMR N/A C-terminal Rabbit 
638 Wnt-1 HMR N/A N-terminal Rabbit 
639 Claudin 4 HM N/A C-terminal Rabbit 
640 MMP-19 H N/A Not determined Rabbit 
641 TNR-R2 HMR N/A C-terminal Rabbit 
642 Pax-5 HMR N/A C-terminal Rabbit 
643 P504S H N/A Not determined Rabbit 
644 S100A4 H N/A Not determined Rabbit 
645 Urocortin HR N/A Not determined Rabbit 
646 Gastrin 1 H N/A Not determined Rabbit 
647 CCK-8 H N/A Not determined Rabbit 
648 IP10/CRG2 H N/A Not determined Mouse 
649 IL17 H N/A Not determined Mouse 
650 Toxoplasma Gondii H N/A Not determined Rabbit 
651 IFN gamma H IgG1 Not determined Mouse 
652 mRANKL M IgG1 Not determined Rat 
653 CD94 H IgG1 Not determined Mouse 
654 ZAP-70 H N/A aa 1-254 Rabbit 
655 Oct-3/ H N/A Not determined Rabbit 
656 PPAR-gamma H N/A Not determined Mouse 
Reactivity: H human, A adenovirus, C cat, Ch Chinese hamster, D dog, E sheep, Gp guinea 
pig, Gt goat, K chicken, M mouse, P pig, Q quail, S hamster, T rabbit, W cow, X xenopus, Y 
monkey 
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6.2 Saturation-DIGE  
Figure 6.2 Examples of differential spots identified by Progenesis SameSpot a) tumour 
versus normal b) ANOVA CRC stages and c) non-metastatic versus metastatic CRC 
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Figure 6.3 Analytical gel scans of a) tumour b) and control samples (saturation-DIGE 
labelled, patient ACPS B2, 5 µl protein) compared to preparative gel scans of c) pooled 
tumour and d) control (double stained: SybrRuby and Coomassie blue, pooled from 16 
tumour or control samples, 500 µl protein).  
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6.3 DotScan antibody microarray 
 
Figure 6.4 Example of the surface profiles obtained with the Dotscan antibody microarray. 
The antibody address a) shows the antibody ID within each leukocyte, CRC and isotype 
control panel. Viable cells from a stage B1 CRC tumour was captured on the DotScan 
microarray; the optical scan b) shows the surface profile of the mixture of cell types within 
the tumour, the EpCAM c) and CD3 d) profiles show the expression of surface proteins on 
epithelial/cancer and T-cells, respectively. TCR α/β T-cell receptor alpha/beta, TCR γ/δ T-
cell receptor gamma/delta, κ kappa light chain, λ lambda light chain, sIg surface 
immunoglobulin, CA-125 cancer antigen 125, DCC deleted in colon cancer protein, FAP 
fibroblast activation protein, PRGR progesterone receptor, TSP-1 thrombospondin-1, 
Mabthera (rituximab) monoclonal antibody against CD20. 
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Table 6.2 DotScan microarray antibody list.  
CD marker 
or antigen 
Clone 
Antibody 
Isotype 
Antibody Source Cat No 
Stock Ab Conc 
(µg/ml) 
TCR a/b BMA031 IgG2b Immunotech IM1466 200 
TCR g/d Immu 510 IgG1 Immunotech IM1349 100 
CD1a BL6 IgG1 Immunotech IM0130 200 
CD2 RPA-2.10 IgG1 Pharmingen 555324 500 
CD3 SP34 IgG3 Pharmingen 556610 500 
CD4 13B8.2 IgG1 Immunotech IM0398 200 
CD5 BL1a IgG2a BioDesign P42116M 200 
CD6 M-T605 IgG1 Pharmingen 555356 500 
CD7 8H8.1 IgG2a BioDesign P42179M 200 
CD8 B9.11 IgG1 Immunotech IMBULK1 1480 
CD9 ALB6 IgG1 Immunotech IM0117 200 
CD10 ALB2 IgG2a Immunotech IMBULK1 200 
CD11a 25.3.1 IgG1 Immunotech IM0157 200 
CD11b BEAR1 IgG1 Immunotech 190 200 
CD11c BU 15 IgG1 Immunotech 712 200 
CD13 L138 IgG1 Pharmingen 347830 100 tests 
CD14 RM052 IgG2a Immunotech IM0643 200 
CD15 HI98 IgM Pharmingen 555400 500 
CD16 3G8 IgG1 Immunotech IM0813 200 
CD19 J4119 IgG1 Immunotech IM1313 200 
CD20 H299 (B1) IgG2a Coulter 6602140 250 
CD21 BL13 IgG1 Immunotech 111 200 
CD22 HIB 22 IgG1 Pharmingen 555423 200 
CD23 9P.25 IgG1 Immunotech 419 200 
CD24 ALB9 IgG1 Immunotech IM0118 200 
CD25 B1.49.9 IgG2a Immunotech 119 200 
CD28 CD28.8 IgG1 Immunotech 1376 200 
CD29 K20 IgG2a Beckman Coulter IMBULK1 200 
CD31 1F11 IgG1 Immunotech 2052 200 
CD32 2E1 IgG2a Immunotech IM0417 200 
CD33 P67.6 IgG1 Biolab sc-19660 200 
CD34 QBEND 10 IgG1 Immunotech 786 200 
CD36 FA6-152 IgG1 Immunotech 765 200 
CD37 BL 14 IgG1 Immunotech 110 200 
CD38 T16 IgG1 Immunotech IM 0366 200 
CD40 MAB89 IgG1 Beckman Coulter IM1374 200 
CD41 P2 IgG1 Immunotech IM0145 200 
CD42a SZ1 IgG2a Beckman Coulter IM0538 200 
CD43 DFT1 IgG1 Immunotech IM1843 200 
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CD44 J-173 IgG1 Immunotech IM0845 200 
CD45 69 IgG1 Pharmingen 610266 250 
CD45RA HI100 IgG2b Pharmingen 555486 500 
CD45RO UCHL1 IgG2a Pharmingen 555491 500 
CD49d HP2/1 IgG1 Immunotech IM 0764 200 
CD49e SAM1 IgG2b Beckman Coulter IM0771 200 
CD52 CF1D12 IgG3 Caltage Lab MHCD5200 200 
CD54 84H10 IgG1 Immunotech 544 200 
CD56 N901(NKH-1) IgG1 Immunotech 6602705  
CD57 NK-1 IgM Pharmingen 555618 500 
CD60 M-T6004 IgM Serotec MCA1314 200 test 
CD61 SZ21 IgG1 Immunotech 0540 200 
CD62L Dreg56 IgG1 Pharmingen 555542 500 
CD62E 1.2B6 IgG1 Immunotech IM1243 200 
CD62P CLB-Thromb/6 IgG1 Immunotech IM1315 200 
CD64 32.2 IgG1 BioDesign P20410M  
CD65 88H7 IgM Sanquin M1719 200 
CD66c KOR-SA3544 IgG1 MBL D028-3 500 
CD71 4DJ1.2.2 IgG1 Immunotech IM2117 200 
CD77 38-13 IgM Immunotech 175 150 
CD79a HM47 IgG1 Pharmingen 555934 500 
CD79b CD3.1 IgG1 Pharmingen 555678 500 
CD80 MAB 104 IgG1 Immunotech 1449 200 
CD86 2331 (FUN-1) IgG1 Pharmingen 555655 500 
CD88 D53-1473 IgG1 Pharmingen 550493 500 
CD95 UB2 IgG1 Immunotech 1505 1000 
CD102 B-T1 IgG1 Serotec MCA1140 1000 
CD103 Ber-ACT8 IgG1 Pharmingen 550258 500 
CD117 YB5.B8 IgG1 Pharmingen 555713 500 
CD120a H398 IgG2a Serotec MCA1340 1000 
CD122 Mik-b2 IgG2a Pharmingen 554520 500 
CD126 M5 IgG1 Pharmingen 551462 500 
CD128 5A12 IgG2b Pharmingen 555937 500 
CD130 A1/gp130 IgG1 Pharmingen 552426 500 
CD134 ACT35 IgG1 Pharmingen 555836 500 
CD135 SF1-340 IgG1 Immunotech 2036 200 
CD138 DL-101 IgG1 Pharmingen 550804 500 
CD138 (40C) Mi15 IgG1 Pharmingen 551902 500 
CD154 TRAP1 IgG1 Immunotech 1842 200 
CD235a 11E4B7.6 IgG1 Immunotech IM2210 200 
HLA-DR L243 IgG2a Immunotech 347360 100 tests 
FMC7 FMC7 IgM  Millipore   MAB1217  500 
Kappa 6E1 IgG1 Immunotech IM0173 200 
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Lambda C4 IgG1 Immunotech IM0174 200 
sIg polyclonal IgG Sigma I-8758 N/A 
CD15s CSLEX1 IgM Pharmingen 551344 500 
CD26 M-A261 IgG1 Pharmingen 555435 500 
CD44v6 2F10 IgG1 R&D BBA13 1000 
CD47 B6H12 IgG1 Pharmingen 556044 500 
CD49f GoH3 IgG2a Pharmingen 555734 500 
CD55 IA10 IgG2a Pharmingen 555691 500 
CD59 p282 IgG2a Pharmingen 555761 500 
CD63 H5C6 IgG1 Pharmingen 556019  
CD69 FN50 IgG1 Pharmingen 555529 500 
CD66e C365D3 IgG1 Serotec MCA1744 1000 
CD82 5B5 IgG2a abcam ab49292  
CD87 VIM5 IgG1 Pharmingen 555767 500 
CD104 450-9D IgG1 Pharmingen 555721 500 
CD151 14A2.H1 IgG1 Pharmingen 556056 500 
CD166 3A6 IgG1 Pharmingen 559260 500 
CD175s BRIC111 IgG1 abcam ab24005 1000 
CD227 HMPV IgG1 Pharmingen 555925 500 
CD244 2-69 IgG2a Pharmingen 550814 500 
CD261 DJR1 IgG1 BioLegend 307202 ?? undil 
CD262 B-37D IgG2b Diaclone 990-85487 1000 
CD324 MB2 IgG2b abcam ab8993 1000 
CD326 158206 IgG2b R&D MAB9601 500 
CD340 191924 IgG2b R&D MAB1129 1000 
CD98 UM7F8 IgG1 Pharmingen 556074 500 
b-catenin  IgG R&D AF1329 500 
Annexin II 5/Annexin II IgG1 Pharmingen 610069 800 
CA-125 X75 IgG1 abcam ab1107 1000 
Claudin-4 382321 IgG2a R&D MAB4219 500 
DCC G92-13 IgG1 Pharmingen 554222 500 
EGFR EGFR.1 IgG2b Pharmingen 555996 500 
FAP F11-24 IgG1 Calbiochem OP188 1000 
Galectin 3 A3A12 IgG1 abcam ab27850 1000 
Galectin 4 198616 IgG2a R&D MAB1227 1000 
Galectin 8 210608 IgG2a R&D MAB1305 1000 
HLA-A,B,C G46-2.6 IgG1 Pharmingen 555551 500 
MICA 159227 IgG2b R&D MAB1300  
MMP-14 128527 IgG2b R&D MAB9181  
pIgR  IgG R&D AF2717 1000 
CA19-9 M39026 IgG1 abcam ab47871 1000 
TSP-1 46.4 IgG1 Calbiochem BA18 500 
mIgG1 500   Pharmingen 557273 500 
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mIgG1 200   Cal-Nova 401122 200 
mIgG1 50   Cal-Nova 401122 50 
mIgG2a 500   Pharmingen 553454 500 
mIgG2a 200   Pharmingen   200 
mIgG2a 50   Pharmingen   50 
mIgG2b 500   Pharmingen 553472 500 
mIgG2b 200   Pharmingen 557351 200 
mIgG3 500   Pharmingen 555742 500 
mIgM 500 G155-228 IgM, k Pharmingen 555581 500 
mIgM 200 G155-228 IgM, k Pharmingen 555581 200 
mIgM 500 G155-228 IgM, k Pharmingen 555581 500 
 
